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Abstract 
 
Globally, women account for more than half of the 36.9 million people living with HIV-1. In some 
regions particularly Sub-Saharan Africa, women of child-bearing age are at great risk of being infected 
with HIV-1 than men of the same age group. Transmission is mainly through penetrative vaginal 
intercourse with an infected male partner. Current evidence suggests that women using certain types 
of progestin-only hormonal contraceptive methods have a higher risk of HIV-1 infection. In addition, 
there is evidence suggesting that genital tract infections (GTIs), which have high prevalence in Sub-
Saharan Africa, also modify the risk of HIV-1 infection in women. Incidentally, regions were 
progestogen-only hormonal contraceptives use and genital tract infections are prevalent also have 
with high rates of HIV-1 prevalence in women. This raises the question whether medroxyprogesterone 
acetate (MPA), norethisterone enanthate (NET) or levonorgestrel (LNG), the active compounds in 
progestogen-only hormonal contraceptives, cooperate with inflammation associated with GTIs to 
further elevate the risk of HIV-1 acquisition in women. Current evidence suggests MPA, LNG and 
NET differentially the expression of immune function genes relevant for HIV-1 infection in the female 
genital tract (FGT). In addition, there is evidence suggest that MPA and LNG impairs the integrity of 
mucosal barrier of the FGT.  
 
This study investigated the central hypothesis that MPA, NET and LNG acting alone or in synergy 
with immune activators [tumour necrosis factor-alpha (TNF) and lipopolysaccharide (LPS)] via the 
glucocorticoid receptor (GR) regulate the expression of genes of relevant for maintaining the integrity 
of genital tract mucosal surfaces, mucosal permeability, select immune function genes and HIV-1 
replication. This hypothesis was investigated in the endocervical epithelial End1/E6E7 cell, 
ectocervical tissues explants from pre-menopausal women, primary genital tract epithelial cells, 
peripheral blood mononuclear cells (PBMCs) and the TZM-bl indicator cell line. Gene expression 
analysis in responses to progestogen alone or in combination with immune activators was performed 
by real-time PCR, ELISA, Luminex assays and western blotting. The role of the GR was investigated 
using RU486 or GR siRNA knockdown. Mucosal barrier integrity and permeability was assessed by 
confocal microscopy and transepithelial electrical resistance measurements. For infection assays, 
TZM-bl cells were exposed to HIV-1Bal-Rellina infectious molecular clones (IMCs) before treatment 
progestogen alone or in combination with immune activators. In addition, TZM-bl cells were pre-
conditioned with supernatants from PBCs treated alone with progestogen or in combination with 
immune activators before exposed to HIV-1Bal-Rellina IMCs. 
 
In the absence of TNF, MPA at physiologically relevant doses acted via the GR to downregulate 
claudin-4 mRNA expression in End1/E6E7 cells, with MPA behaving like a partial GR agonist when 
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compared to dexamethasone (DEX). Similarly, MPA acted via the GR to selectively upregulate CCL20 
mRNA expression in End1/E6E7 cells, with MPA behaving like a full GR agonist when compared to 
hydrocortisone (CORT). It was also observed that MPA upregulated toll-like receptor (TLR)2 mRNA 
expression, but reduced interleukin (IL)6 and IL1β mRNA expression in End1/E6E7 cells. Neither NET 
not LNG regulated claudin-4 and immune function expression in End1/E6E7 cells. The addition of 
TNF, on the other hand, did not alter the effect of MPA on claudin-4 expression, suggesting that there 
is no cooperativity between MPA and TNF in regulating this gene. Neither NET nor LNG was found 
to cooperate with TNF to regulate claudin-4 expression in End1/E6E7 cells. However, MPA unlike 
NET acted synergistically via the GR with TNF or LPS to upregulate C-C motif chemokine ligand 
(CCL)20 expression in End1/E6E7 cells. This was not an isolated event as MPA was also found to 
enhance TNF-induced expression of TNF receptor 2 (TNFRSF1B). The occurred against the 
backdrop of MPA but not NET repressing TNF-induced expression of IL6, IL1β and CCL5. In 
ectocervical tissues, MPA like NET did not regulate basal claudin-4 expression, but unlike NET 
downregulated desmoglein-1 expression. This suggest that MPA may increase the permeability of the 
endocervix and ectocervix via different mechanisms. This study was unable to established whether 
MPA and TNF synergistically upregulate CCL20 in ectocervical tissues. In PBMCs, however, MPA 
selectively enhanced LPS-induced expression of CCL20, but suppressed LPS-induced expression of 
IL6, IL8, IL1β and CCL5. Finally, MPA unlike NET was found to act alone or additively with TNF or 
LPS to increase HIV-1 replication in TZM-bl cells. While this suggest MPA directly affects HIV-1 
replication, it was observed that the effects may also be indirect as secretions from PBMCs cotreated 
with MPA and LPS but not NET and LPS enhanced HIV-1 replication in TZM-bl cells.       
 
Taken together, the results shown in this study provides new insight into plausible mechanisms by 
MPA but not NET acting via the GR may enhance the susceptibility of the endocervix to HIV-1. Firstly, 
they suggest that MPA unlike NET may increase the permeability of the endocervix via a mechanism 
that is different from the ectocervix. Secondly, they suggest that the upregulation of select immune 
mediators and innate immune receptors by MPA but not NET in the endocervix in the absence of 
immune activation may render the endocervix vulnerable to HIV-1 infection. Thirdly, that MPA unlike 
NET is more likely to synergise with immune activators to further upregulate the expression of select 
immune function, but not tight junction genes in the endocervix. Collectively, this suggest MPA unlike 
NET can cooperate with GTIs to further increase the risk of HIV-1 acquisition in women residing in 
high risk regions. In this setting, NET-EN but not DMPA-IM would be a safer choice of injectable 
progestin-only contraceptive.     
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Thesis Outline 
 
This thesis is comprised of six chapters as well as three appendices for supplementary data. 
 
Chapter One: Literature Review. This chapter is the literature review and it gives a brief overview 
of the effects of progestogens used in hormonal contraception on HIV-1 acquisition risk in women. It 
also focuses on the molecular mechanisms, detailing the role of the glucocorticoid receptor. 
Chapter Two: Materials and Methods. Describes the materials and methods used to obtain the 
results presented in the thesis. 
Chapter Three: Medroxyprogesterone acetate, like glucocorticoids but unlike other select 
progestins, regulates select tight junction and immune function target genes, including 
CCL20, alone and in combination with pro-inflammatory stimulators, in a gene-specific manner 
in an endocervical epithelial cell line. This chapter focuses on whether glucocorticoids and 
progestogens differ in the manner in which they regulate gene expression in the absence and 
presence of immune activators. More specifically, this chapters attempts to establish whether 
glucocorticoids and progestogens cooperate with immune activators to regulate the expression of 
genes relevant for HIV-1 infection and pathogenesis in an endocervical epithelial cell line.   
Chapter Four: The glucocorticoid receptor mediates the potent partial agonistic MPA-induced 
downregulation of claudin-4 gene expression as well as the gene-specific and synergistic 
interactions between MPA and immune activators that upregulate CCL20 gene expression in 
the endocervical epithelial cell line. This chapters focuses on whether the effects of glucocorticoids 
and select progestogens on the expression of select tight junction and immune function genes in an 
endocervical epithelial cell line occur at physiologically relevant concentrations and whether they are 
mediated by the glucocorticoid receptor . The chapter also attempts to establish the biocheracter of 
select progestogens via the glucocorticoid receptor relative to reference glucocorticoids. 
Chapter Five: MPA unlike NET downregulates desmoglein-1 mRNA levels in ectocervical 
tissue explants, positively cooperate with immune activators to increase HIV-1 infection in 
TZM-bl cells and augments CCL20 expression in PBMCs. This chapter attempts to establish 
whether the effects seen in the cell line model can be replicated in vitro using physiologically relevant 
primary models (ectocervical tissue explants, PBMCs and primary genital epithelial cells). This 
chapter also focuses on the effects of glucocorticoids and select progestogens alone or in combination 
with immune activators on HIV-1 replication in the TZM-bl HIV-1 indicator cell line. 
Chapter Six: Discussion, Conclusions and Future Perspective.  This chapter focuses on the 
short-comings of the study, physiological relevance of the results, possible molecular mechanisms 
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involved and draws conclusions based in the context of the field. This chapter also proposes future 
research questions 
References: Provides a list of the literature reviewed throughout this study. 
Appendix A: Contains supplementary results for Chapter Three 
Appendix B: Contains supplementary results for Chapter Four 
Appendix C: Contains supplementary results for Chapter Five 
 
The following are peer reviewed publication arising from this thesis: 
Hapgood, J, P., Avenant, C. and Moliki, J.M. Glucocorticoid-independent modulation of GR activity: 
Implications for immunotherapy. Pharmacology and Therapeutics. 165:93-113. 
The present author wrote section 5 and 7 of the review.  
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Chapter One 
 
Literature Review 
 
1.1: Introduction 
Human immunodeficiency virus type 1 (HIV-1) transmission is the transfer of infectious viral particles 
from an infected host to another regardless of whether they were previously infected.  In women, this 
occurs primarily in the female genital tract (FGT) where HIV-1 target cells become infected after 
exposure to pathogenic cell-free or cell-bound viral particles in semen from an infected male partner 
(Sewankambo et al., 1987). The probability of male-to-female HIV-1 transmission after a single 
episode of unprotected vaginal sex ranges from 1:200 to 1:2000 (Hladik & McElrath, 2008). This may 
vary around the world, with developing countries usually having higher transmission rates than 
developed countries (Boily et al., 2009). This low probability of transmission per coital act suggests 
that the FGT is endowed with innate protective mechanisms that protect against infection. However, 
the FGT can be compromised and rendered vulnerable to infection by factors the roles of which have 
been controversial in HIV-1 disease acquisition and transmission.  
 
1.2: The FGT mucosal and immune systems – understanding the first line of defence against 
HIV-1 infection 
Mucosal surfaces of FGT are the main sites of heterosexual transmission of HIV-1 infection. They 
comprise the vagina, ectocervix, endocervix, endometrium and fallopian tubes (Figure 1.1). They 
provide a physical barrier against infection by pathogens including HIV-1. The vagina and ectocervix 
constitute the lower portion of the FGT and are lined by multiple layers of squamous epithelial cells. 
On the other hand, the endocervix like the rest of the upper FGT is lined by a single layer of columnar 
epithelial cells (Blaskewicz et al., 2011). The epithelial cells rest on a basement membrane and remain 
as a single layer (or stratum) in the upper FGT mucosa. In the lower FGT, however, they proliferate 
to form several strata of cells at different stages of differentiation. An intact lower FGT epithelium can 
restrict the passage of HIV-1 viral particles (Blaskewicz et al., 2011; Carias et al., 2016). However, 
productive infection can still occur in the lower FGT if the mucosal surface is impaired (Carias et al., 
2013). Because it is lined by a single layer of columnar epithelial cells, HIV-1 viral particles are thought 
to be more efficiently transported across mucosal surfaces of upper than those of the lower FGT. 
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Figure 1.1: A schematic representation of the FGT showing cellular components of mucosal 
epithelia and immune systems. Source of image: Nguyen et al., 2014. 
 
In healthy women, the vagina and ectocervix are colonised by lactic acid- and hydrogen peroxide 
(H2O2)-producing bacteria, which are predominantly of the genus Lactobacillus. These bacteria 
metabolize glycogen made by epithelial cells under the control of estrogen (E2) to produce lactic acid. 
This allows the FGT to maintain an acidic or low pH that is hostile to HIV-1 (Boskey et al., 1999). It 
has been reported that low pH reduces the net negative charge on the surfaces of cell-free HIV-1 viral 
particles. This interferes and disrupts interactions between the viral envelop and host cell receptors 
and explains why cell-free viral particles are less infectious at low pH (Martin et al., 1985; Lai et al., 
2009). In addition, HIV-1 target cells are less activated at low pH and as a result are less susceptible 
to infection (Hill & Anderson, 1992; Olmsted et al., 2005). Moreover, in vitro studies have found that 
lactic acid inhibits the expression of pro-inflammatory cytokines associated with HIV-1 acquisition in 
the FGT (Hearps et al., 2017). Despite the presence of these protective mechanisms, HIV-1 infection 
can still be established in the FGT and the mechanisms involved are not fully understood. 
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Underneath the mucosal epithelial tissues of the FGT are cells of the innate and adaptive immune 
system (Thurman et al., 2016; Nguyen et al., 2014). The following cell types have been identified; 
cluster of differentiation (CD)4+ T cell, CD8+ T cells, macrophages (CD68+), monocytes (CD14+), 
neutrophils (CD177+), natural killer cells (NK, CD56+), Langerhans (CD1a+) and dendritic cells 
(CD11c+), with CD4+, CD1a+, CD11c+ and CD14+ expressing cells constituting targets for HIV-1 
infection. Most of these cells reside in the lamina propria, but Langerhans cells and sometimes CD4+ 
T cells and dendritic cells (DCs) can be found in intraepithelial spaces (Thurman et al., 2016; Nguyen 
et al., 2014).  It has recently been reported that the risk of HIV-1 infection in humanised murine models 
is associated with the frequency of CD45+CD4+ T cells in the FGT (Nguyen et al., 2017). However, 
the majority of CD4+ T cells in the FGT are effector memory T [C-C chemokine receptor (CCR7)-
CD45-] cells (Smith-McCune et al., 2017), although the proportion of central memory CD4+T 
(CCR7+CD45-) cells may increase during the luteal phase of the menstrual cycle (Swaims-Kohlmeier 
et al., 2016). Central memory like naïve (CCR7+CD45+) CD4+ T cells especially of CCR6+Th17 
phenotype have been shown to be very susceptible to HIV-1 infection (Saleh et al., 2007; Gosselin et 
al., 2010; Gosselin et al., 2017; Stieh et al., 2016; Rodriquez-Garcia et al., 2014). This suggest that 
changes in the frequency of specific CD4+ T cell subsets in the FGT may significantly alter the risk of 
HIV-1 infection 
 
1.2.1: The FGT mucosal epithelial barrier function and HIV-1 infection 
One of the main functions of the mucosal systems of the FGT is to restrict the exchange of material 
between the luminal and basal surfaces of the structures they protect (Kaushic et al., 2011). This 
function depends on junctional proteins which are strands of interconnecting transmembrane protein 
complexes expressed between neighbouring epithelial cells. They regulate paracellular flux and 
alterations in their composition and structure results in changes in paracellular permeability. There 
are three major junctional proteins; desmosomes, adherens junctions and tight junctions. All three 
types of junctional proteins are expressed in epithelial cells of the upper FGT, whereas only stratum 
basal epithelial cells of the lower FGT express these proteins (Blaskewicz et al., 2011).  
 
Epithelial tight junctions (TJs) are usually formed on the apical surfaces of polarised epithelial cells. 
This arrangement maintains the polarity of epithelial cells as well as the integrity of the mucosal 
surfaces they line (Shin et al., 2006). However, these are very dynamic complexes, the structure and 
composition of which are regulated by physiological stimuli including growth factors, steroids and 
cytokines (Sekiyama et al., 2012; Ogawa et al., 2012; Al-Sadi et al., 2009). Three main families of TJ 
proteins have been identified. This include zonula occludens (ZO), occludin and claudins. ZO and 
occludin are mainly scaffolding proteins that are stabilised by claudins. Compared to ZO and occludin, 
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claudins are the most diverse TJ protein comprising at least 27 members (Günzel & Fromm, 2012). 
Based on their barrier forming properties, claudins are categorised as sealing and leaky. Sealing 
claudins include claudin-1, -4, -5 and -8, whereas leaky claudins include claudin-2, -7 and -10 (Shen 
et al., 2011). Overexpressing claudin-4 has been shown to enhance the mucosal barrier functions of 
epithelial cells (Balda et al., 1996; van Itallie et al., 2001). On the other hand, overexpressing claudin-
2 in epithelia cells has been found to induce channel formation within the junctional complexes, which 
renders them porous and so more permeable (Luettig et al., 2015). Interestingly, claudin-2 and 
claudin-4 have been found to be incompatible and are inversely regulated at TJs (Capaldo et al., 
2014). It has been reported that TJ genes are differential expressed and distributed in mucosal 
surfaces of the FGT (Blaskewicz et al., 2011). However, little is known concerning their regulation and 
how this affects mucosal barrier function and susceptibility to infection. 
 
Cell- free or cell-associated HIV-1 viruses are likely to enter the body through cuts and micro-lesions 
in the mucosal surface (Dickerson et al, 1996). However, others have shown that these are not always 
required for infection as cell-free HIV-1 can most likely compromise the mucosal surface through 
mechanisms, which are not fully understood (Miller et al, 1994; Spira et al, 1996). Evidence from in 
vitro studies suggests that during heterosexual transmission in the FGT, cell-free HIV-1 viral particles 
might breach the mucosal barrier by opening up TJs between epithelial cells (Nazli et al., 2010; Nazli 
et al., 2013; Ferreira et al., 2015a; Ferreira et al., 2015b). Cell-free HIV-1 viral particles or viral proteins 
such as gp120 have been shown to downregulate the expression of TJ genes including ZO-1, 
occludin, claudin-1, claudin-2, claudin-3, claudin-4 and claudin-5 in primary genital epithelial cells 
(PGECs) (Nazli et al., 2010). Similarly, HIV-1 Tat has been shown to downregulate claudin-1, -3 and 
-4, while upregulating claudin-2 expression in retinal epithelial cells (Bai et al., 2008). This may allow 
viral particles to access target cells in the lamina propria via paracellular penetration. Alternatively, 
some studies have suggested that cell-free HIV-1 viral particles can be ferried across intact epithelial 
cells in a process called transcytosis; however, this is an inefficient process (Bohardt et al., 2007; 
Ferreira et al., 2015a). The study by Bohardt and colleagues showed that only 0.02% of the initial 
inoculum traverses the epithelium by transcytosis (Bohardt et al., 2007). This low efficiency can be 
explained by the fact that viral particles are recycled back to the apical surface as soon as they are 
translocated to the basolateral surface (Ferreira et al., 2015a). However, there is ex vivo and in vitro 
evidence showing that cell-associated HIV-1 virus is transmitted more efficiently across the mucosal 
surfaces compared to cell-free HIV-1 virus (Kolodkin-Gal et al., 2013; Lawrence et al., 2013).  
 
In summary, the mucosal epithelia lining the FGT presents a physical barrier against HIV-1 infection. 
However, HIV-1 viral particles can breach this barrier by disrupting junctional proteins. In addition, 
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viral particles can be internalised by epithelial cells from the luminal surface and translocated across 
to the laminar propria.  
 
1.2.2: The role of FGT and systemic inflammation in HIV-1 acquisition and disease progression  
Inflammation is a process that involves the production of soluble immune mediators in response to an 
invading pathogen and the subsequent recruitment of immune cells to the site of invasion (Stankov, 
2012). Evidence from animal studies suggests that inflammation plays a very important role in simian 
HIV-1 (SHIV) infection (Li et al., 2009; Shang et al., 2017). These studies observed that when 
macaques are challenged intravaginally with SHIV infectious molecular clones (SHIV IMCs), target 
cells are recruited to the site of exposure, most likely attracted by chemokines secreted by epithelial 
cells in responses to encountering viral particles (Li et al., 2009; Shang et al., 2017).  
 
Current evidence also suggests that pre-existing inflammation associated with genital tract infections 
(GTIs) increases the risk of HIV-1 acquisition in women (Mirmonsef et al., 2012; Passmore et al., 
2016; Alcaide et al., 2017). Pre-infection cervicovaginal lavages (CVL) from HIV-1 seroconverters 
have been found to have high levels of mostly pro-inflammatory immune mediators compared to non-
converters (Masson et al., 2015; Selhorst et al., 2017). Some of these such as interleukin (IL)1β, IL6, 
IL8, chemokine (C-C motif) ligand (CCL)3, CCL4 and chemokine (C-X-C motif) ligand (CXCL)10 have 
been associated with an increased risk of HIV-1 acquisition (Mlisana et al., 2012; Masson et al., 2015).  
 
The exact roles of these cytokines in HIV-1 infection in the human FGT are not known. Nonetheless, 
it has been suggested that they may enhance the recruitment of HIV-1 target cells, disrupt mucosal 
barrier function and modulate processes involving viral entry, integration and replication (Levine et 
al., 1998; Fichorova et al., 2001; Reddy et al., 2004; Masson et al., 2014). It has also been shown 
that HIV-1 IMCs replicate more readily in ectocervical tissue explants with high levels of IL1β, IL6, 
CCL2, CXCL10 and CXCL1 (Rollenhagen & Asin, 2011). In addition, highly infectious variants have 
been isolated from seroconverters with no FGT inflammation whereas lowly infectious strains have 
been isolated from seroconverters with FGT inflammation (Selhorst et al., 2017). This suggest that 
less infectious viral particles, unlike highly infectious clones, may not be able to establish infection in 
the absence of pre-existing inflammation. 
 
Systemic inflammation and immune activation may influence the risk of HIV-1 acquisition in the FGT 
(Lehman et al., 2014). One study found that women who seroconvert have high levels of pro-
inflammatory immune mediators in pre-infection blood samples compared to non-seroconverters, and 
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some of these cytokines namely CXCL10, tumour necrosis factor-α (TNF) and IL1β show significant 
positive association with risk of HIV-1 acquisition (Naranbhai et al., 2012; Kahle et al., 2015; 
Liebenberg et al., 2017). In addition, seroconverters had more activated NK and CD8+ T cells in 
circulation than non-converters (Naranbhai et al., 2012). In contrast, HIV-1 exposed seronegative 
women have very low serum levels of pro-inflammatory cytokines and show low levels of immune 
activation compared to HIV-1 unexposed or HIV-1 positive women (Lajoie et al., 2012; Jaumdally et 
al., 2017).  
 
Taken together, these studies suggest that elevated systemic inflammation and immune activation 
increases the risk of HIV-1 acquisition. However, it is not fully understood how systemic inflammation 
influences risk of HIV-1 acquisition in the FGT. Liebenberg and colleagues recently observed that if 
FGT inflammation superseded systemic inflammation, a cytokine gradient is created that attracts 
target cells from circulation to the FGT (Liebenberg et al., 2017). These authors computed the 
difference between FGT and systemic inflammation and found that certain cytokines such as 
CXCL10, CCL2, IL8 and CCL4 had positive gradients and were significantly associated with an 
increased risk of HIV-1 acquisition (Liebenberg et al., 2017).  
 
Taken together, results from these studies suggest that inflammation in very critical for HIV-1 infection 
and disease progression. However, it is not fully understood how inflammatory genes are regulated 
in the FGT and blood.   
 
1.2.2.1: Lipopolysaccharides and FGT or systemic inflammation 
Lipopolysaccharide or LPS is the major component in the cell walls of Gram-negative bacteria. LPS 
is the ligand for toll-like receptor 4 (TLR4), which is expressed on peripheral blood mononuclear cells 
(PBMCs) and on genital epithelial cells (Pivarcsi et al., 2005; Fazeli et al., 2005; Schaefer et al., 2004; 
Lashkari & Anumba, 2017). Evidence in the literature suggests that LPS is a marker for immune 
activation in patients with acute and chronic HIV-1 infection (Vassallo et al., 2012; Zhang et al., 2015). 
Compared to controls, HIV-1 positive individuals have been reported to have high levels of LPS in 
plasma, with a few studies reporting concentrations ranging between 87.2 pg/mL and 170.8 pg/mL 
(Brenchley et al., 2006; Funderburg et al., 2012; Valiathan et al., 2014). It has been demonstrated 
that gut bacteria are the source of plasma LPS during active HIV-1 infection (Brenchley et al., 2006).  
 
LPS in the FGT is contributed mainly by bacterial vaginosis (BV), which is an asymptomatic 
pathological condition characterised by a decrease in the number of lactic acid-producing bacteria 
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and an increase in the number of anaerobic gram-negative bacteria in the FGT (Woodman, 2016). 
Women with BV have been found to have high levels of LPS in vaginal washes, with one study 
reporting concentrations as high as 323.5 ng/mL (Aroutcheva et al., 2008). Evidence from 
epidemiological studies suggests that BV increases the risk of HIV-1 infection in women (Cohen et 
al., 1995; Sewankambo et al., 1997; Taha et al., 1999; Martin et al., 1999; Myer et al., 2005; van de 
Wijgert et al., 2013; Gosmann et al., 2017). Several pro-inflammatory immune mediators have been 
reported to be elevated in CVL from women with BV (Spandorfer et al., 2001; Hedges et al., 2006; 
Ryckman et al., 2008; Kyongo et al., 2015). Current evidence suggests that the severity of 
inflammation depends on diversity of the microbiome (Lennard et al., 2017) and could explain the 
heterogeneity in pro-inflammatory cytokine expression profiles reported by different studies 
(Spandorfer et al., 2001; Hedges et al., 2006; Rid et al., 2008; Ryckman et al., 2008; Doerflinger et 
al., 2014; Kyongo et al., 2015; Deese et al., 2016).  
 
1.3: Hormonal contraceptives and the risk of HIV-1 acquisition and disease progression 
According to the United Nations (UN), progestogen-only injectable hormonal contraceptives (IHCs) 
are the most prevalent contraceptive method used by women of child-bearing age in Sub-Saharan 
Africa (UN, 2015). Two types of IHCs are used in the region: medroxyprogesterone acetate (MPA) 
and norethisterone enanthate (NET-EN). MPA is marketed as Depo-Provera® (DMPA) and is 
administered as a three-monthly 150 mg intramuscular (IM) injection (DMPA-IM). MPA is also 
administered as a three-monthly low-dose 104 mg subcutaneous (SC) injection (DMPA-SC). NET-
EN is provided as a two-monthly 200 mg intramuscular injection and marketed as Nur-Iterated®. 
Other progestins used in contraception include levonorgestrel (LNG), administered in implants 
(Jardell®) delivering 150 mg LNG or in an LNG-releasing intrauterine device (LNG-IUD).  LNG 
(implants or IUD) is sparsely used in Sub-Saharan Africa (UN, 2015). MPA, NET, LNG and P4 are 
collectively referred to as progestogens (Figure 1.2).  
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Figure 1.2: Chemical structures of some progestogens and glucocorticoids. (A) 
medroxyprogesterone acetate (MPA), (B) levonorgestrel (LNG), (C) norethisterone enanthate (NET), 
(D) progesterone (P4), (E) hydrocortisone (CORT) and (F) dexamethasone (DEX). (Source: Sigma 
Aldrich website) 
 
1.3.1.1: Evidence from clinical and observational studies 
Evidence from epidemiology studies suggest that women using DMPA-IM have an increased risk of 
HIV-1 acquisition (Martin et al., 1998; Baeten et al., 2007; Leclerc et al., 2008; Wand & Ramjee, 2012; 
Heffron et al., 2012; Crook et al., 2014; Noguchi et al., 2015). In contrast, others have not found any 
significant association between DMPA-IM use and HIV-1 acquisition (Kapiga et al., 1998; Kiddugavu 
et al., 2003: Myer et al., 2007; Morrison et al., 2007; Morrison et al., 2012; McCoy et al., 2013; Lutalo 
et al., 2013; Whiteman et al., 2016; Balkus et al., 2016; Hofmeyr et al., 2017). However, recent 
systematic reviews and meta-analyses of higher quality published data have found a significant 
association between DMPA-IM use and HIV-1 infection risk (Ralph et al., 2015; Morrison et al., 2015; 
Brind et al., 2015; Polis et al., 2016). These studies have also found that the risk of HIV-1 acquisition 
is more elevated in commercial sex workers and women in serodiscordant relationships with HIV-1 
positive male partner, irrespective of their herpes simplex virus type 2 (HSV-2) status or age (Ralph 
et al., 2015; Morrison et al., 2015).   
 
Unlike DMPA-IM, clinical studies have found no significant association between NET-EN or combined 
oral contraceptive (mainly containing LNG) use and HIV-1 acquisition in women (Wand & Ramjee, 
2012; Myer et al., 2007; Noguchi et al., 2015; Crook et al., 2014; Morrison et al., 2007; Morrison et 
al., 2012; Kleinschmidt et al., 2007; McCoy et al., 2013; Wall et al., 2015; Lavreys et al., 2004; Ralph 
et al., 2015; Morrison et al., 2015). Furthermore, systematic reviews with meta-analyses have found 
A B C 
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no significant association between NET-EN and the risk of HIV-1 acquisition in high risk populations 
(Ralph et al., 2015; Morrison et al., 2015). In contrast, head-to-head comparisons between the 
different types of IHCs showed that women using DMPA-IM unlike those using NET-EN are more 
susceptible to HIV-1 infection (Noguchi et al., 2015; Morrison et al., 2015).  
 
It has recently been reported that women with BV using DMPA-IM are 6.5 times more likely to become 
infected with HIV-1 than women with BV not using DMPA-IM (Haddad et al., 2018). This suggests 
that DMPA enhances the risk of HIV-1 acquisition associated with BV in women, but the mechanisms 
are not fully understood. It is possible that DMPA-IM use favours the growth of Lactobacilli species 
such as L. iners that produce low hydrogen peroxide and lactic acid (Eschenbach et al., 1989; Hillier 
et al., 1992; Hillier et al., 1993; Tachedjian et al., 2017). However, this is unlikely the case as some 
studies have shown that DMPA-IM use specifically cause a decline in L. iners (Achilles et al., 2018) 
and does not alter the overall vaginal microbiome (Achilles et al., 2018; Mitchell et al., 2014). On the 
other hand, prolonged use of DMPA-IM might induce hypoestrogenism, which could result in a 
decrease in lactic acid production in the FGT (Hickey et al., 2016; Miller et al., 2000). In addition, 
DMPA use has been shown to alter the levels of pro-inflammatory immune mediators in cervical 
secretion from women with BV (Cherpes et al., 2008). However, it remains unclear whether the effects 
of DMPA use on genital inflammation are the consequence of DMPA modifying the genital 
microbiome. Taken together, this suggests that the mechanisms by which DMPA use enhance the 
risk of HIV-1 in women with BV are complex and may include changes in the pH and levels of pro-
inflammatory immune mediators in the FGT. 
 
It remains unknown whether prolonged use of LNG-IUD or NET-EN can induce hypoestrogenism. In 
addition, it remains unclear whether LNG-IUD or NET-EN use can modify the risk of HIV-1 infection 
associated with BV. This is very unlikely as it has been reported that neither LNG-IUS nor NET-EN 
alters the vaginal microbiome (Donders et al., 2011; Hashway et al., 2014; Jacobson et al., 2014; 
Brooks et al., 2017; Bassis et al., 2017; Achilles et al., 2018). These results suggest that LNG-IUD 
and NET-EN might be safer to use in women with BV.   
 
Evidence from some clinical observational studies or systematic reviews with meta-analyses also 
suggest that DMPA-IM use does not accelerate disease progression to acquired immune deficiency 
syndrome (AIDS) in HIV-1 infected women (Whiteman et al., 2016; Morrison et al., 2011; Heffron et 
al., 2013; Richardson et al., 2007; Phillips et al., 2016). However, results from other studies did 
suggest that DMPA-IM use might accelerate HIV-1 disease progression to AIDS, but these studies 
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were flawed by high rates of DMPA-IM failures (Stringer et al., 2007; Stringer et al., 2009a; Stringer 
et al., 2009b). The effects of NET-EN or LNG-IUD on HIV-1 disease progression remain unknown.    
 
Taken together, the clinical evidence indicates that DMPA-IM, unlike NET-EN or combined oral 
contraceptives (COCs)-containing LNG, increases the risk of HIV-1 acquisition in women but does 
not accelerate disease progression to AIDS. However, the mechanisms for DMPA-IM may occur at 
multiple levels and are currently unclear. It remains unknown whether LNG used in an IUD or implant 
for contraception modifies the risk of HIV-1 acquisition or disease progression in women.  
 
1.3.1.2: Evidence from animal and in vitro studies 
Evidence from animal studies further supports the link between DMPA-IM use and the risk of HIV-1 
acquisition. Studies conducted in pigtail and rhesus macaques showed that animals treated with 
DMPA-IM are more susceptible to SHIV infection (Trunova et al., 2006; Radzio et al., 2014; Carias et 
al., 2016). In addition, studies involving the use of the mouse and humanised mouse models have 
shown that animals treated with DMPA-IM as well as LNG and exogenous progesterone (P4) were 
more susceptible to HSV-2 and HIV-1 infection, respectively (Quispe-Calla et al., 2016; Quispe-Calla 
et al., 2018). This is consistent observations that female macaque monkeys are more susceptible to 
infection with SHIV in the luteal phase than in the follicular phase, with the window for infection determined 
as the period during or just after the surge in serum P4 levels (Vishwanathan et al. 2011; Kersh et al., 
2014; Sodora et al., 1998). Taken together, this suggest that a progestogen-dominant state increases the 
vulnerability of laboratory animals to infection. 
 
Because MPA is metabolised and cleared quicker in macaques than in humans, some studies used 
doses higher than that used in humans. Considering that the average macaque weighs 7 kg, this 
equates to 4.3 mg/kg as opposed to 2 mg/kg for a woman with the average body weight of 75 kg 
(Trunova et al., 2006; Carias et al., 2016). Thus, peak serum concentrations of MPA may differ 
drastically between macaques and humans. This raises questions as to the relevance of these studies 
when assessing the association between DMPA and the risk of HIV-1 acquisition. However, other 
studies have used lower doses (3 mg) and found that the average peak serum concentration is 6.98 
nM (3.62 – 12.41), which equates peak serum levels in humans (Radzio et al., 2014; Butler et al., 
2016). Similarly, doses used in mice achieve the serum concentrations that approximate those 
measured in women using DMPA-IM (Vicetti et al., 2012; Quispe-Calla et al., 2018). Therefore, 
reported increase in SHIV or HIV-1 infection in animal models is very unlikely to be an artifact caused 
by suprapharmalogical serum concentrations. 
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Additionally, evidence from in vitro studies support the association between DMPA and the risk of 
HIV-1 acquisition t (Huijbregts et al., 2013; Sampah et al., 2015; Ferreira et al., 2015a; Irvin & Herold, 
2015; Tasker et al., 2017; Maritz et al., 2018). It has previously been reported that MPA doses ranging 
between 7.79 pM and 12.93 nM enhance HIV-1 infection in unactivated CD4+ T cell (Sampah et al., 
2015). This is consistent with findings from a more recent study that showed for the first time that 
MPA enhances viral replication in CD4+ T cells and TZM-bl indicator cells exposed to HIV-1 (Maritz 
et al., 2018). These effects were observed at doses as low as 10 nM, suggesting that DMPA at 
physiologically relevant doses may enhance the risk of HIV-1 infection in women (Maritz et al., 2018). 
In fact, findings from another recent study showed that in the presence of DMPA CD4+ T cells are 
rendered more vulnerable to infection in vivo (Tasker et al., 2017). This study showed that PBMCs 
isolated from women using DMPA-IM are more readily infected ex vivo with HIV-1 IMCs compared to 
PBMCs obtained before DMPA-IM injection (Tasker et al., 2017). However, it has also been reported 
that MPA at 1 µM but not 100 nM can increase HIV-1 infection in activated CD4+ T cells (Huijbregts 
et al., 2013). Taken together, these findings suggest that MPA at physiologically relevant doses 
renders unactivated CD4+ T cells vulnerable to infection, whereas higher doses do the same for 
activated CD4+ T cells. MPA at 10 nM has been shown to induce that activation of CD4+ T cells (Maritz 
et al., 2018). In contrast, higher doses of MPA have been shown to prevent the deactivation of 
activated CD4+ T cells (Huijbregts et al., 2013). Thus, it appears MPA utilises different mechanisms 
to increase the susceptibility of unactivated and activated CD4+ T cells.  
 
The studies above suggest that the effects of MPA on PBMCs are direct. However, there is also 
evidence suggesting that the effects may be indirect. It has been reported that supernatants from 
PGECs treated with 1 nM MPA in the absence or presence of HIV-1 IMCs enhances trans infection 
of Jurkat T cells (Ferreira et al., 2015a). Trans infection is when HIV-1 traverses across an epithelial 
mucosal barrier to access and infection target cells. Suprapharmalogical doses of MPA ranging 
between 38.81 µM and 388.1 µM), but not a 100-times less were shown to enhance trans HIV-1 
infection of Jurkat-Tat-CCR5 (JT-CCR5) cells (Irvin & Herold, 2015). In addition, it has been 
demonstrated that supernatants from vaginal epithelial cells treated with 388.1 µM, but not 38.81 µM 
enhanced HIV-1 replication in a chronically infected cell line (Irvin & Herold, 2015).      
  
Evidence from animal studies show LNG enhances the susceptibility of humanise mice to infection 
(Quispe-Calla et al., 2016; Quispe-Calla et al., 2018). It remains to be established whether LNG can 
enhance HIV-1 infection in vitro. There is paucity of data from animal studies for NET. However, 
findings from in vitro studies suggest that NET does not enhance the risk of infection in HIV-1 target 
cells and ectocervical tissue explants (Maritz et al., 2018; Ray et al., manuscript under review). 
Therefore, head-to-head studies are needed to compare the effects of MPA, LNG and NET on HIV-1 
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infections.  Taken together, these findings suggest that a progestogen-dominant state increases the 
susceptibility to infection. It remains unclear whether all progestins can enhance the risk of HIV-1 
infection. However, these findings suggest that MPA unlike NET enhances HIV-1 infection of target 
cells and that it occurs at physiologically relevant doses. This suggests that some progestogens might 
be safer than others.       
 
1.3.2: The influence of injectable hormonal contraceptives on FGT epithelial thickness and 
mucosal permeability 
It remains unclear whether the vaginal epithelium of female macaques becomes thinner in the luteal 
phase compared to the follicular phase (Hadzic et al., 2014; Butler et al., 2015; Hild-Petito et al., 1998; 
Radzio et al., 2014; Butler et al., 2016). However, it has been reported that treating luteal phase 
macaques with DMPA or exogenous P4 reduces the thickness of the ectocervical or vaginal epithelial 
tissues (Marx et al., 1996; Smith et al., 2000; Hild-Petito et al., 1998; Radzio et al., 2014; Butler et al., 
2015; Carias et al., 2016; Butler et al., 2016). It has also been reported that DMPA-treated mice, like 
those treated with LNG, have thinner vaginal epithelia compared to mice in estrus phase (Quispe-
Calla et al., 2016). Most studies have shown that DMPA- as well as LNG-treated animals are more 
susceptible to infection by SHIV, HSV-2 and HIV-1 (Gillgrass et al., 2003; Radzio et al., 2014; Butler 
et al., 2016; Carias et al., 2016; Quispe-Call et al., 2016; Quispe-Calla et al., 2018; Bosinger et al., 
2018). It has also been reported that LNG in COC at 66% human dose caused a reduction in the 
vaginal epithelial thickness of pigtail macaques (Dietz Ostergaard et al., 2015). Together, these 
findings suggest that DMPA and LNG compromise the integrity of the vaginal and ectocervical 
epithelial mucosal tissues and renders them more vulnerable to infection.   
 
In humans, however, it remains unclear whether DMPA-IM use alters the thickness of the vaginal and 
ectocervical epithelia (Mauck et al., 1999; Kuhn et al., 1999; Bahamondes et al., 2000; Chandra et 
al., 2013; Bahamondes et al., 2014; Mitchell et al., 2014; Ildgruben et al., 2003). Also controversial is 
the question whether the luteal phase alters the thickness of vaginal and ectocervical epithelial tissues 
in women (Patton et al., 2000; Miller et al., 2000; Thurman et al., 2016). The discordance between 
human and animal studies may results from differences between the biology and structures of monkey 
and human FGT. 
 
It remains unclear what the effects of LNG and DMPA are on genital epithelial thickness. One study 
found that women using DMPA, COC and LNG implants had thicker vaginal epithelia compared to 
controls (Ildgruben et al., 2003). Another study found that women on LNG-IUD had thinner 
ectocervical stratum corneum compared to COC users or non-HC controls (Tjernlund et al., 2015). 
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However, the study by Tjernlund and colleagues also reported no difference in the overall thickness 
of the ectocervix between the groups ((Tjernlund et al., 2015). Thus, it remains unclear whether the 
mode of administration of LNG elicits different effects on genital epithelial thickness. Nonetheless, it 
has recently been reported that ectocervical mucosal tissue biopsies from women using DMPA-IM 
and LNG-IUD are very porous (Quispe-Calla et al., 2016; Quispe-Call et al., 2017). This could indicate 
thinning of the epithelium; however, this was not investigated by the authors. On the other hand, they 
reported that tissues from DMPA-IM and LNG-IUD users expressed low levels of desmoglein-1 and 
desmocollin compared to controls (Quispe-Calla et al., 2016; Quispe-Call et al., 2017). Unlike DMPA 
and LNG, there is paucity on the effects of NET-EN on genital epithelial thickness in the literature.  
 
Collectively, the data suggest that MPA and LNG can disrupt the integrity of mucosal tissues of the 
lower FGT. In animal models, this is achieved via reducing the thickness of mucosal epithelial tissues 
and down-regulating the expression of desmosomal junctions. In humans, however, this may be 
achieved only by down-regulating desmosomes.  
 
1.3.3: The influence of injectable hormonal contraceptives on the activation and distribution 
of HIV-1 target cells in the FGT 
Evidence from human and animal studies collectively suggests that DMPA-IM use causes HIV-1 
target cells to infiltrate the FGT, including CD4+ T cells (Ildgruben et al., 2003; Carias et al., 2016; 
Quispe-Calla et al., 2018; Goode et al., 2014; Smith-McCune et al., 2017), macrophages (Smith-
McCune et al., 2017; Ildgruben et al., 2003) and monocytes (Quispe-Calla et al., 2016). Some of these 
studies also show that CD4+ T cells recruited to the FGT are activated (Smith-McCune et al., 2017) 
and express the mucosal tissue homing marker α4β7 (Goode et al., 2014). Findings from recent 
studies showed that DMPA-IM or MPA enhances the expression of α4β7 and/or CCR5 on CD4+ T 
cells (Tasker et al., 2017; Maritz et al., 2018). This suggests that MPA prepares systemic CD4+ T cells 
to home to mucosal tissues. A recent study showed that women using DMPA-IM had more 
CCR5+CD4+ T cells in the endometrium compared to controls (Smith-McCune et al., 2017). However, 
another study found DMPA-IM use caused a decrease in the proportion of CCR5+CD4+ T cells in the 
vagina (Mitchell et al., 2014). This suggests that effects of DMPA-IM on the homing of CCR5+CD4+ T 
cells in the FGT are compartment specific. This is consistent with evidence from a study that reported 
the frequency of CCR5+CD4+ T cells in DMPA-treated macaques was higher in vaginal tissue, but 
lower in endocervix (Goode et al., 2014). 
 
It has also been reported that women using LNG-IUD have a high proportion of CCR5+CD4+ T cells 
in circulation (Sciaranghella et al., 2015). In addition, LNG-IUD use has been reported to increase the 
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proportion of activated CCR5+CXCR4+CD4+ T cells in the FGT (Shanmugasundaram et al., 2016). In 
contrast, it is currently unclear whether NET-EN use changes the frequency of systemic CCR5+CD4+ 
T cells and induces their homing to mucosal tissues of the FGT. A recent study reported women using 
IHC (without distinguishing between type) had more CCR5+CD4+ T cells in circulation and in the cervix 
compared to controls (Byrne et al., 2016). However, this study did not differentiate between DMPA-
IM and NET-EN. Current evidence from an in vitro study suggests that unlike MPA, NET does not 
alter CCR5 levels and the activation status of CD4+ T-cells (Maritz et al., 2018). Thus, it is possible 
that effects reported in the Byrne study were DMPA-IM induced.   
 
Taken together, these observations suggest that DMPA and LNG-IUD, unlike NET, activate and 
induce the migration of systemic CD4+ T cells to mucosal surfaces of the FGT. This may render the 
FGT more susceptible to HIV-1 infection.  
 
1.3.4: Physiological relevant concentrations of MPA, NET-EN and LNG 
A key question regarding the effects of contraceptives on HIV-1 acquisition/infection is the dose and 
hence concentration-dependency of such possible effects. Several studies have been undertaken to 
measure MPA levels in serum after an DMPA-IM injection is administered (recently reviewed by 
Hapgood et al., 2018). Pooled data from the literature suggest that an average serum concentration 
of 21 nM is attained within 20 days after administration, but this may range between 3 nM to 100 nM. 
At day 30 post-administration, serum concentrations level off at 2.6 nM (Hapgood et al., 2018). The 
time it takes to reach maximum serum concentration (tmax) as well as the maximum serum 
concentration (Cmax) vary greatly (Hapgood et al., 2018). This may reflect differences in the different 
methods used to quantify serum levels of steroids as well as bioavailability (Hapgood et al., 2018). It 
has also been determined that peak serum concentrations of NET range between 10 nM and 50 nM, 
whereas those of LNG-IUD range between 0.2 and 2.4 nM, although higher concentrations have been 
reported for LNG implants and LNG in COC (Hapgood et al., 2018). 
 
The biological effects of DMPA-IM are most probably observable at peak serum concentrations. This 
could explain why studies in which biological samples obtained from women just before the next 
DMPA-IM injection often reported that DMPA-IM had no effect of on the parameters being 
investigated. For example, the average serum concentration of DMPA-IM reported in two studies that 
investigated its effects on human vaginal epithelial thickness was 2.59 nM (Bahamondes et al., 2000; 
Bahamondes et al., 2014). Because the effects of DMPA on vaginal epithelial thickness in monkeys 
are dose-and time-dependent (Radzio et al., 2014; Butler et al., 2016), it is possible that significant 
changes in this parameter can only be observed at peak serum concentrations. In macaques, 
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significant changes in vaginal epithelial thickness have been found to occur within two weeks after 
MPA administration and are sustained for an additional 7 weeks before the effect is lost (Radzio et 
al., 2014). This suggests that the effects of MPA on vaginal epithelial thickness are transient and can 
be observed only at specific time points corresponding to time of peak serum concentration. While 
tissue biopsies are obtained from macaques between injections, in humans they are obtained just 
before the next MPA shot is administered (Mauck et al., 1999; Kuhn et al., 1999; Bahamondes et al., 
2000; Chandra et al., 2013; Bahamondes et al., 2014; Mitchell et al., 2014; Radzio et al., 2014; Butler 
et al., 2016). This raises the question whether MPA-induced thinning of the human vaginal epithelium 
can be observed if tissue sampling is done around the time peak serum concentrations are reached 
in humans. Until this is done, the effects of MPA on the thickness of human FGT mucosal epithelia 
will remain elusive. Thus, it remains unclear whether this is one of the mechanisms by which MPA 
enhances the risk of HIV-1 acquisition in women. Nonetheless, in vitro studies have shown MPA can 
affect HIV-1 transcytosis and/or infection at physiological concentrations: 1 nM (Ferreira et al., 2015a), 
7.79 pM to 12.93 nM (Sampah et al., 2015) and 10 nM to 100 nM (Maritz et al., 2018).  
 
In summary, there are wide variations in peak serum concentrations of the different progestogen-only 
hormonal contraceptives. Biological effects of the different progestogen are most likely to be observed 
at the time peak serum concentrations are attained. However, this may be different in different 
individuals.     
 
1.4: Glucocorticoids and the glucocorticoid receptor 
Glucocorticoids (GCs) bind to and activate the   glucocorticoid receptor (GR). Hydrocortisone (CORT) 
is the natural GCs in humans. Several synthetic GCs also exist including prednisolone, 
dexamethasone (DEX), budesonide (Bud), fluticasone propionate (FP), etc (Barnes, 2014). 
Endogenous GCs are steroid hormones produced by the adrenal cortex under the influence of the 
hypothalamus-pituitary-adrenal (HPA) axis in response to stress (Zhou & Cidlowski, 2005). The HPA 
axis is activated by invading pathogens or stress to release GCs that resolve inflammatory responses 
associated with the inducing stimuli. Consequently, both natural and synthetic GCs are used widely 
to treat inflammatory and autoimmune diseases (Hapgood et al., 2016). However, GCs show 
substantial variations in their biological effects with synthetic GCs being more potent that natural GCs 
(Meikle & Tyler, 1977; Langhoff & Ladefoged, 1983).  
 
Through alternative splicing, the human GR gene encodes several isoforms with the main ones, by 
relative abundance, being GRα, GRβ and GRᵞ (Zhou & Cidlowski, 2005; Cian & Cidlowski, 2017; 
Rivers et al., 2009; Morgan et al., 2016). More isoforms are generated through alternative start codon 
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usage (Lu & Cidlowski, 2005; Zhou & Cidlowski, 2005; Nicolaides et al., 2010; Nicolaides et al., 2014). 
However, GRα is the transcriptionally active isoform and will be referred to as the GR (Oakley & 
Cidlowski, 2013; Vandevyver et al., 2014). Structurally, the GR is a modular protein made up of four 
distinct domains; an N-terminal domain (NTD), a deoxyribonucleic acid (DNA)-binding domain (DBD), 
a hinge region and a C-terminal ligand-binding domain (LBD) (Oakley & Cidlowski, 2013; Cruz-Topete 
& Cidlowski, 2015). The NTD contains a transcriptional activation function 1 (AF-1) domain that is 
required for basal as well as maximal transcriptional activity in the presence of GCs (Kumar & 
Thompson, 2005; Heitzer et al., 2007). In addition, the NTD recruits co-regulators and is subject to 
site-specific phosphorylation - both events can occur in the absence or presence of GCs (Godowski 
et al., 1987; Faus & Haendler, 2006; Verhoog et al., 2009; Hapgood et al., 2016). The DBD contains 
two zinc-finger motifs that bind to specific DNA sequences called glucocorticoid response elements 
(GREs) in the promoter or enhancer regions of target genes (Freedman et al., 1988; Dahlman-Wright 
et al., 1991). The DBD and LBD are separated by a hinge region which allows the receptor to change 
conformation (Picard & Yamamoto, 1987). In addition, the hinge contains a nuclear localisation signal 
and is required for receptor dimerization (Picard & Yamamoto, 1987; Bledsoe et al., 2002). The LBD 
on its part contains a hydrophobic ligand-binding pocket, a second nuclear localisation signal and a 
transcriptional activation function 2 (AF-2) domain. The AF-2 region recruits co-regulator in a ligand-
dependent manner (Oakley & Cidlowski, 2013; Cruz-Topete & Cidlowski, 2015). 
 
1.4.1:  Classic GR signaling pathway (genomic effects)  
In the absence of ligands, the GR is sequestered in the cytoplasm as part of a multi-protein complex 
(Pratt et al., 2004; Baschant & Tuckermann, 2010). This complex comprising heat-shock proteins and 
immunophilins keeps the GR in an inactive conformation, but one that allows it to recognise and bind 
GCs. Ligand binding causes the GR to become phosphorylated at specific serine residues namely 
Ser-203, Ser-211 and Ser-226 (Beck et al., 2009; Avenant et al., 2010a; Avenant et al., 2010b). It 
also induces a conformational change GR that allows the GR to dissociate from the complex and 
translocate to the nucleus where it regulates gene expression. The liganded GR, acting via its LBD, 
recognises and binds to GREs in the promoter regions of target genes and activates their expression 
(Meijsing et al., 2009). This process is known as transactivation and results in the expression of 
multiple genes including those involved in inflammation (Chinenov et al., 2013; Hapgood et al., 2016; 
Cain & Cidlowski, 2017), maintaining mucosal barrier function (Felinski & Antonetti, 2005) and 
metabolism (Garabedian et al., 2017). On the contrary, gene expression is inhibited by a mechanism 
known as transrepression. This can involve the liganded GR tethering other transcription factors 
namely nuclear factor kappa beta (NFκB), activator protein (AP)-1 or signal transducer and activator 
of transcription (STAT) and inhibiting the transcriptions of genes activated by these transcription 
factors (De Bosscher & Haegeman, 2009; Langlais et al., 2012; Ratman et al., 2013). This interaction 
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may sometimes occur in the cytoplasm and result in the sequestration of NFκB subunits by the GR 
(Widen et al., 2003). The liganded GR can also interact through composite binding with other 
transcription factors. Such interactions may inhibit or activate gene expression depending on the 
transcription factors (Cain & Cidlowski, 2015; Cruz-Topete & Cidlowski, 2015). Alternatively, the 
liganded GR may bind to negative GREs (nGREs) or GRE half-sites in the promoter of target genes 
to inhibit their expression (Surjit et al., 2011; Schiller et al., 2014). Binding of the liganded GR to GR 
binding sites (GRBS) present in promoter or enhancer regions of target genes remodels the chromatin 
around those regions and makes it more accessible to other transcription factors (Jubb et al., 2017; 
King et al., 2012). In addition, that the presence of other transcription factors in the promoter or 
enhancer regions have been shown to affect GR occupancy (John et al., 2011). For instance, it has 
been reported that, in the absence of GCs, the majority of GRBs are occupied by transcription factors 
such AP-1, CCAAT/Enhancer Binding Protein Beta (C/EBPβ) and Forkhead box A1 (FoxA1) and GR 
recruitment to chromatin in the presence of GCs is reduced when these factors are prevented from 
binding to DNA (Grøntved et al., 2013; Belikov et al., 2009; Biddie et al., 2012). This suggest that 
these factors direct the recruitment of the GR to target genes and by so doing modulate the responses 
mediated by the GR in the presence of GCs.   
 
The GR is largely a ligand-activated transcription factor, but it has been found to be transcriptionally 
active in the absence of GCs (Kotitschke et al., 2009; Verhoog et al., 2011; Hapgood et al., 2016). 
Some studies have demonstrated that knocking down or over-expressing the GR results in changes 
in basal gene expression (Verhoog et al., 2009; Ritter et al., 2012; Robertson et al., 2013a; Robertson 
et al., 2013b; Ritter et al., 2014). In addition, stimuli such as TNF, gonadotropin-releasing hormone 
(GnRH) and the cell-cycle have been shown to phosphorylate the unliganded GR at Ser-206, Ser-
211 and Ser-226, thereby increasing its basal transcriptional activity (Kotitschke et al., 2009; Verhoog 
et al., 2011; Matthews et al., 2015). This might sensitise the unliganded GR for subsequent GC-
dependent activation (Hapgood et al., 2016). For example, one study found that in the absence of 
GCs Interleukin (IL)13 increases phosphorylation of the GR at Ser-203 and Ser-211 and nuclear 
translocation without evoking DNA binding and transcription (Hu et al., 2013). In the presence of GCs, 
Hu and colleagues showed that these initial events prompted by IL13 are augmented as well as DNA 
binding (Hu et al., 2013). On the other hand, some non-GC stimuli cannot modify the unliganded GR 
on their own. However, they can enhance GC-induced modification of the GR by activating other 
signalling pathways such as mitogen activated protein kinases (MAPKs) that enhance the GC-induced 
effects. Such is the case with tissue growth factor β (TGFβ) which has been shown to augment DEX-
induced phosphorylation of the GR at Ser-211, and hence upregulated the expression of plasmogen 
activator inhibitor 1 in human ovarian epithelial cells (Pan et al., 2015). On the other hand, some non-
GC stimuli may desensitise and make the unliganded GR less responsive to GC-dependent 
activation. Pro-inflammatory cytokines such as TNF, IL1α and IL1β have been shown to reduce GC-
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binding, nuclear translocation and DNA-binding abilities of unliganded GR (Pariante et al., 1999; 
Wang et al., 2005; Escoll et al., 2015). Furthermore, GC-independent cleavage of the unliganded GR 
by caspase-1 or the GC-independent phosphorylation of the GR at Ser-134 have been shown to 
reduce GC-mediated transcription by the GR (Galliher-Beckley et al., 2011; Paugh et al., 2015). Taken 
together, these observations suggest that the microenvironment in which the GR operates determine 
the outcome of the responses mediated by the receptor.  
 
1.4.2: Non-classical GR signalling pathway (non-genomic effects) 
The above mechanisms constitute the genomic effects of GCs. However, several GC-induced effects 
are rapid, do not require the GR to bind to DNA or TFs and cannot be prevented by inhibitors of 
transcription or protein synthesis (Sanden et al., 2000; Buttgereit & Scheffold, 2002; Buttgereit et al., 
1998; Pérez et al., 2013; Liu et al., 2005). These are termed non-genomic effects. Non-genomic 
effects are induced by GC doses higher than 1 µM, but doses as low as 1 nM have been found to 
induce non-genomic effects as well (Urbach et al., 2002).  It has been suggested that higher GC 
doses elicit very rapid non-specific effects that occurs within seconds, whereas lower doses elicit 
specific non-genomic effects that occur within minutes (Buttgereit et al., 2002). A membrane-bound 
GR (mGR) that is structurally different from cytosolic GR (cGR) mediates non-genomic effects of GCs 
(Pérez et al., 2013; Mitre-Aguilar et al., 2015). However, the latter has also been localised in the 
plasma membrane (Oppong et al., 2014) and mitochondrial membrane (Sionov et al., 2006). This 
suggests that non-genomic effects can also be mediated by cytosolic GR. Unlike mGR, non-genomic 
effects mediated by cytosolic GR are sensitive to RU486 and GR siRNA (Kotitschke et al., 2009). 
 
1.4.3: Anti-inflammatory effects mediated by the GR 
Glucocorticoids substantially inhibit the expression and action of several pro-inflammatory cytokines 
and chemokines (Mukaida et al., 1994; Meduri et al., 2002; de Kruif et al., 2008; Abou-Raya et al., 
2014; Leigh et al., 2016; Dantas et al., 2017). The liganded GR inhibits the expression of many 
inflammatory mediators through its interactions with transcription factors such as NFκB and AP-1 
(Mukaida et al., 1994; De Bosscher & Haegeman, 2009; Langlais et al., 2012; Ratman et al., 2013). 
Alternatively, GCs acting via the GR have been shown to reduce the stability of pro-inflammatory 
mRNAs (Lee et al., 1988; Amano et al., 1993). The mechanisms involved include the liganded GR 
binding to the 5’-untranslated regions of messenger ribonucleic acid (mRNA) transcripts and initiating 
their decay (Ishmael et al., 2011). Chemokines regulated this way include CCL2 and CCL7. In 
addition, GCs have been shown to induce the expression of the mRNA destabilising protein 
tristetraprolin (TTP), which recognises specific transcripts through adenylated/uridylated rich 
elements (AREs) in the 3’ untranslated region (Ishmael et al., 2008; Smoak & Cidlowski, 2006; 
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Stojadinovic et al., 2007). Inflammatory mediators targeted by TTP include CCL2, CCL20, IL6, TNF, 
IL1α and IL1β (Brooks & Blackshear, 2013; Patial et al., 2016). Another mechanism by which GCs 
suppress inflammation is by inducing the expression of anti-inflammatory genes such as 
glucocorticoid-induced leucine zipper (GILZ), inhibitor of NFκB (IκBα), mitogen-activated protein 
kinase phosphatase (MKP)-1, interleukin-1 receptor-associated kinase-M (IRAK-M) and TNF Alpha 
Induced Protein 3 (TNFAIP3) to control inflammation (Govender et al., 2014; Kassel et al., 2001; 
Vandevyver et al., 2012; Altonsy et al., 2014; Newton et al., 2017; Miyata et al., 2015). Activation and 
transcriptional activities of NFκB and AP-1 is triggered by mitogen-activated protein (MAP) kinases 
namely p38, extracellular signal-regulated kinase (ERK)1/2 and c-Jun N-terminal kinase (JNK). IκBα 
like GILZ and TNFAIP3 have been reported to antagonise NFκB and AP-1 thereby inhibiting 
inflammatory responses mediated by these transcription factors (Ronchetti et al., 2015; Ayroldi & 
Riccardi, 2009). Furthermore, GC-induced MKP-1 expression and activity has been reported to 
abrogate NFκB and AP-1 activation by inactivating MAP kinases (Kassel et al., 2001; Vandevyver et 
al., 2012; Lasa et al., 2002). IRAK-M is a negative regulator of myeloid differentiation factor 88 
(MyD88), which is a critical downstream adaptor molecule of all TLRs, except TLR3. It has recently 
been reported that GC-induced expression of IRAK-M attenuates TLR-mediated expression of pro-
inflammatory immune mediators in murine macrophages (Miyata et al., 2015). 
 
1.4.4:  Pro-inflammatory effects mediated by the GR 
While they are mostly anti-inflammatory, GCs may also promote pro-inflammatory immune responses 
in some cell types by enhancing the expression of select pro-inflammatory genes (Sorrells & Sapolsky, 
2007; Bellavance & Rivest, 2014; Cruz-Topete & Cidlowski, 2014; Duque Ede & Munhoz, 2016). The 
context under which this occurs is not well established. Some studies have shown that cells pre-
treated with the GCs and thereafter stimulated with specific immune activators express more pro-
inflammatory cytokine and chemokines compared to controls (Homma et al., 2004; Busillo et al., 2011; 
Yeager et al., 2009; Loram et al., 2011; Munhoz et al., 2010; Barber et al., 1993; Smyth et al., 2004; 
Zhang et al., 2017; van de Garde et al., 2014). This suggested that some cells are primed by GCs to 
respond more robustly to specific immune activators. In fact, it has been reported that GCs induce 
the expression of innate immune receptors such as nod-like receptor family, pyrin domain containing 
(NLRP)1, NLRP3, TLR2 and TLR4 in some cell types, which makes them more sensitive to specific 
immune activators (Sakai et al., 2004; Homma et al., 2004; Pace et al., 2015; Su et al., 2017; Busillo 
et al., 2011; Zhang et al., 2017). However, in some cell types, concurrent treatment with GCs and 
immune activators resulted in the upregulation of CCL20 (Zijlstra et al., 2014). This suggest that 
mechanisms other than priming are involved in GC-induced expression of pro-inflammatory genes.  
Some authors have proposed that low doses of GCs are pro-inflammatory, whereas high doses are 
anti-inflammatory (Sorrells & Sapolsky, 2007). This view is supported by evidence from a study that 
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showed CORT at 27.59 mM, but not 275.9 mM enhanced basal and LPS-induced expression of TLR2, 
TLR4, IL6 and IL8 in human corneal epithelial cells (Xie et al., 2011). In addition, hydrocortisones 
doses between 0.01 pM and 100 pM, but not doses between 0.01 µM and 1 µM have been found to 
induce the expression of macrophage migration inhibitory factor (MIF) in murine RAW 264.7 
(Calandra et al., 1995). However, some studies suggest that 1 nM DEX can enhance TNF-induced 
expression of CCL20 in human airways epithelial cells, whereas at the same dose DEX represses 
nontypeable Haemophilus influenzae-induced expression of pro-inflammatory cytokines in human 
primary macrophages. This suggest that the effects of GC dose on the expression of pro-inflammatory 
gene expression are gene- as well as cell-specific.   
 
The molecular mechanisms by which GCs upregulate the expression of pro-inflammatory genes are 
not well understood. It has been demonstrated that genes such as TLR2 and CCL20 have GREs in 
their promoter or enhancer regions (Hermoso et al., 2004; Wang et al., 2004). This suggests that they 
can be transactivated by the liganded GR. However, other genes including CCL2, CCL7, IL8, IL1B 
and CCL8 have not been reported to contain GREs and the GR transactivates these genes by 
interacting with other transcription factors. Even for genes with known GREs, the GR has been found 
to interact with other TFs to regulate gene expression. For instance, the GR has been reported to 
interact with the GRE, STAT and NFκB binding sites in the TRL2 minimal promoter (Hermoso et al., 
2004). Hermoso and colleagues found that DEX on its own could neither transactivate the minimal 
nor a full-length promoter that contained two more GREs (Hermoso et al., 2004). CCL20 has been 
reported to contain a GRE site that is located +4000 kb from the transcription start site (Wang et al., 
2004). In addition, its minimal promoter has been found to contain NFκB, AP-1, C/EBPβ and STAT 
binding elements (Miao et al., 2012). It remains unknown whether the GR interacts with these sites to 
upregulate basal-, TNF- or LPS-induced CCL20 expression.  
 
1.4.5: Synergistic interactions between glucocorticoids and immune activators affects gene 
expression and HIV-1 infection 
GCs can crosstalk and modulate signalling pathways activated by immune activators (Adcock & 
Caramori, 2001; Van Bogaert et al., 2010; Arango-Lievano & Jeanneteau, 2016). Conversely, several 
immune activators can modulate and influence the activity of the GR. While GCs and immune 
activators are mostly antagonistic towards each other, evidence in the literature suggest that they can 
coregulate gene expression in a synergistic manner (Imasato et al., 2002; Shuto et al., 2002; Sakai 
et al., 2004; Homma et al., 2004; Shibata et al, 2009; Lannan et al., 2012; Miyata et al., 2015; Altonsy 
et al., 2014). 
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Synergism involves two ligands inducing a response that is larger than the sum of the individual 
responses induced by each ligand. When one ligand does not induce a response but causes an 
increase in the response elicited by another, the effect is termed potentiation or enhancement (Chou, 
2010). Immune activators have been reported to induce the expression of anti-inflammatory genes 
such as TNFAIP3 (A20) and MKP-1 to control inflammatory responses (Boone et al., 2004; Altonsy 
et al., 2014; Zhang et al., 2012; Talavera et al., 2015). GCs, in some cell types, have been reported 
to synergise with immune activators to upregulate the expression of these genes. For example, DEX 
has been found to synergise with NTHi to upregulate the expression of IRAK-M in murine as well as 
human primary macrophages, via a mechanism that required the GR and p65 (Miyata et al., 2015). 
Similarly, DEX has been reported to synergise with LPS to upregulate (sphingosine kinase) SphK1 
expression in murine macrophages, requiring the GR and p38-activated mitogen- and stress-activated 
protein kinase-1 in the process (Vettorazzi et al., 2015). It has also been reported that DEX and LPS 
synergise to upregulate MKP-1 expression in murine cardiomyocytes to inhibit p38-dependent 
expression of TNF (Zhang et al., 2012). Collectively, these examples constitute negative feedback 
mechanisms that most likely control inflammatory responses to protect against tissue damage from 
excessive inflammation (Ruland, 2011).  
 
Alternatively, synergistic interactions between GCs and immune activators may also result in the 
upregulation of pro-inflammatory genes (Lannan et al., 2012). Several studies have reported that GCs 
can synergise with TNF, IL1β or NTHi to upregulate TLR2 expression in human airways epithelial 
cells, endocervical epithelial cells and keratinocytes (Homma et al., 2004; Shuto et al., 2002; Imasato 
et al., 2004; Sakai et al., 2004; Shibata et al., 2009; Hermoso et al., 2004). This occurs via a 
mechanism involving the GR, p65, STAT and MPK-1-dependent inactivation of p38 and JNK 
(Hermoso et al., 2004; Sakai et al., 2004; Shibata et al., 2009; Imasato et al., 2004). Homma and 
colleagues additionally showed that airways epithelial cells concurrently pre-treated with DEX and 
TNF and thereafter stimulated with TLR2-ligands secreted more pro-inflammatory immune mediators 
than control cells (Homma et al., 2004). This suggests that GCs and immune activators can prime 
and sensitise airways epithelial cells towards specific immune responses. It has also been reported 
that FP synergises with LPS to upregulate CCL2, CCL7, CCL8 and CCL20 expression in monocyte-
derived macrophages (van de Garde et al., 2014). One study found that the GR and ADAM (A 
Disintegrin And Metalloproteinase Domain)-7 were involved in the synergistic upregulation of CCL20 
expression by Bud and TNF in human bronchial epithelial cells (Zijlstra et al., 2014). Taken together, 
these observations suggest that the GR can interact with other signalling pathways in a context-
specific manner to upregulate the expression of select pro-inflammatory genes. Therefore, synergism 
between GCs and immune activators may exacerbate specific inflammatory responses.  
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It has also been reported that CORT synergises with IL7 to increase the proliferation and survival of 
activated systemic CD4+ T cells (Cima et al., 2006). Because activated CD4+T cells are vulnerable to 
HIV-1 infection, this suggests that GCs acting via the GR may enhance the risk of HIV-1 infection in 
the presence of specific immune activators. Interestingly, it has been reported that GCs synergistically 
interact with TNF or IL6 to upregulate HIV-1 replication in a chronically infected cell line (Kinter et al., 
2001; Bressler et al., 1997). Moreover, it has been reported that DEX enhances HIV-1 infection and 
replication in CD4+ T cells (Huijbregts et al., 2013). However, it remains unclear whether this effect is 
via the GR, and whether GCs acting via the GR and immune activators can synergise to increase de 
novo HIV-1 infection in target cells.  
 
1.4.6:  The GR and select synthetic progestins 
MPA, unlike NET and LNG, binds to the GR with a relatively high affinity similar or greater to that of 
CORT and can activate the receptor (Stanczyk et al., 2013; Bamberger et al., 1999; Koubovec et al., 
2004; Ronacher et al., 2009; Hadley et al., 2011; Hapgood et al., 2013). It has been reported that 
MPA is a partial to full GR agonist for transactivation and transrepression (Ronacher et al., 2009). 
Moreover, MPA has been shown to induce the phosphorylation of the GR at Ser-211 and Ser-226, 
resulting in enhanced GR nuclear translocation and turnover (Avenant et al., 2010a; Hadley et al., 
2011). NET and LNG, on the other hand, have no partial or full GR agonist activity (Stanczyk et al., 
2013; Ronacher et al., 2009; Hapgood et al., 2018). Taken together, these reports show that MPA, 
NET and LNG differentially regulate gene expression via the GR.  
 
1.4.6.1: The influence of MPA, NET and LNG on FGT and systemic inflammation  
Evidence from in vitro studies shows that MPA is pre-dominantly anti-inflammatory and suppresses 
the expression of pro-inflammatory cytokines and chemokines in the FGT and blood (Govender et al., 
2014; Huijbregts et al., 2013; Mantovani et al., 1997; Huijbregts et al., 2013; Huijbregts et al., 2014; 
Hapgood et al., 2014b; Kleynhans et al., 2011). These findings corroborate results from a single 
clinical study that showed DMPA-IM suppressed IL8 and IL6 protein levels in the FGT (Roxby et al., 
2016). It has been reported that the in vitro immunosuppressive and anti-inflammatory effects of MPA 
are mediated by the GR (Govender et al., 2014; Hapgood et al., 2014a; Koubovec et al., 2005). This 
suggests that MPA acting via the GR might reduce the ability of the immune system in the FGT and 
blood to protect against HIV-1 infection.  
 
However, there also exist evidence suggesting that MPA is pro-inflammatory i.e. it can induce or 
enhance the expression of select pro-inflammatory genes in the FGT (Louw du Toit et al., 2014; 
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Francis et al., 2016; Deese et al., 2016; Quispe-Calla et al., 2016; Irvin & Herold, 2015; Zheng et al., 
2012; Woods et al., 2018). In addition, some studies have shown that MPA can selectively induce or 
enhance the expression of some pro-inflammatory genes, while at the same time repressing others 
(Ferreira et al., 2015a; Cordeaux et al., 2010; Goldfien et al., 2015; Smith-McCune et al., 2017; 
Africander et al., 2011; Goode et al., 2014; Kleynhans et al., 2013; Fichorova et al., 2015; Morrison 
et al., 2014). By selectively upregulating pro-inflammatory immune mediators, MPA may create an 
immune microenvironment that is conducive to specific HIV-1 target recruitment (Woods et al., 2018; 
Deese et al., 2016). 
 
Results from clinical study suggests that LNG-IUD increases the levels of pro-inflammatory immune 
mediators in the FGT (Shanmugasundaram et al., 2016). Similarly, endometrial tissue biopsies from 
women using LNG-IU have been found to express more pro-inflammatory genes compared to controls 
(Goldfien et al., 2015). These findings suggest that LNG-IUD induces a pro-inflammatory response in 
the FGT. However, evidence from in vitro studies show that LNG does not regulate cytokine 
expression by activated systemic mononuclear and pDC cells and ectocervical tissue explants 
(Huijbregts et al., 2014; Ray, 2015). This suggests that the effects of LNG are compartment specific.  
 
Unlike MPA and LNG, evidence from some in vitro studies show that NET does not regulate the 
expression of pro-inflammatory immune mediators in epithelial cells from the FGT (Govender et al., 
2014; Africander et al., 2011) and in PBMCs (Hapgood et al., 2014a; Tomasicchio et al., 2013; Maritz 
et al., 2018). Conversely, others have shown that NET suppresses TNF-induced expression of pro-
inflammatory immune mediators in endometriotic stromal cells in vitro (Grandi et al., 2016). This 
suggests that the effects of NET on gene expression are cell-specific and if there is an effect it likely 
to be anti-inflammatory. However, findings from a recent clinical study show that women using NET-
EN have high levels of select pro-inflammatory immune mediators in the FGT but is less pro-
inflammatory than DMPA-IM (Deese et al., 2016). This suggests NET-EN might be pro-inflammatory 
to some extent, but more studies are needed to confirm this observation.   
 
Given the contradictory data for DMPA-IM, and paucity of data for NET-EN and LNG, it is possible 
that their effects on immune function in FGT and blood in women may be confounded by intrinsic 
confounding factors and differences in study design. Therefore, more careful head to head clinical 
studies are needed.  
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1.4.6.2: The role of specific pro-inflammatory immune mediators in HIV-1 infection and their 
regulation by MPA    
1.4.6.2.1: CCL20/CCR6 Axis 
One of the main functions of CCL20 is to direct the migration of CCR6+ immune cells to the site of 
inflammation. CCR6 is the sole receptor for CCL20 and is expressed on a variety of immune cells 
notably Th17 cells, macrophages, Langerhans cells and neutrophils (Acosta-Rodriguez et al., 2007; 
Annunziato et al., 2007; Gosselin et al., 2010; Greaves et al., 1997; Liao et al., 1999; Lee & Körner, 
2017). Systemic CCR6+CD4+ T cells have been shown to be more permissive to HIV-1 infection than 
CCR6-CD4+ T cells (Gosselin et al., 2010). In addition, it has been reported that CCR6+CD4+ T cells, 
which constitute HIV-1 latent reservoirs, are mostly central memory cells of Th17 or Th1Th17 
phenotype (Gosselin et al., 2017). Besides expressing CCR6, central memory Th17 cells also express 
α4β7 and CXCR4, but not CCR5 (Alvarez et al., 2013; Gosselin et al., 2017). The majority of CD4+ T 
cells in FGT mucosal tissues are effector memory cells, but populations of naïve and central memory 
T cells have also been identified (Smith-McCune et al., 2017). It has recently been found that Th17 
cells are present in the FGT and like systemic Th17 cell genital Th17 cells are also more permissive 
to HIV-1 infection than non-Th17 cells (Rodriguez-Garcia et al., 2014). Furthermore, it has been 
reported that SIV preferentially infects genital Th17 than non-Th17 cells (Stieh et al., 2016). Thus, the 
infiltration of Th17 or other CCR6+ cells in the FGT could substantially elevate the risk of HIV-1 
acquisition in women. 
 
Besides trafficking of immune cells, CCL20 may also regulate events in HIV-1 infection within target 
cells.  It has been reported that CCL20 enhances latent HIV-1 infection in resting CD4+ T cells and 
may thus contribute to the dissemination of infected cells from the site of infection (Cameron et al., 
2010; Gosselin et al., 2010). In fact, evidence from some studies show that CCL20 inhibits production 
of new virus particles in the FGT of HIV-1 positive women (Mauck et al., 2016). In addition, it has been 
reported that CCL20 suppresses HIV-1 replication in CD4+ T cells (Lafferty et al., 2010) and in TZM-
bl cells (Ghosh et al., 2010). The mechanism involves CCL20 inducing the expression of 
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G), an enzyme that 
prevents the accumulation of HIV-1 transcripts in the cytoplasm of infected cells (Lafferty et al., 2010).   
Taken together, this suggests that CCL20 facilitates HIV-1 entry and integration into target cells but 
does allow new viruses to be made by creating a microenvironment that degrades nascent HIV-1 
mRNA transcripts.  
 
It has recently been reported that that MPA at 1 nM increases CCL20 mRNA levels in primary genital 
epithelial cells (Woods et al., 2018). This result suggests that MPA-induced expression of CCL20 
 
25 
 
might be involved in the trafficking of CCR6+CD4+ T cells that are very permissive to HIV-1 infection 
in the FGT. In addition, this finding suggests that these cells might become latently infected in an 
MPA-induced CCL20-rich microenvironment. However, evidence from clinical studies show that 
DMPA-IM use does not alter CCL20 protein levels in genital secretions obtained by cervical wicks   
from women irrespective of GTI status (Morrison et al., 2014; Fichorova et al., 2015). While this effect 
might be compartment specific, this nonetheless suggests that there might be differences in the way 
MPA regulates CCL20 mRNA and protein levels in the FGT. Thus, it remains unclear how MPA 
regulates CCL20 expression in the FGT.  
 
1.4.6.2.2: CCL5/ CCR5 Axis 
There has been an interest in determining whether MPA regulates CCL5 and CCR5 expression in 
HIV-1 target cells and in the FGT.  Findings from some clinical studies show that women using DMPA-
IM have high levels of CCL5 protein in the FGT (Fichorova et al., 2015; Morrison et al., 2014; Deese 
et al., 2016). In addition, MPA has been shown to enhance CCL5 expression in PGECs in the 
presence of HIV-1 (Ferreira et al., 2015a), in vaginal epithelial Vk2/E6E7 cells at suprapharmalogical 
doses (Irvin & Herold, 2015) or in vaginal mucosal tissues from mice infected with HSV-2 (Zheng et 
al., 2012). CCL5 is one of the natural ligands of CCR5 co-receptor for HIV-1 entry into target cells, 
the others being CCL2 and CCL4 (Gross et al., 2003; Secchi et al., 2012). This implies that high levels 
of CCL5 in the FGT may protect against HIV-1 infection (Hirbod et al., 2006; Novak et al., 2007). 
Conversely, because CCL5 is a chemoattractant, increases in its expression might result in the 
infiltration of CCR5 expressing cells in the FGT (Iqbal et al., 2005; Kaul et al., 2008). In this scenario, 
the likelihood of infection occurring will depend on the ratio of CCR5 to CCL5. 
 
However, there exists evidence from in vitro studies that MPA suppresses CCL5 expression in 
epithelial cells from the FGT (Govender et al., 2014; Africander et al., 2011) and in PBMCs (Hapgood 
et al., 2014a; Ray, 2015). This suggests that MPA reduces the ability of HIV-1 target cells in the FGT 
or blood to protect themselves or neighbouring cells against infection (Alvarez et al., 2013). This might 
render the FGT or blood more vulnerable to HIV-1 infection. This also suggests that MPA might 
prevent the recruitment of CCR5 expressing cells in the FGT. Results from a recent in vitro study 
showed that MPA increases the expression of CCR5 on CD4+ T cells from blood (Maritz et al., 2018). 
Furthermore, the Hapgood group has found evidence that MPA increases CCR5+ expression in 
ectocervical tissue explants (Ray et al., manuscript under review). Thus, MPA might be involved in 
recruiting new CCR5+ cells to the FGT, but it may change the density of CCR5 on target cells already 
present in the FGT.  
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Taken together, these findings suggest that MPA enhances the expression of CCR5 on CD4+ T cells. 
In contrast, the effects of MPA on CCL5 expression remains controversial. However, it is very likely 
that the effects are heterogeneous as well as cell-, tissue or subject-specific. 
 
1.4.6.2.3: IL8, IL1β and IL6  
It has been reported that IL1β and IL6 increase HIV-1 replication in chronically infected cells in vitro, 
with IL6 synergising with IL1β or TNF (Poli et al., 1990; Poli et al., 1994; Granowitz et al., 1995; 
Rollenhagen & Asin, 2011; Irvin & Herold, 2015). IL8 like CCL5 and CCL20 is a chemoattractant that 
induces the migration of HIV-1 target cells (Chuntharapai et al., 1994; Appay & Rowland-Jones, 2001; 
Stanford & Issekutz, 2003; Takata et al., 2004). In addition, IL8 has been found to regulate viral 
replication in cells or tissues infected with HIV-1 (Lane et al., 2001; Rollenhagen & Asin, 2010). 
Furthermore, it has been suggested that IL8, like IL1 and IL6, helps to spread HIV-1 in mucosal tissues 
following infection (Guha & Ayyavoo, 2013). Thus, regulating the expression of these immune 
mediators in the FGT and blood may affect the outcome of HIV-1 infection in these tissues.   
 
Several studies have investigated the effects of MPA on IL6, IL8 and IL1β levels in the FGT and the 
results are conflicting. Some clinical studies have reported that DMPA-IM use increases IL6 protein 
levels in genital secretions (Deese et al., 2015; Francis et al., 2016), whereas others have found the 
opposite effect (Roxby et al., 2016; Smith-McCune et al., 2017). Yet others have reported that DMPA-
IM use does not affect IL6 levels in genital secretions (Morrison et al., 2014; Fichorova et al., 2015) 
as well as in serum (Batista et al., 2017). The variability of the results may indicate inter-individual 
variations as well as differences in study design and methods. However, the majority of animal and in 
vitro studies have shown that MPA suppresses IL6 expression in the simian vaginal swabs (Goode et 
al., 2014), PBMCs (Kleynhans et al., 2011; Hapgood et al., 2014a; Huijbregts et al., 2013), human 
primary endometrial epithelial cells (Ferreira et al., 2015a) and endocervical epithelial End1/E6E7 cell 
line (Govender et al., 2014). However, one in vitro study found MPA at supraphysiological doses 
enhanced IL6 in vaginal epithelial cells (Irvin & Herold, 2015). This suggests that effects of MPA on 
the regulation of IL6 is cell-specific and dose-dependent.   
 
A clinical study recently reported that DMPA-IM use increases IL8 in genital secretions (Deese et al., 
2014). This is consistent with findings from some in vitro studies that MPA induces IL8 expression in 
endometrial epithelial cells (Woods et al., 2018; Ferreira et al., 2015a), vaginal epithelial cells (Irvin & 
Herold, 2015), ectocervical epithelial cells (Africander et al., 2011) and in endometrial stroma cells 
(Arici et al., 1999). In contrast, other clinical studies have reported DMPA-IM use reduces genital IL8 
protein levels over time (Roxby et al., 2016). This has also been demonstrated in some in animal and 
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in vitro studies: simian vaginal swabs (Goode et al., 2014), endocervical epithelial cells (Govender et 
al., 2014), PBMCs (Kleynhans et al., 2011; Hapgood et al., 2014a; Huijbregts et al., 2013) and 
endometrial explants (Kelly et al., 1994).  However, there also is evidence from some clinical studies 
that DMPA-IM does not alter IL8 levels in genital secretions (Smith-McCune et al., 2017; Francis et 
al., 2016; Morrison et al., 2014; Fichorova et al., 2015).  
 
Evidence from a single clinical study showed that DMPA-IM use increased IL1β levels in genital 
secretions (Francis et al., 2016). However, findings from others clinical studies revealed DMPA-IM 
use may (Smith-McCune et al., 2017) or may not reduce IL1β levels in genital secretions (Deese et 
al., 2014; Morrison et al., 2014; Fichorova et al., 2015). It has recently been shown that DMPA 
increases IL1β mRNA expression in murine vagina in vivo, whereas in human it has been reported 
that MPA suppresses IL1β expression in BCG-treated PBMCs in vitro (Kleynhans et al., 2011). 
 
Collectively, evidence from in vitro studies suggests that MPA suppresses IL6, IL8 and IL1β 
expression. However, the in vivo effects of MPA on the expression of these immune mediators in the 
FGT are heterogeneous due to inter-individual variations. Moreover, these effects may be 
compartment–specific and further confounded by factors such as the presence of GTIs, age and 
duration of exposure to MPA.  
 
1.4.7: Epithelial TJs are regulated by GCs and MPA 
It has been reported that DMPA-IM or LNG-IUD use increases the permeability of the ectocervix and 
vagina in women (Tjernlund et al., 2015; Quispe-Calla et al., 2016; Quispe-Call et al., 2017). Similarly, 
DMPA-IM and LNG have been found to increase the permeability of murine ectocervix and vagina, 
acting via the progesterone receptor (PR) (Quispe-Calla et al., 2016; Quispe-Calla et al., 2018). It is 
currently known that MPA and LNG downregulate the expression of specific junctional genes 
(Tjernlund et al., 2015; Quispe-Calla et al., 2016; Quispe-Call et al., 2017; Quispe-Calla et al., 2018). 
However, it remains unclear whether these progestins target the same genes in the different 
compartments of the FGT to increase mucosal permeability. One study found that ectocervical tissue 
biopsies from women using LNG-IUD had reduced ZO-1 mRNA levels compared to controls, whereas 
claudin-1, occludin and E-cadherin mRNA levels remained the same between the groups (Tjernlund 
et al., 2015). In vaginal tissues from women or mice, neither DMPA-IM nor LNG-IUD treatment altered 
ZO-1, claudin-1, occludin and E-cadherin expression levels (Chandra et al., 2013; Quispe-Calla et al., 
2016). On the other hand, desmoglein-1α and desmocollin-1 mRNA levels have been found to be 
reduced in ectocervical tissues from women and in vaginal tissues from mice treated with DMPA-IM 
or LNG (Quispe-Calla et al., 2016; Quispe-Calla et al., 2017; Quispe-Calla et al., 2018). Taken 
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together, this suggests that LNG downregulates both desmosomes and TJs in ectocervical mucosal 
tissues, but only desmosomes in vaginal mucosal tissues. It also suggests MPA downregulates 
desmosomes in ectocervical mucosal tissues, but it remains unclear whether it can regulate TJs in 
this tissue.  
 
Another study reported that MPA like P4 might increase the permeability of primary endometrial and 
endocervical epithelial monolayers in vitro (Ferreira et al., 2015a). However, a recent study found that 
DMPA-IM increases claudin-8 mRNA levels in endometrial mucosal tissues (Goldfien et al., 2015). 
Additionally, MPA has been found to increase claudin-5 mRNA levels in myometrial tissue explants 
(Cordeaux et al., 2010). Because claudin-5 and -8 are sealing TJs, this suggests that MPA might 
increase rather the decrease the barrier functions of the endometrium. Nonetheless, the findings show 
that MPA can regulate the expression of TJ genes in the endometrium. It remains unclear whether 
and how MPA regulates the expression of TJ genes in the endocervix and whether the GR is involved.    
 
It has been reported that GCs acts via the GR to increase the mucosal barrier functions of intestinal, 
mammary and airways epithelial cells (Singer et al., 1994; Boivin et al., 2007; Fischer et al., 2014; 
Kielgast et al., 2016). GCs have been reported to increase the expression of claudin-8 in human 
tracheal epithelial cells (Kielgast et al., 2016), claudin-4 in human colonic Caco-2 epithelial cells 
(Fischer et al., 2014) and ZO-1 in human mammary 31EG4 epithelial cells (Singer et al., 1994). In 
addition, GCs have been shown to transactivate occludin plasmid constructs transiently transfected 
into COS-7 cells (Fӧrster et al., 2005; Felinski et al., 2008). Conversely, GCs have also been reported 
to supress claudin-2 expression in human colonic Caco-2 epithelial cells (Fischer et al., 2014). This 
suggests that GCs inversely regulate sealing and leaky TJs to enhance the barrier functions of 
mucosal tissues. Moreover, there is evidence suggesting that the effects of GCs on mucosal barrier 
function and expression of TJ genes are tissue-specific (Zheng et al., 2013). Recently, it has been 
reported that treating mice exogenously with methylprednisolone did not alter mucosal barrier 
properties of the lower FGT (Quispe-Calla et al., 2016). However, these authors did not investigate 
the serum concentrations of this GC. It remains unknown whether GCs acting via the GR can regulate 
mucosal barrier functions and TJ gene expression in the human FGT, as well as the dose-dependency 
and steroid-specific effects.  
 
Taken together, the finding suggests that MPA increases the mucosal permeability of the lower FGT 
by downregulating desmosomes, but not TJs. However, it remains unclear whether MPA can alter the 
permeability of the endocervix and if it does what junctional genes are targeted.   
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1.5: Hypothesis and Aims 
1.5.1: General hypothesis 
The main hypothesis is that medroxyprogesterone acetate (MPA), like glucocorticoids (GCs), acts via 
the glucocorticoid receptor (GR) to synergise with immune activators to decrease female genital tract 
(FGT) mucosal barrier function via the downregulation of tight junction (TJ) genes and increase the 
expression of select pro-inflammatory cytokines and chemokines in the FGT and blood, thereby 
synergistically increasing HIV-1 infection.  
 
1.5.2: Specific aims 
A. What are the effects of GCs and progestogens on the expression of select TJ and immune 
function genes in an endocervical epithelial cell line?  
B. Do these ligands cooperate with immune activators to regulate this gene expression?  
C. What are the efficacies, potencies and biocharacters of these ligands for gene expression?  
D. Is this gene regulation dependent on the GR? 
E. Does this regulation occur in physiologically relevant primary tissue and primary cells from the 
FGT and blood? 
F. What are the effects of these ligands alone or in combination with immune activators on 
mucosal barrier function and HIV-1 infection? 
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Chapter Two 
 
Materials and Methods 
 
2.1: Ethical Statement 
This thesis was done as part of a larger study investigating whether synthetic progestins enhance 
HIV-1 infection in human cervical tissue explants and PBMCs. Ethical approval for both studies was 
obtained the Human Research Ethics Committee at the University of Cape Town, with reference 
number HREC 210/2011 and HREC 021/2018. Signed informed consents was obtained from 
individuals donating tissue and blood samples used in this study.   
 
2.2: Compounds and antibodies 
The following compounds were obtained from Sigma Aldrich, South Africa: (11β,6α)-9-Fluoro-11,17, 
21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione (dexamethasone, DEX, catalogue #D4902); 4-
Pregnene-3, 20-dione (progesterone, P4, catalogue #P0130); 17α-Ethynyl-17β-hydroxy-19-nor-4-
androsten-3-one (norethindrone, NET, catalogue #N4128); 13β-Ethyl-17α-ethynyl-17β-hydroxygon-
4-en-3-one (levonorgestrel, LNG, catalogue #N2260); 11β-(4-Dimethylamino)-phenyl-17β-hydroxy-
17-(1-propynyl)-estra-4,9-dien-3-one (mifepristone, RU486, catalogue #M8046); 11β,17α,21-
Trihydroxypregn-4-ene-3,20-dione (hydrocortisone, CORT, catalogue #H0888); 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazoliumbromide (MTT, catalogue #M5655); Lipopolysaccharides (LPS, 
E. coli O111:B4, catalogue #L4391). Recombinant human TNF was obtained from Peprotech, United 
States of America (USA, catalogue #300-01A); Bovine serum albumin (BSA, R&D Systems, USA, 
catalogue #DY995. Interleukin 2 (IL2) was obtained from Gentaur, Belgium (catalogue #04RHIL2-08E02). 
Phytohaemoagglutinin (PHA) was obtained from Remel (USA, catalogue #HA16/30852801) 
 
Steroids were made up in absolute ethanol (EtOH). Human TNF was made up in 0.1% (v/v) BSA, 
whereas LPS was made in sterile Milli-Q water. TNF and LPS are referred to in this thesis as immune 
activators. All ligands working stocks were stored at -20°C. MMT was made up in Milli-Q water, filtered 
with a 0.22 µM filter and stored at 4°C.  
 
The following primary antibodies against human GR (H-300; 8992), PR (C-20; sc-539) and GAPDH 
(0411; sc-47724) were obtained from Santa Cruz Biotechnology, United States of America (USA). 
Antibodies against hyaluronic acid (HA, catalogue #12CA5) were obtained from Roche Applied 
Science, South Africa; whereas antibodies against human claudin-4 (3E2C1; catalogue #32-9400), 
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occludin (OC-3F10; catalogue #33-1500) and ZO-1 (ZO1-1A12; catalogue #33-9100) were obtained 
from Invitrogen, Thermo Fisher Scientific, USA. The following horseradish peroxidise-conjugated 
secondary antibodies were obtained from Santa Cruz Biotechnology, USA: anti-mouse (sc-2005) and 
anti-rabbit (sc-2313). Donkey anti-mouse IgG Cy3 conjugated antibody (catalogue #715-166-150) 
was obtained from Jackson ImmunoResearch Laboratories, USA.  
 
2.3: Plasmids 
The pMT-PR-B plasmid encoding human PR-B was a gift from Prof. S. Okret (Karolinska Institute, 
Sweden) and has been described previously (Cairns et al., 1993).  The pcDNA3-hGR plasmid 
encoding human GR was a kind gift from Prof.  D.W.  Ray (University of Manchester, UK) and has 
been described previously (Ray et al.,1999). The pcDNA3 (empty vector, catalogue #A-150228) 
plasmid was obtained from Invitrogen, USA. 
 
2.3.1: Transformation, preparation, purification and restriction enzyme digestion  
Plasmids were transformed into competent E. coli DH5α cells as described previously (Sambrook et 
al., 1989). Briefly, 10 ng plasmid DNA was added to 100 µL competent cells and the mixture incubated 
on ice for 20 minutes, heat-shocked at 42°C for 2 minutes followed by 2 minutes of incubation on ice. 
Thereafter, the mixture was added into 900 µL Luria broth [LB: 1% (w/v) tryptone, 0.5% (w/v) yeast 
extract, 0.5% (w/v) sodium chloride (NaCl)] and incubated at 37°C for 1 hour with shaking. The 
transformed cells were then plated onto LB-agar plates [1% (w/v) tryptone, 0.5% (w/v) yeast extract, 
1% (w/v) NaCl, 1.5% (w/v) agar] containing 100 µg/mL ampicillin and incubated overnight at 37˚C. 
Single colonies were selected and inoculated into 5 mL LB containing 100 µg/mL ampicillin and 
incubated at 37°C for 8 hours with shaking. Overnight cultures were made by adding 200 µL day 
cultures to 200 mL LB containing 100 µg/mL ampicillin and incubated at 37°C with shaking. Plasmid 
DNA was purified using the PureYield™ Plasmid Midi-prep system (Promega, USA, Catalogue 
#A2492) according to manufacturer’s instruction. The yield and purity of the isolated DNA was 
assessed using the NanoDrop ND-100 spectrophotometer (Thermo Fisher, USA). The integrity of the 
plasmid preparation was analysed by restriction enzyme digestion and agarose gel electrophoresis.    
 
2.4: Mammalian tissue culture 
All cell lines were cultured in humidified (90%) 37°C incubators containing 5% CO2 and were regularly 
tested for mycoplasma by means of Hoechst staining and fluorescent microscopy (Freshney, 1987). 
Only mycoplasma negative cells were used. 
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2.4.1: End1/E6E7 cells 
The human endocervical epithelial cell line End1/E6E7 was a kind gift from Prof. R. Fichorova 
(Brigham & Women’s Hospital, Boston, USA) and has been described previously (Fichorova et al., 
1997). They were maintained in 75 cm2 flasks (Greiner Bio-one International, Austria) in  Stemline® 
Keratinocyte Medium II (SKM, Sigma Aldrich, South Africa, Catalogue #s0196) supplemented with 4 
mM L-glutamine (Sigma Aldrich, South Africa, catalogue # G7513), Stemline® Keratinocyte Growth 
supplement (Sigma Aldrich, South Africa, catalogue #S9945), 100 units (U)/mL penicillin  and 100 
µg/mL streptomycin (Sigma Aldrich, South Africa, catalogue #P4333) and 0.5 µg/mL amphotericin B 
(Sigma Aldrich, catalogue # A2942), hence referred to as full SKM. 
  
For TJ gene expression studies, End1/E6E7 cells are seeded at a density of 500,000 cells/mL/well in 
12 well plates (Greiner Bio-One International, Austria) in full SKM and grown for 3 days until confluent. 
Thereafter, the cells were washed once with 1 X PBS and stimulated with 100 nM steroids or vehicle 
[0.1% (v/v) EtOH and 0.0001% (v/v) BSA] in the presence or absence of 1.15 nM TNF in serum-free 
SKM (without Stemline® Keratinocyte Growth supplement) for 24 hours. The cells were harvested in 
Tri-Reagent® (Sigma Aldrich, South Africa, catalogue #T9424) for total RNA isolation or in 50 µL 2 X 
sodium diodecyl sulphate (SDS) sample buffer for Western blotting to verify whether HA-Vpr was 
expressed.  
 
For immune function gene expression studies, End1/E6E7 cells are seeded at a density of 100,000 
cells/mL/well in 12 well plates in full SKM and grown for 2 days. Thereafter, cells were washed once 
with 1 X PBS and stimulated with 100 nM steroids or vehicle [0.1% (v/v) EtOH and 0.0001% (v/v) BSA 
or sterile Milli-Q water] in the presence or absence of 1.15 nM TNF or 5 µg/mL LPS in serum-free 
SKM for 24 hours or at different time points as indicated elsewhere. For some experiments, the cells 
were initially pre-treated with 100 nM DEX, MPA, CORT and NET prior to stimulation with immune 
activators. In others, the cells were treated with 100 nM DEX, MPA, CORT or NET alone or in 
combination 1.15 nM TNF and incubated at different time points. 
 
Dose-responses were performed by treating the End1/E6E7 cells with concentrations of progestogens 
ranging between 10-9 and 10-6 M. For specific experiments, cells were treated with 10-9 to 10-6 M 
concentrations of MPA or CORT in the presence or absence of 1.15 nM. In another experiment (not 
parallel), cells were treated with increasing concentrations of TNF in the absence or presence of 100 
nM MPA or CORT.  
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2.4.2: TZM-bl cells 
The TZM-bl indicator cell line was obtained from the Nation Institute of Health AIDS Reagent Program 
(USA). They were maintained in 75 cm2 flasks in phenol red Dulbecco’s Modified Eagle’s Medium 
(DMEM, Sigma Aldrich, South Africa, catalogue #D5648) supplemented with 1 mM sodium pyruvate 
(Sigma Aldrich, South Africa, catalogue #S8636), 44 mM sodium bicarbonate (Sigma Aldrich, South 
Africa),10% (v/v) foetal calf serum (FCS, Thermo Scientific, South Africa), 100 U/mL penicillin and 
100 µg/mL streptomycin. 
 
2.4.3: COS-1 and HEK293T cells 
The human embryonic kidney cells (HEK293T) and the African green monkey kidney fibroblast (COS-
1) were purchased from America Type Culture Collection (ATCC, USA). They were maintained in 75 
cm2 flasks in phenol red Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma Aldrich, South Africa, 
catalogue #D5648) supplemented with 1 mM sodium pyruvate (Sigma Aldrich, South Africa, catalogue 
#S8636), 44 mM sodium bicarbonate (Sigma Aldrich, South Africa),10% (v/v) foetal calf serum (FCS, 
Thermo Scientific, South Africa), 100 U/mL penicillin and 100  µg/mL streptomycin.   
 
2.4.5: Peripheral blood mononuclear cells 
Blood was obtained from the Western Cape Province Blood Transfusion Services (Cape Town, South 
Africa). It was collected from women donating at the facility. Written informed consent was obtained 
from all donors. PBMCs was isolated from blood using the Histopaque® density gradient centrifugation 
method (Thorsby & Bratlie, 1970). Briefly, 15 mL Histopaque®-1077 reagent (Sigma Aldrich, South 
Africa) was placed in a 50 mL Leucosep tube (Greiner, Germany) and centrifuged in a swing-bucket 
centrifuge (Heraeus Megafuge 40, ThermoScientific, USA) at 2,500 rpm for 1 minute at room 
temperature. Whole blood was diluted 1:3 using a solution containing equal volumes of serum-free 
Roswell Park Memorial Institute medium (RPMI 1640, Lonza, Germany, catalogue #BE12-7012) and 
phosphate buffered saline (PBS, Sigma Aldrich, South Africa). Thirty (30) mL of the diluted blood was 
layered onto Histopaque in the 50 mL Leucosep tube and centrifuged at 2,500 rpm for 15 minutes at 
room temperature without brake. Thereafter, the buffy coat was aspirated using a serological pipette 
and washed twice by spinning at 1,200 rpm for 5 minutes, with each wash requiring 50 mL of PBS 
supplemented with 1% (v/v) charcoal-stripped (c-s) FCS. During the second wash, cell count and 
viability were determined by diluting the PBS-suspended PBMCs 1:10 with trypan blue dye (Lonza, 
Germany) and counting using a haemocytometer. After the second wash, isolated PBMCs were then 
resuspended and maintained in full RPMI 1640 media containing 10% (v/v) c-s FCS, 2 mM L-
glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin at 37℃ with 90% humidity and 5% CO2.  
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For gene expression studies, 2 million cells/mL PBMCs were seeded into 15 mL cell culture tubes in 
full RPMI I640 media and then stimulated with 100 nM steroids or 0.1% (v/v) EtOH (vehicle) in the 
presence or absence of 5 µg/mL LPS for 24 hrs. Thereafter, supernatants were collected for 
downstream applications, cells washed once with 1 x cold PBS by centrifuging at 1,200 rpm for 5 
minutes using a Heraeus Megafuge 40 centrifuge (ThermoScientific, USA)   and then harvested in 
800 µL of Tri-Reagent® 
 
2.4.6: Ectocervical tissue explants 
Ectocervical explants were obtained after informed consent from pre-menopausal women undergoing 
hysterectomy for benign conditions. The women tested negative for HIV-1 and had normal Pap smear; 
however, 100% tested for HSV-1, while 30% tested positive for HSV-2. Samples were collected from 
Groote Schuur and Tygerberg Hospitals in Cape Town and transported in full RMPI 1640 media 
containing 10 U/mL IL2 and 10 µg/mL fungizone (Sigma Aldrich, South Africa) to the Mammalian 
Tissue Culture facility at the Department of Molecular and Cell Biology, University of Cape Town, 
where they were processed within 4 hours after surgery. In brief, the tissue explants were rinsed in 1 
X PBS and a customised stainless-steel punch was used to cut out 3 mm3 tissue pieces.  For gene 
expression studies, the pieces were randomly selected and transferred into round bottomed 96 well 
plate (Greiner Bio-One International, Germany). They were then treated with 100 nM DEX, MPA or 
vehicle containing 0.1% (v/v) EtOH and 0.0001% (v/v) BSA in the presence or absence of 1.15 nM 
TNF made up in full RPMI 1640 media containing 10 U/mL IL2, 100 U/mL penicillin and 10 µg/mL 
fungizone. Each ligand condition was at least done in triplicates. The tissue explants were then 
cultured for 24 hours at 37˚C with 90% humidity and 5% CO2. At the end of the incubation period, 
supernatants were harvested and stored at -80˚C until use. Tissue pieces were harvested in Tri-
Reagent® and stored at -80˚C until use. 
 
2.4.7: Primary genital epithelial cells 
PGECs were isolated from endocervical and endometrial tissue explants obtained from women 
undergoing hysterectomy for benign conditions at McMaster University Medical centre, Hamilton, 
Canada. Informed written consent was obtained in accordance with the approval of the Hamilton 
Health Sciences Research Ethics Board. The protocol for isolation and culture of PGECs has been 
described previously (Kaushic et al., 2011). Briefly, endometrial and endocervical tissues were cut 
into small pieces and digested in an enzyme mixture containing 0.1 mg/mL Hyaluronidase from sheep 
testes (Roche Diagnostics, Germany, catalogue #46254), 3.45 mg/mL pancreatic from porcine 
pancreas (Sigma Aldrich, Canada, catalogue #P3292), 1.5 mg/mL collagenase-D from Clostridium 
histolyticum (Roche Diagnostics, Germany, catalogue #11088882001) and 2 mg/mL D-glucose (EMD 
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Chemicals, USA, catalogue #DX01451) for 30 minutes at 37˚C with shaking. Thereafter, the digested 
tissue was passed through a series of nylon mesh filters of two different pores sizes: 250 µM and 20 
µM (Component Supply Company, USA). The 250 µM filter retains tissue debris and the filtrate is 
passed through the 20 µM filter to separate PGEC sheets from single cell population. The PGEC 
sheets retained on the 20 µM filters were collected into a falcon tube and pelleted by centrifugation 
(Heraeus Megafuge 40, ThermoScientific, USA) at 2,500 rpm for 15 minutes at room temperature 
with no brake. The cells were counted and then resuspended in phenol red-free DMEM/F12 
(Invitrogen, Canada, catalogue #11039021) containing 10 mM HEPES (Invitrogen, Canada, 
Catalogue #15630080), 2.5% Nu serum culture supplement (Becton Dickinson and Co, USA, 
Catalogue #355104), 2.5% Hyclone defined foetal bovine serum (Thermo Scientific, Canada, 
catalogue # SH3053102), 250 µg/mL fungizone (Invitrogen, Canada, catalogue #15290018), 4 mM L-
glutamine (Invitrogen, Canada, catalogue #21051024) and 100 U/mL Penicillin-Streptomycin 
(Invitrogen, Canada, catalogue #P4338), hence referred to as full DMEM/F12.  
 
2.5: Transepithelial electrical resistance (TER) measurements 
TER measurements were used to assess the barrier function of End1/E6E7 cells and PGECs. One 
hundred thousand (100,000) End1E6E7 cells in 300 µL full SKM were seeded onto 0.4 µM pore-size 
polycarbonate Transwell® filters (Becton Dickinson and Co, USA, catalogue #353095) and 500 µL full 
SKM added to the basolateral chamber (see Figure 2.1). Similarly, 100,000 PGECs in 300 µL full 
DMEM/F12 were seeded onto Matrigel-coated (Becton Dickinson and Co, USA, catalogue #356235) 
0.4 µM pore-size polycarbonate Transwell® filters and 500 µL full DMEN/F12 added to the basolateral 
chamber. The cells were then incubated at 37˚C for several days. Growth media in both chambers 
was changed every second day. Before this was done, the cells were allowed to rest at room 
temperature for 5 minutes and TER measurements were then taken using a Millicell ERS-2 
Voltohmmeter with chopstick electrodes (Merck, USA). The chopstick electrodes were sterilised by 
rinsing with 70% ethanol followed by another rinse with sterile PBS. The resistance was calculated by 
subtracting blank resistance from the sample-well resistance. This value was then multiplied by the 
surface area of the filter. Confluency was defined as TER values higher than 1 KΩ/cm2. Confluent 
PGECs monolayers were treated with ligands and subsequently exposed to virus as described in 
section 2.10.3 
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Figure 2.1: Transepithelial electrical resistance measurement with chopstick electrodes. Image 
source: https://ebrary.net/24380/health/measurement_transepithelial_electrical_resistance_teer 
 
2.6: Generation of positive controls for western blotting 
To generate GR and PR positive controls for western blotting, 250,000 COS-1 cells/mL were seeded 
in 6-well plates (Greiner Bio-One International, Austria) in full DMEM [10% FCS, 100 U/mL penicillin 
and 100 µg/mL streptomycin]. Twenty-four (24) hours later, they were transiently transfected with 1 
µg pcDNA3-hGR, pMT-PR-B or empty vector using FuGENETM 6 (Roche Applied Sciences, South 
Africa, catalogue #11814443001) according to manufacturer’s instruction and incubated for another 
24 hours. Thereafter, the cells were harvested in 50 µL 2 X SDS sample buffer, incubated for 10 
minutes at 100°C and stored at -20°C until used. 
 
2.7: GR Knockdown 
End1/E6E7 cells at a density of 500,000 cells/mL in full SKM were seeded in 12-well plates and 
allowed to adhere for 24 hours. Thereafter, the media was changed, and the cells were transfected 
with 10 nM GR5 siRNA (HS_NR3C1_5, Qiagen, USA, catalogue #SI02654757) or non-silencing 
scrambled control (NSC) siRNA (Qiagen, USA, catalogue #1027310) using HiPerfect transfection 
reagent (Qiagen, USA, catalogue #301705). Briefly, a transfection mix was made by adding GR5 or 
NSC siRNAs diluted in Opti-MEM medium with GlutaMAXTM (Gibco, Thermo Fisher Scientific, USA, 
catalogue # 51985034) to 3.5 µL HiPerfect reagent. The mixture was incubated for 15 minutes at room 
temperature and thereafter added in a drop-wise manner to the cells. The cells were incubated for 48 
hours after which they were washed with 1 X PBS and stimulated with ligands for 24 hours on serum-
free media. Cells were then harvested in Tri-Reagent® for total RNA isolation or in 2 X SDS sample 
buffer (5X stock: 0.1 M Tris-Cl pH 6.8, 5% (v/v) SDS, 20% (v/v) glycerol, 5% β-mercaptoethanol and 
0.1% (w/v) bromophenol blue) for Western blotting to verify GR knockdown.  
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2.8: Gene expression analysis 
2.8.1: RNA isolation 
Total RNA from End1/E6E7 cells, PBMCs or ectocervical tissue explants was isolated using Tri-
Reagent® according to the manufacturer’s instructions with slight modification. Briefly, Tri-Reagent® 
was added to End1/E6E7 cells or PBMCs pellets and incubated for 5 minutes at room temperature. 
Ectocervical tissue pieces were placed in cryovials and homogenised in Tri-Reagent® on ice using a 
hand-held homogeniser with disposable probes (TissueRuptor Probes, Qiagen, USA) according to 
the manufacturer’s instructions and the homogenate incubated at room temperature for 5 minutes.  
The cell lysates or tissue homogenates were transferred into RNase-free micro-centrifuge tubes and 
centrifuged at 12,000 x g for 10 minutes at 4˚C to pellet cell debris. Supernatants were collected, 
transferred into new RNase-free micro-centrifuge tubes, 80 µL chloroform added and vortexed 
vigorously for 15 seconds at room temperature. The tubes were incubated for 2 minutes at room 
temperature and then centrifuged at 20,000 x g for 15 minutes at 4˚C. The aqueous phase was 
collected, transferred into new micro-centrifuge tubes, 200 µL isopropanol added and mixed gently 
by inverting several times. The tubes were incubated for 10 minutes at room temperature and then 
spun at 20,000 x g for 10 minutes at 4˚C to precipitate the RNA. Supernatants were discarded, and 
the precipitated RNA washed twice with 400 µL of 75% EtOH made in diethyl pyrocarbonate (DEPC)-
treated water by centrifuging at 20,000 x g for 5 minutes at 4˚C. The resulting RNA pellets were air 
dried, resuspended in 10 µL of RNase-free water and incubated at 55˚C for 5 minutes. The isolated 
RNA was quantified using a NanoDrop®ND-1000 spectrophotometer (Thermo Fisher, USA) and its 
integrity assessed by running 250 ng on a 1% denaturing formaldehyde agarose gel (Sambrook et 
al., 1989). The RNA was then re-precipitated using 3 M sodium acetate (Ambion®, Thermo Fisher, 
USA) and stored as a pellet at -80˚C until use.  
 
2.8.2: cDNA synthesis 
cDNA was synthesized from 250 ng RNA using High-Capacity cDNA Reverse Transcription Kit 
(Applied BiosciencesTM, Thermo Fisher, USA) according to manufacturer’s instruction. cDNA samples 
were stored at -20 ˚C until use. 
 
2.8.3: RT2-PCR array profiling 
For the specific purpose of RT2-PCR array, total RNA was isolated from End1/E6E7 cells using the 
RNeasy® Plus Mini Kit (Qiagen, USA) according to manufacturer’s instruction. RNA quantity and purity 
were determined using the NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, DE, USA). 
RNA integrity was assessed using the RNA 6000 Nano Chip on a Bioanalyzer 2100 (Agilent 
Technologies, Santa Clara, CA, USA). Four hundred (400) ng of RNA was converted to cDNA using 
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the RT2 First Strand kit (Qiagen, USA. Catalogue #330401). The amplified cDNA was then diluted 
with nuclease-free water and added to the RT2SYBR® Green ROXTM qPCR mastermix (Qiagen, USA, 
catalogue #330521) and 25 µL was then loaded onto the Human HIV Host Response PCR array 
(PAHS-051ZE-1, Qiagen, USA, catalogue #330231). Real-Time PCR was performed on the ABI 
7900HT Fast Real-Time PCR System (Thermo Fisher, USA). The following thermal profile: stage 1 – 
1 cycle at 95°C for 10 minutes; stage 2 –  95°C for 15 seconds followed by 60°C for 1 minute with 40 
cycles; stage 3 (dissociation curve) – 95°C for 1 minute, 55°C for 30 seconds, and 95°C for 30 
seconds. All data was acquired using using qbase+ (BioGazelle, USA) and analysed using Qiagen 
Data Analysis Centre. Data were normalised to glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH) mRNA levels. Except for bioanalyzing and qRT-PCR that were performed at a commercial 
facility (Center for Proteomics and Genomic Research, Cape Town, South Africa), sample preparation 
and setting up PCR reaction was done by the candidate.   
  
2.8.4: Quantitative Real-Time PCR 
Quantitative Real-Time PCR (qRT-PCR) was performed using the Bioline SensiMix™ SYBR® no ROX 
kit (Bioline USA, catalogue # QT650-05) on a Corbett RotorGene 3000 qRT-PCR machine (Qiagen, 
USA) according to manufacturer’s instructions. In brief, the reason mix contained; 10 µL SensiMixTM, 
forward and reverse primers (see Table 2.1), 1 µL cDNA and PCR-grade water in a final volume of 
20 µL. The reactions were amplified using the following protocol: 95˚C for 10 seconds followed by 40 
cycles of 95°C for 10 seconds, annealing for 10 seconds (see Table 2.1 for annealing temperatures) 
and 72˚C for 10 seconds. Data were acquired and analysed using the RotorGene software version 
1.7 (Qiagen, USA). Melting curves analysis was performed to verify amplification and the PCR 
products were resolved on a 2% agarose gel to confirm product size. For each primer set, standard 
curves were generated using pooled cDNA and the primer efficiencies determined from these curves. 
The relative quantities of mRNAs were determined using the ‘’Fit Points’’ method described by Pfaffl 
(2010) and were normalised using GAPDH as endogenous control. 
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Table 2.1: Primer details 
Primer Sequence 5‘– 3; Annealing ˚C Product size Kb Reference 
GILZ Quantitect Primer QT00091035 60 69 Qiagen, USA 
IL6 F: TCTCCACAAGCGCCTTCG 
R: CTCAGGGCTGAGATGCCG 60 193 
Wolf et al., 2002  
IL8 F: TGCCAAGGAGTGCTAAAG 
R: CTCCACAACCCTCTGCAC 60 197 
Wolf et al., 2002  
IL1β F: CTGAAAGCTCTCCACCTC 
R: GATCTACACTCTCCAGCTG 57 184 
Miao et al., 2012  
CCL20 F: GCAAGCAACTTTGACTGCTG 
R: CAAGTCCAGTGAGGCACAAA 58 342 
Miao et al., 2012  
CCL5 F: TACCATGAAGGTCTCCGC 
R: GACAAAGACGACTGCTGG 
 
60 199 
Wolf et al., 2002  
Claudin-4 F: CTGGGAAGTGCAGAGTGGAT 
R: AAGGAAGAGGAAAAAACCCCA 60 279 
Varley et al., 2006 
Occludin F: CATTGCCATCTTTGCCTGTG 
R: AGCCATAACCATAGCCATAGC 55 149 
Nazli et al., 2010 
ZO-1 F: CGGTCCTCTGAGCCTGTAAG 
R: GGATCTACATGCGACGACAA 60 371 
Yamaguchi et al., 2010 
DSG-1 F: AATGGCTACATTTGCAGGACA 
R: ATCTCGGTCAGAGCCTCTTACA 60 256 
This study 
GAPDH F: TGAACGGGAAGCTCACTGG 
R: TGTCAGTTGATAAAACCGCTGCC 55 307 
Ishibashi et al., 2003 
  
TNFRSF1B F: GTC CAC ACG ATC CCA ACA C 
R: CACACCCACAATCAGTCCAA 
 
58 
 
145 
This study 
TNF F: CAG AGG GCC TGT ACC TCA TC 
R: GGA AGA CCC CTC CCA GAT AG 
 
60 
 
219 
This study 
TLR2 F: GGCATGTGCTGTGCTCTGTT 
R: GCTTTCCTGGGCTTCCTTTT 
 
60 
 
125 
Shan et al., 2011 
TLR4 F: TTGAGCAGGTCTAGGGTGATTGAAC 
R: ATGCGGACACACACACTTTCAAATA 
 
60 
 
143 
Shan et al., 2011 
IRF1 F: AGATCCCATGGAAGCATGCTG 
R: CCTGGAACTGTGTAGCTGC  
 
60 
 
400 
This study 
IRF2 F: CAAGTGGCTTAACAAGG 
R: GGACCGCATACTCAGGAG 
 
60 
 
410 
This study 
 
 
2.9: Ligand combination (Chou) analysis 
Chou analysis (Chou, 2010) was used to determine whether MPA or CORT synergises with TNF to 
upregulate gene expression. In brief, dose response experiments were performed as described in 
section 2.4.1. Cells were harvested, total RNA isolated, cDNA made, and real-time PCR performed 
as described in section 2.8 for CCL20 and GAPDH. CCL20 fold changes in respond to single ligand 
or ligand combinations were calculated relative to GAPDH. Thereafter, the maximum fold change was 
set to 0.99 and the other responses calculated relative to this value. Each single or ligand combination 
dose and their respective responses were keyed into the Compusyn software (ComboSyn, Inc., USA) 
to determine the Combination indices (CI).     
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2.10: Protein Expression analysis 
2.10.1: ELISA 
Supernatants collected from End1/E6E7 cells, PBMCs, PGECs or ectocervical tissue explants were 
centrifuged at 1,500 rpm using a Microfuge® 20R Centrifuge (Beckman Coulter, USA) for 10 mins at 
4°C to pellet cellular debris and supernatants were analysed for TNF, CCL20, IL6, CCL5 and IL1β 
protein levels by using DuoSet ELISA kits from R&D Systems (USA) according to manufacturer’s 
instruction. However, a more sensitive kit was required to quantify CCL20 in ectocervical tissue 
explant supernatants (RayBio® Human MIP-3 alpha ELISA Kit, Raybiotech, USA) according to 
manufacturer’s instructions.   
 
2.10.2: Luminex 
Aliquots of supernatants collected from ectocervical tissue explants (see section 2.9.1 for sample 
preparation) were shipped to Prof. Robbin Shattock’s research group at Imperial College, London, 
UK where they were assessed for soluble immune proteins using an in-house Luminex panel. The 
following immune mediators were measured: TNF, IL8, CCL2, IFNβ, CCL5, IL1β, IL12, IL15, IL1α, 
IL4, IL2, CCL20, IL16, IL6, CXCL9, IFNy, TGFβ, G-CSF, CXCL12, CCL4, CXCL10, GM-CSF, IL7 and 
CCL8. This assay was performed by Dr. Julia Makinde. 
 
2.10.3: Western blotting 
Western blotting was performed according to the method described by Avenant et al (2010a). Equal 
amounts of End1/E6E7 or COS-1 whole-cell lysates (generated as described in section 2.6) were 
separated on 8% or 10% SDS-polyacrylamide gels at 120 V in 1 X running buffer [25 mM Tris-Cl, 250 
mM glycine and 0.1% (w/v) SDS]. The separated proteins were transferred onto Hybond-ECL 
nitrocellulose membranes (Amersham Biosciences, South Africa, catalogue #RPN303D) for 1 hour at 
180 mA in transfer buffer [25 mM Tris-Cl, 250 mM glycine and 20% (v/v) methanol]. The membranes 
were then blocked for 1 hour at room temperature in 4% (w/v) ECL blocking solution [4g ECL blocking 
powder in 100 mL Tris-buffered saline; 50 mM Tris-Cl, pH7.5 and 150 mM NaCl (TBS) containing 
0.1% (v/v) Tween 20 (TBST)]. Thereafter, the membranes were incubated overnight with primary 
antibodies (see Table 2.2 for dilutions) in 4% ECL blocking solution at 4°C. After washing three-times 
with 1 X TBST (each wash lasting for 5 minutes), the membranes were incubated with secondary 
antibodies made up in 5% non-fat dry milk–TBST solution at room temperature for 1 hour. The 
membranes were again washed 3 X with TBST and then rinsed in 1 X TBS. The proteins were 
visualised using Pierce® ECL Western blotting detection reagents (Thermo Scientific, USA, catalogue 
#32106) and Hyperfilm MP high performance autoradiography film (Amersham Biosciences, South 
Africa, catalogue #28906837) according to manufacturer’s instructions. Bands on the X-ray film were 
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scanned, and quantification was performed using the AlphaEaseFC FluorChem 5500 software (Alpha 
Innotech, USA). 
 
Table 2.2: Dilution of primary antibodies used in Western blotting analysis 
Antibody Dilution 
GR 1:4,000 
PR 1:1,000 
Claudin-4 1:4,000 
Occludin 1:2,000 
HA 1:2,000 
GAPDH 1:15,000 
 
 
2.11: Preparation of HIV-1 infectious molecular clones and infection assay 
HIV-1 M-tropic (or R5) infectious molecular clones were used in this study except indicated otherwise. 
HIVBaL-Renilla was a kind gift from Dr. Christina Ochsenbauer (University of Alabama, Birmingham, 
USA). It was made by inserting the Renilla luciferase gene next to the env in the HIV-1 NL4.3 
backbone (Edmonds et al., 2010). HIV-1BaL-Renilla IMCs stocks were made as described previously 
(Pear et al., 1993). Briefly, 4 X 106 HEK293T cells were seeded in 75 cm2 flasks and grown in phenol 
red DMEM containing 10% FCS, 100 U/mL penicillin and 100 µg/mL streptomycin for 24 hours. 
Thereafter, culture media was changed to phenol red-free DMEM (Sigma Aldrich, South Africa, 
catalogue #D1145) supplemented with 10% c-s FCS, 100 U/mL penicillin and 100 µg/mL 
streptomycin. The cells were then transfected with 20 µg HIV-1BaL-Renilla plasmid DNA using X-
tremeGENETM 9 transfection reagent (Roche Applied Sciences, South Africa, catalogue #06366236 
001) or control (DMEM) and incubated for 48 hours.  Thereafter, supernatants were harvested, filtered 
through a 0.22 µM filter and cs-FCS added to final concentration of 40%. The stocks were aliquoted 
and stored at -80 ˚C until use. 
  
HIV-1 IIIB (X4 tropic) were prepared from the chronically infected human CD4+ T cell line H9 (AIDS 
Reagent Program, NIH, USA, catalogue #398). Cells were maintained in RPMI 1640 media containing 
80% L-glutamine and 20% c-s FCS for 3 days. Supernatants were collected and concentrated using 
the Amicon Ultra-15 filtration system (Millipore, Billerica, US). The stocks were aliquoted and stored 
at -80 ˚C until use. 
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The TZM-bl TCID50 assay was used to determine viral titre of the stocks using the method previously 
described by Edmonds and colleagues (Edmonds et al., 2010). In brief, TZM-bl indicator cells were 
seeded at a density of 100,000 cells/well in 96-well plates in full phenol red DMEM [10% FCS, 100 
U/mL penicillin and 100 µg/mL streptomycin] and incubated for 24 hours. The following day, an initial 
1:5 dilution of the viral stocks was made in full phenol red-free DMEM [10% c-s FCS, 100 U/mL 
penicillin and 100 µg/mL streptomycin] and this was further diluted 8 more times, with each dilution 
done in quadruplicate in a separate 96-well plate. The media in the 96-well plate containing TZM-bl 
was removed and replaced with the diluted virus or no-virus control, with each dilution done in 
quadruplicate. The cells were then incubated for 72 hours after which they were harvested in 70 
µL/well Bright-Glo™ Luciferase Assay System reagent (Promega, USA). Fifty (50) µL of the cell 
lysates was transferred onto white luminometer plates (Griener, Germany) and fluorescence 
[expressed as relative light units (RLU)] read on a Turner Biosystems Modulus Microplate reader 
(Promega, USA). Viral titres were determined as log infectious units (IU)/mL (Reed & Muench, 1938). 
The typical viral titre ranged from 1 X 104 - 4 X 105 IU/mL.  
 
2.11.1: TZM-bl infection assay 
The TZM-bl assay was used to investigate the effects of ligands on HIV-1 replication. In brief, TZM-bl 
indicator cells were seeded at a density of 10,000 cells/well in two 96-well plates in full phenol red 
DMEM [10% FCS, 100 U/mL penicillin and 100 µg/mL streptomycin] and incubated for 24 hours. 
Thereafter, the cells were washed one-time with PBS and exposed to 10 IU/mL HIV-1BaL-Renilla or virus 
control made up in full phenol red free DMEM [10% c-s FCS, 100 U/mL penicillin and 100 µg/mL 
streptomycin] for 24 hours. The following day, the cells were washed and stimulated with or without 
ligands in full phenol red-free DMEM. After 48 hours, cells in one plate were washed and lysed using 
70 µL Bright-Glo™ Luciferase Assay System reagent (Promega, USA). Fifty (50) µL of the cell lysates 
was transferred onto white luminometer plates (Griener, Germany) and fluorescence [expressed as 
relative light units (RLU)] read on a Turner Biosystems Modulus Microplate reader (Promega, USA). 
Cells in the other plate were treated with 0.5 mg/mL MTT and incubated for another 2 hours. 
Thereafter, the media was aspirated and 100 µL acidified isopropanol to lyse the cells. The plate was 
read on a spectrophotometer (Thermo Scientific, USA) at 520 nm and 695 nm (background 
absorbance). Infectivity was expressed as RLU on MTT to account for differences in cellular viability 
over time.    
 
2.11.2: Add back assay 
The effects of supernatants from PBMCs treated with or without ligands on HIV-1 infection was 
assessed using TZM-bl indicator cells as described previously (Patel et al., 2014). Briefly, TZM-bl 
indicator cells were seeded at a density of 10,000 cells/mL in two 96-well plates in full phenol red 
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DMEM [10% FCS, 100 U/mL penicillin and 100 µg/mL streptomycin] and incubated for 24 hours. The 
following day, supernatants from PBMCs or control media with or without ligands stored at -80˚C were 
thawed and diluted 1:4 in full phenol red-free DMEM [10% c-s FCS, 100 U/mL penicillin and 100 
µg/mL streptomycin] in a 24 well-plate. The cells were washed one-time with 1 X PBS and the culture 
media replaced with 100 µL of the diluted supernatants and control media and incubated for 1 hour 
at 37˚C. In parallel, 20 IU/mL HIV-1BaL-Renilla or virus control was added to 100 µL diluted supernatants 
and control media and incubated at 37˚C for 1 hour. The virus mixture was then added to the cells 
and incubated for another 48 hours. Thereafter, the cells were harvested as described in section 
2.11.1 above.  
 
2.11.3: Exposure of genital epithelial to HIV-1 IMCs 
2.11.3.1: PGECs  
This experiment was performed in the laboratory of Prof. Charu Kaushic at McMaster University’s 
Department of Pathology and Molecular Medicine, Hamilton, Canada. Confluent PGECs monolayers 
were pre-treated 100 nM DEX, MPA or 0.1% (v/v) EtOH (vehicle) in serum-free DMEM/F12 [100 U/mL 
Penicillin-Streptomycin, 10 mM HEPES, 250 µg/mL fungizone and 4 mM L-glutamine] for 24 hours. 
TER measurements were made before and after hormonal treatment. Thereafter, the monolayers 
were exposed to 105 IU/mL HIV-1 IIIB (X4 tropic) or virus control for 24 hours. Again, TER 
measurements were taken before and after HIV-1 exposure. Supernatants from the apical chamber 
were collected, inactivated with 5% (v/v) Empigen (Sigma-Aldrich, Canada) and centrifuged at 1,500 
rpm for 10 minutes at 4°C using an Eppendorf 542R refrigerated microcentrifuge (Eppendorf, 
Canada). TNF- protein levels determined by means of ELISA assays. For each ligand condition, 
post-exposure/treatment TER are normalised to pre-exposure/treatment TER and expressed as a 
percentage (% pre-exposure). The data presented in Figure 4.3.7.2 was obtained by comparing TER 
post HIV-1 exposure to TER pre-hormonal treatment.  
 
2.12: Confocal microscopy 
Coverslips were prepared by washing twice in 3% (v/v) hydrochloric (HCl) acid with each wash lasting 
30 minutes. This was followed by three 10-minute washes using Milli-Q water. The coverslips were 
then sterilised in absolute ethanol, rinsed several times with PBS and placed in 6-well plates. 
End1/E6E6 cells were seeded onto coverslips at a density 100,000 cells/mL in full SKM and grown 
for 10, 14, 16 and 18 days. Cells were harvested by washing with cold PBS, and then fixed and 
permeabilised using cold methanol for 10 minutes at -20˚C. The cells were washed three-times with 
PBS and then blocked with 5% (w/v) bovine serum albumin (BSA) in PBS for 1 hour at toom 
temperature. This was followed by staining with mouse monoclonal antibody raised against human 
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claudin-4 (1:100) made up in 5% (w/v) BSA in PBS for 1 hour at room temperature. The cells were 
washed three-times with 1% (w/v) BSA in PBS and stained with secondary anti-mouse-Cy3 
conjugated antibody (diluted 1:1000, excitation maximal = 550 nm and emission maximal = 570 nm) 
in 5% BSA in PBS for 1 hour at room temperature in the dark. The cells were again washed three-
times with 1% BSA and then counterstained with 100 µg/mL Hoechst in PBS for 5 minutes at room 
temperature. The coverslips were then mounted in Mowiol (Calbiochem, Merck, South Africa) 
containing the anti-fading agent n-propyl gallate (Sigma Aldrich, South Africa) and allowed to dry 
overnight at room temperature in the dark. The following day, the slides were rinsed with PBS, airdried 
and stored in the dark at 4˚C until visualisation. Images were acquired on a laser-scanning LSM 510 
confocal microscope (Carl Zeiss, Germany) using the 40 X water-immersion objective, at the Confocal 
and Light Microscope Unit, University of Cape Town. Multiple z-stacks (0.1 µm) were acquired, 
exported as .tiff images and reconstructed using ImageJ (NIH). The representative middle slide of 
each stack is shown in XY (en face) projection. XZ projections were also generated to view the cell 
layer top to bottom.  
 
2.13: Statistical analysis 
Statistical analysis was performed using Graph Pad Prism version 7 (GraphPad Software Inc, USA). 
Cell line, ectocervical tissues, PGECs, PBMCs or addback data were plotted as mean ± SEM. Dose 
response curses were plotted as Log [ligand] vs response with the maximal responses set to 100% 
and the Hill slope set to 1. Normality testing was performed on all data set using either Kolmogorov-
Smirnov test for n ≥ 5 or Shapiro-Wilk test for n ≥ 3. This initial test was done to determine whether 
the data was geometrically distributed and hence the type of statistical analysis to be performed.  
Parametric data was analysed using One-Way ANOVA with post-hoc Tukey multiple comparison. 
Non-parametric data was analysed using Kruskal-Wallis One-Way ANOVA with Dunn’s multiple 
comparison. When multiple comparisons failed to established statistical significance between 
treatments (as they are more stringent tests), less stringent pairwise comparisons was performed 
using either Mann-Whitney U test (when a ligand condition in the pair being compared was not set to 
1 or 100%) or Kolmogorov-Smirnov test (when no condition in the pair being compared has been set 
to 1 or 100%) for non-parametric data,  and the Student’s t-test for parametric data if the overall 
ANOVA was significant. The following notations have been used in this thesis to differentiate between 
the various comparisons.  
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Table 2.3: Summary of statistical tests performed 
Test Notation Explanation 
One-Way ANOVA or  
Kruskal-Wallis 
* For multiple comparisons. Lines are used to indicate treatments being 
compared. Other comparison is between vehicle only and Steroids ± 
TNF/LPS   
Unpaired Student’s t-test or 
Mann-Whitney or 
Kolmogorov-Smirnov 
# For comparison between vehicle only and treatments –TNF/LPS 
$ For comparison between vehicle and treatments +TNF/LPS  
& For comparisons between corresponding conditions in steroids - 
TNF/LPS and steroids +TNF/LPS 
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Chapter Three 
 
Medroxyprogesterone acetate, like glucocorticoids but unlike other select progestins,  
regulates select tight junction and immune function target genes, including CCL20, alone 
and in combination with pro-inflammatory stimulators, in a gene-specific manner  in an 
endocervical epithelial cell line  
 
3.1:Aims 
It has recently been reported that women with BV using DMPA-IM are more likely to acquire HIV-1 
than their counterpart not usng hormonal contraception (Hadda et al., 2018). This suggests that 
DMPA-IM might cooperate with GTIs to further increase the risk of HIV-1 acquisition in women. The 
dysregulation of epithelial TJ and immune function genes is one of the several mechanisms by which 
HIV-1 infection can be established in the FGT (Nazli et al., 2010; Nazli et al., 2013; Quispe-Calla et 
al., 2016; Li et al., 2009; Shang et al., 2017; Rollenhagen & Asin, 2011; Naranbhai et al., 2012; Kahle 
et al., 2015; Liebenberg et al., 2017). Therefore, the objectives of this chapter were to investigate 
aims A and B (section 1.5) with the following specific questions: 
• Do GCs and progestogens regulate the expression of select TJ and immune function genes 
in female genital epithelial cells? 
• Do GCs and progestogens cooperate with immune activators to regulate TJ and immune 
function gene expression in female genital epithelial cells? 
 
The endocervical epithelial End1/E6E7 cell line was chosen because current evidence suggests that 
the endocervix is more readily infected with HIV-1 compared to mucosal surfaces of the lower FGT 
(Carias et al., 2016; Hladik & Hope, 2009). Unlike other endocervical epithelial cell lines, End1/E6E7 
cells are non-cancerous and were generated by immortalising primary endocervical epithelial cells 
and so closely resemble their primary counterparts (Fichorova et al., 1997; Fichorova et al., 1999). 
The cells were treated with 100 nM GCs or select progestogens alone or in combination with 1.15 nM 
TNF or 5 µg/mL LPS. The concentrations of steroids used was chosen to reflect the highest peak 
serum concentration reported for MPA (Hapgood et al., 2018), although peak serum levels for DEX 
and endogenous CORT have been reported to be higher than 100 nM (Cho et al., 2017; Egerman et 
al., 1997). TNF and LPS, referred to as immune activators, were used to induce inflammatory 
responses like the type associated with microbial and non-HIV-1 viral GTIs, respectively. The 
concentration of TNF used has been shown to induce pro-inflammatory responses in End1/E6E7 cells 
(Verhoog et al., 2011) and most likely reflects the serum concentrations during infection. The 
concentration of LPS was chosen to reflect levels of LPS in CVL from women with bacterial vaginosis 
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((Aroutcheva et al., 2008). The cells were treated with ligands for 24 hours because they have been 
shown in previous studies to induce responses at this time point (Verhoog et al., 2011; Govender et 
al., 2014). Initial gene expression analysis was performed for the following TJ (claudin-4, occludin and 
ZO-1) and immune function genes (IL1β, IL6, IL8, CCL5, CCL20 and TLR2). These genes were 
selected because they have been shown to be relevant for HIV-1 infection (Nazli et al., 2010; Nazli et 
al., 2013, Bolduc et al., 2017; Cameron et al., 2010; Fichorova et al., 2015). Additional gene 
expression analysis was formed using the Human Host HIV-1 response RT2 profiler to identify 
additional genes relevant for HIV-1 infection and pathogenesis that could be coregulates by 
progestogen and immune activators.          
 
3.2: Results 
3.2.1: DEX like MPA selectively represses basal and TNF-induced claudin-4, but not occludin 
and ZO-1 mRNA levels 
First, the effects of DEX, MPA, P4, NET and LNG on claudin-4, occludin and ZO-1 mRNA levels were 
investigated. End1/E6E7 cells grown to confluence were treated with 100 nM of each hormone for 24 
hours. As shown in Figure 3.2.1.1, treatment with DEX resulted in a significant reduction of claudin-
4 (Figure 3.2.1.1 A) but not occludin (Figure 3.2.1.1 B) or ZO-1 (Figure 3.2.1.1 C) mRNA expression. 
 
                                   
Figure 3.2.1.1: DEX differentially regulates claudin-4, occludin and ZO-1 mRNA expression in End1/E6E7 
cells. (continued on the next page) 
A B 
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Figure 3.2.1.1: DEX differentially regulates claudin-4, occludin and ZO-1 mRNA expression in 
End1/E6E7 cells. End1/E6E7 cells grown to confluence were treated with 100 nM DEX, MPA, P4, NET LNG 
or 0.1% (v/v) EtOH (vehicle) for 24 hours. Cells were then harvested in Tri-Reagent®, total RNA isolated and 
500 ng converted to cDNA. The relative mRNA levels of claudin-4 (A), occludin (B), ZO-1 (C) and GILZ (D) 
were determined by qRT-PCR performed using gene specific primers and normalised to GAPDH mRNA levels. 
The data include at least two independent biological repeats plotted as mean ± SEM in Graph Pad Prism 7 
software. The data was plotted relative to vehicle only, which has been set to 1. Statistical analysis was 
performed using one-way ANOVA with Tukey’s multiple comparisons and statistical significance denoted as *** 
to indicate p<0.005. 
 
As expected, DEX also resulted in the induction of GILZ mRNA expression (Figure 3.2.1.1 D). 
Although not statistically significant, MPA appeared to suppress claudin-4, but not occludin or ZO-1 
mRNA levels. The other ligands i.e. P4, NET and LNG did not alter mRNA levels of either claudin-4, 
occludin or ZO-1. Interesting, in this experiment neither MPA, P4, NET nor LNG significantly induced 
GILZ mRNA expression. Taken together, this result suggested only treatment with DEX and 
potentially MPA result in the selective downregulation of claudin-4 mRNA levels in End1/E6E7 cells. 
The other progestogens investigated i.e. P4, NET and LNG did not alter the expression of claudin-4, 
occludin and ZO-1 in End1/E6E7 cells. 
 
The effects of DEX and MPA on the expression of TJ genes in presence of TNF were next 
investigated. In this experiment, confluent End1/E6E7 cells were treated with 100 nM DEX or MPA 
alone or in combination with 1.15 nM TNF for 24 hrs. As shown in Figure 3.2.1.2, both DEX and MPA 
significantly reduced claudin-4 mRNA levels but not occludin or ZO-1. TNF significantly upregulated 
claudin-4 and ZO-1, and also  appeared to increase occludin mRNA levels although not significantly. 
While DEX and MPA significantly inhibited TNF-induced increase in claudin-4 mRNA expression, only 
DEX repressed TNF-induced increase in ZO-1 mRNA expression.  
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Figure 3.2.1.2.: MPA like DEX selectively suppress basal and TNF-induced claudin-4 mRNA 
expression in End1/E6E7 cells. Confluent End1/E6E7 cells were treated with 100 nM DEX, MPA or 0.1% 
(v/v) EtOH (vehicle) in the presence or absence of 1.15 nM TNF for 24 hrs. Cells were then harvested in Tri-
Reagent®, total RNA isolated and converted to cDNA. The relative mRNA levels of claudin-4 (A), occludin (B), 
ZO-1 (C) were measured by qRT-PCR using gene specific primers and normalised to GAPDH mRNA levels.  
Fold changes in mRNA expression was determined by normalising the data relative to TNF only, which has 
been set to 100%. The data include four independent biological repeats plotted as mean ± SEM in Graph Pad 
Prism 7 software. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparisons. 
Statistical significance denoted as * and **** to indicate p<0.05 and p<0.005, respectively for comparisons 
between vehicle only and other treatments or between pairs of treatments. In some cases, the unpaired 
Student’s t-test was used for comparisons between vehicle only and other treatments and statistical significance 
is denoted by # to indicate. When the test compared TNF alone with TNF + steroids statistical significance is 
denoted by $$$ to indicate p<0.005. 
 
3.2.2: DEX is more effective than MPA, NET, P4 and LNG in regulating claudin-4 and occludin 
protein levels in End1/E6E7 cells. 
In the previous sections, it was established that DEX and MPA, unlike P4, NET and LNG, decreased 
claudin-4, but not occludin mRNA levels. It was next investigated whether the hormones also 
modulate claudin-4 and occludin protein levels.  
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Figure 3.2.2.1: The effects of DEX and select progestogens on claudin-4  and occludin protein 
levels in End1/E6E7 cells.  End1/E6E7 cells grown to confluence were treated with 100 nM DEX, MPA, P4, 
NET, LNG or 0.1% (v/v) EtOH (vehicle) for 24 hrs. Thereafter, cells were harvested in 2X SDS Loading Buffer, 
boiled for 10 minutes and resolved on a 10% SDS-PAGE. Thereafter western blot analysis was performed with 
antibodies specific for the claudin-4 (A, 24KD), occludin (C, 65KD) and GAPDH (36KD). The blots were then 
scanned, densitometrically quantified and expressed relative to vehicle control. (A, C): representative 
immunoblot from three biological repeats; (B, D): densitometry data plotted as mean ± SEM in Graph Pad Prism 
7 software. B was analysed using one-way ANOVA with Tukey’s multiple comparisons. D was analysed using 
the unpaired Kolmogorov-Smirnov test with statistical significance denoted as # to indicated p<0.05. 
 
As shown in Figure 3.2.2.1 A, only treatment with DEX but not MPA, P4, NET or LNG appeared to 
decrease claudin-4 protein levels. Similarly, only DEX significantly reduced occludin protein levels 
(Figure 3.2.2.1 B). MPA appeared to reduce the occludin protein levels, although the effect was not 
statistically significant. Neither P4, NET nor LNG showed any significant effect on claudin-4 and 
occludin protein levels (Figure 3.2.2.1 B). 
 
Next, it was also investigated whether DEX can alter claudin-4 and occludin protein levels in the 
presence of TNF. Figure 3.2.2.2 shows that DEX significantly reduced claudin-4 (Figure 3.2.2.2 A) 
and occludin (Figure 3.2.2.2 B) protein levels.  
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Figure 3.2.2.2: The effect of DEX on claudin-4 and occludin protein levels in End1/E6E7 cells 
in the absence and presence of TNF.  End1/E6E7 cells grown to confluence were treated with 100 nM 
DEX or 0.1% (v/v) EtOH (vehicle) in the absence or presence of 1.15 nM TNF for 24 hrs after which cells were 
harvested and thereafter analysed by western blotting using antibodies specific for the claudin-4 (A, 24KD), 
occludin (C, 65KD) and GAPDH (36KD). The blots were then scanned, densitometrically quantified and 
expressed relative to vehicle control (NB: the average of the two vehicle control samples was used to normalise 
the data). (A, C): representative immunoblot from three biological repeats; (B, D): densitometry data plotted as 
mean ± SEM in Graph Pad Prism 7 software. Statistical analysis was performed using the unpaired Student’s 
t-test and statistical significance denoted as ## or ### to indicate p<0.01 and p<0.005, respectively for comparison 
between vehicle and other treatments; or denoted as $$ to indicate p<0.01 for comparison between TNF and 
TNF + steroids 
 
TNF also appeared to reduce claudin-4, but significantly decreased occludin protein levels (Figure 
3.2.2.2). This observation contrasted with the effect of TNF on claudin-4 and occludin mRNA levels, 
in which TNF increased claudin-4 mRNA levels and appeared to do the same with occludin mRNA 
levels (Figure 3.2.1.2). Co-treatment with DEX and TNF resulted in a decrease in claudin-4 and 
occludin protein levels, but the response was like that elicited by DEX alone.  
 
Taken together, these results suggest DEX regulates mRNA and protein levels of select TJ genes. 
They also suggest that TNF increases mRNA levels of select TJ genes, but at the same time reduces 
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protein levels of the same genes. Moreover, the results suggest that MPA like DEX inhibits TNF-
induced increase in TJ gene expression but has no effect on TNF-induced decrease in TJ protein 
levels.  
 
3.2.3: MPA like GCs, but unlike NET, enhances basal and TNF-induced CCL20 mRNA 
expression, but supresses basal and TNF-induced IL6, IL1β, IL8 and CCL5 mRNA expression 
in End1/E6E7 cells. 
Next, DEX, CORT, MPA and NET-mediated regulation of basal and induced CCL20, IL6, IL1β, IL8, 
CCL5 and GILZ mRNA expression in End1/E6E7 cells was investigated. To this end, 
End1/E6E7E6/E7 cells were treated with steroid hormones alone or in combination with TNF for 24 
hours (co-stimulation – see Figure 3.2.3.1). TNF was used to induce inflammation. In the absence of 
TNF, treatment with DEX, CORT, MPA, but not NET resulted in a significant increase in CCL20 mRNA 
expression (Figure 3.2.3.1 A). In contrast, DEX, CORT and MPA, but not NET significantly inhibited 
basal IL6 mRNA expression (Figure 3.2.3.1 B). In addition, DEX, CORT and possibly MPA, but not 
NET reduced IL1β mRNA expression (Figure 3.2.3.1 C). However, all four steroids did not induce 
any statistically significant changes in basal IL8 and CCL5 mRNA expression (Figure 3.2.3.1 D, E). 
It was also observed that DEX, CORT and potentially MPA, but not NET increased GILZ mRNA levels 
(Figure 3.2.3.1 F).  
 
Treating End1/E6E7 cells with TNF resulted in increased CCL20, IL6, IL1β, IL8 and CCL5 mRNA 
levels (Figure 3.2.3.1 A - E). However, the effects of DEX, CORT, MPA and NET on TNF-induced 
gene expression were not always similar as some gene-specific differences were observed. For 
instance, DEX, CORT and potentially MPA, but not NET enhanced TNF-induced increase in CCL20 
mRNA levels (Figure 3.2.3.1 A). 
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Figure 3.2.3.1:  DEX, CORT and MPA, unlike NET, selectively upregulate CCL20 and GILZ, but 
repress IL6, IL1β, IL8 and CCL5 mRNA levels in End1/E6E7 cells in the presence of TNF. 
End1/E6E7 cells were stimulated with 100 nM DEX, CORT, MPA, NET or 0.1% (v/v) EtOH (vehicle) in the 
presence or absence of 1.15 nM human TNF for 24 hours. Thereafter, cells were harvested in Tri-Reagent®, 
total RNA isolated and converted to cDNA. The relative mRNA levels of CCL20 (A), IL6 (B), IL1β (C), IL8 (D), 
CCL5 (E) and GILZ (F) were then determined by qRT-PCR using gene specific primers and normalised to 
GAPDH mRNA levels. The relative effects of steroids and TNF on mRNA levels of the selected genes were 
determined by normalising to the vehicle only control, which has been set to 100%. The data include three 
independent biological repeats plotted as mean ± SEM in Graph Pad Prism 7 software. Statistical analysis was 
performed using one-way ANOVA with Tukey’s multiple comparisons. Statistical significance is denoted as *, 
*** or **** to indicate p<0.05, p<0.005 and p<0.0001, respectively for comparisons between vehicle only and 
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other treatments or between pair of treatments. In some cases, the unpaired Student’s t-test was used for 
comparisons between vehicle only and other treatments and statistical significance is denoted as #, ###, or #### 
to indicate p<0.05, p<0.005 and p<0.0001, respectively. When the comparison is between TNF and steroids + 
TNF statistical significance is denoted as $, $$ or $$$ to indicate p<0.05, p<0.01 and p<0.005, respectively.    
 
 
In contrast, DEX, CORT and MPA, but not NET inhibited IL6 and IL1β MRNA regulation by TNF 
(Figure 3.2.3.1 B, C). Similarly, TNF-induced CCL5 mRNA expression seemed to be inhibited by 
DEX, MPA and potentially CORT, but not NET; on the other hand, all four steroid hormones did not 
alter TNF-induced increase in IL8 mRNA levels (Figure 3.2.3.1 D, E). It was also observed that TNF 
significantly inhibited DEX- and CORT-induced increase in GILZ mRNA expression despite not 
showing a similar effect on basal GILZ expression (Figure 3.2.3.1 F). 
 
 
Because treatment with DEX, CORT, MPA and NET did not alter TNF-induced expression of IL8, it 
was next investigated whether pre-treatment with hormones prior to TNF challenge would result in 
changes in findings reported in Figure 3.2.3.1 above. In these experiments, End1/E6E7E6/E7 cells 
were initially pre-treated with steroid hormones for 2 hours before stimulating with TNF for another 24 
hours (hormonal pre-treatment – see Figure 3.2.3.2).  
 
 
                      
Figure 3.2.3.2: MPA like GCs, but not NET enhance TNF-induced CCL20 mRNA levels, but 
supress TNF-induced IL6, IL8 and IL1β mRNA levels in End1/E6E7E6/E7 cells. (continued on 
the next page) 
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Figure 3.2.3.2: MPA like GCs, but not NET enhance TNF-induced CCL20 mRNA levels, but 
supress TNF-induced IL6, IL8 and IL1β mRNA levels in End1/E6E7E6/E7 cells. End1/E6E7 cells 
were pre-treated with 100 nM DEX, CORT, MPA, NET or 0.1% (v/v) EtOH (vehicle) for 2 hours and then 
stimulated with or without 1.15 nM human TNF for another 24 hours. Thereafter, cells were harvested in Tri-
Reagent®, total RNA isolated and converted to cDNA. The relative mRNA levels of CCL20 (A), IL6 (B), IL1β 
(C), IL8 (D) and GILZ (E) were then determined by qRT-PCR using gene specific primers and normalised to 
GAPDH mRNA levels. The relative effects of steroid hormones and TNF on mRNA levels of the selected genes 
were determined by normalising to the vehicle only control, which has been set to 100%. The data include three 
independent biological repeats plotted as mean ± SEM in Graph Pad Prism 7 software. Statistical analysis was 
performed using one-way ANOVA with Tukey’s multiple comparisons and statistical significance denoted as *, 
**, *** or **** to indicate p<0.05, p<0.01, p<0.005 and p<0.0001, respectively for comparisons between vehicle 
only and other treatments or between pair of treatments. In some cases, the unpaired Student’s t-test was used 
for comparisons between vehicle only and other treatments, and statistical significance is denoted by #, ##, or 
### to indicate p<0.05, p<0.01 and p<0.005, respectively. When the comparison was between TNF and TNF + 
steroids, statistical significance is denoted by $ to indicate p<0.05.  
 
It was observed that DEX, CORT and MPA, unlike NET, significantly enhanced TNF-induced CCL20, 
but suppressed TNF-induced IL6, IL1β and IL8 mRNA expression (Figure 3.2.3.2 A – D). As seen in 
Figure 3.2.3.1 F above, treatment with TNF repressed DEX- and CORT-, but not MPA-induced 
expression of GILZ (Figure 3.2.3.2 E). 
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Taken together, the results suggest that the effects of MPA like GCs, unlike NET, on mRNA 
expression in End1/E6E7 cells are gene-specific. They show that MPA like GCs, but unlike NET, 
increase basal as well as TNF-induced expression of a pro-inflammatory gene (CCL20). The results 
also suggest that MPA like GCs selectively suppressed basal as well as TNF-induced expression of 
some pro-inflammatory gene. Some gene could only be repressed by MPA and GCs in the presence 
of TNF. Moreover, some like IL8 was only repressed by MPA and GCs after the cells were pre-treated 
with the steroids prior to TNF stimulation. These results suggest that the regulation of pro-
inflammatory gene expression by MPA is more complex them previously thought. Overall, there were 
no remarkable differences between the co-stimulation and hormonal pre-treatment protocols. 
Therefore, the co-stimulation method was used in subsequent experiments.  
 
It was next investigated whether the regulation of gene expression by MPA, DEX and NET in 
End1/E6E7 cells was time-dependent. The cells were treated with steroids alone or in combination 
with TNF for 4, 24 and 48 hours. The results indicate that DEX- and MPA-induced enhancement of 
TNF-induced CCL20 mRNA expression might occur as early as 4 hours and is sustained 24 hours 
later; however, only MPA appeared to enhance TNF-induced increase in CCL20 expression at 48 
hours (Appendix A, Figure 1 A). It was also observed that NET might not exhibit any time-dependent 
effects on TNF-induced CCL20 mRNA expression. Using IL6 as a model for transrepression, it was 
observed that DEX appeared to repress TNF-induced IL6 mRNA expression as early as 4 hours and 
this repression was sustained at 48 hours. However, neither MPA nor NET appeared to regulate IL6 
mRNA expression in these experiments (Appendix A, Figure 1 B). However, because these effects 
were not statistically significance, caution should be taken in interpreting these results.   
 
Next, the Human Host HIV-1 Response RT2 Profiler PCR array (Qiagen, USA) was used to identify 
additional genes that are relevant to HIV-1 infection and pathogenesis coregulated by TNF and MPA 
in End1/E6E7 cells. Because CCL20 was not included in the panel, RNA samples used in the PCR 
array were assessed to verify that MPA and TNF coregulated CCL20 mRNA levels (Appendix A, 
Figure 2). As shown in Appendix A (Table 1) (which shows pooled data drawn from three 
independent experiments), most of the genes constituting the array appeared not to be regulated by 
MPA or TNF. However, 19 genes (22.62% of the array) appeared to show some form of regulation 
with either MPA or TNF. A gene was said to be regulated if it had a fold change ≥ 1.5 for any of the 
ligand treatment conditions.  
 
As shown in Appendix A (Figure 3 A – C), MPA alone did not alter basal levels of most genes 
evaluated herein, but for CCL5 and IL1β that appeared to be suppressed. In contrast, TNF 
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significantly induced IL2, TNF, TNF receptor 2 (TNFRSF1B), interferon regulatory factor (IRF)1, IRF2, 
killer cell lectin-like receptor D (KLRD)1, NFKB inhibitor alpha (NFKB1A) and serine protease inhibitor 
alpha (SERPINA)1 expression. It was also observed that MPA significantly enhanced TNF-induced 
expression of IRF2. Although not statistically significant, MPA also appeared to enhance TNF-induced 
increase in IRF1, NFKBIA, TNFRSF1B, TNF, SERPINA1, IL1β, CCR4, CD69 and SLPI. Additionally, 
co-stimulation with MPA and TNF significantly upregulated STAT3 expression despite neither ligand 
altering its basal expression. Although MPA appeared to suppress basal IL1β and CCL5 expression, 
this apparent repressive effect was lost for IL1β, but retained for CCL5 in the presence of TNF 
(Appendix A, Figure 3 A - C). Hierarchical clustering was performed to assess the overall effect of 
MPA on TNF-induced activation of gene expression. This analysis revealed that in most cases MPA 
either enhanced or did not alter TNF-induced responses (Appendix A, Figure 4 D). 
 
Furthermore, qRT-PCR was used to validate the PCR array data. Fresh RNA samples were isolated 
by Tri-Reagent® method for this analysis. By comparing the results obtained by qRT-PCR to those 
obtained in the array, some discrepancies were observed. For instance, the array predicted that MPA 
and TNF significantly coregulated IFR2 expression (Appendix A, Figure 3 A). In addition, the array 
predicted that MPA and TNF might coregulate IRF1, NFKBIA, SERPINAI, TNFRSF1B, IL1β, and TNF 
expression (Appendix A, Figure 3 A – D). However, the qRT-PCR validation showed that MPA 
repressed TNF-induced IL1β, IRF2 and potentially IRF1 expression (Figure 3.2.3.3 A, E, F). A 
combination of small responses induced by the ligands coupled with high technical error in the array 
experiment could explain these discrepancies.  
 
 
                       
Figure 3.2.3.3: MPA selectively enhances TNF-induced TNFRSF1B expression in End1/E6E7 
cells. (continued on the next page) 
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Figure 3.2.3.3: MPA selectively enhances TNF-induced TNFRSF1B expression in End1/E6E7 
cells. End1/E6E7 cells were treated with 100 nM MPA or 0.1% (v/v) EtOH (vehicle) in the presence or absence 
of 1.15 nM TNF for 24 hours. Thereafter, total RNA was isolated using RNeasy Mini kit (Qiagen, USA), assessed 
for integrity by Bioanalysis and then converted. The relative mRNA levels of IL1β (A), SLPI (B), TNF (C), 
TNFRSF1B (D), IRF2 (E), IRF1 (F), NFKB1A (G), SERPINAI (H) and CCL20 (I) were determined by qRT-PCR 
performed using gene specific primers and normalised to GAPDH mRNA levels. The relative effects of MPA, 
TNF or combo on mRNA levels of the selected genes were determined by normalising to vehicle only control, 
which has been set to 100%. The data include three independent biological repeats pooled and plotted as mean 
± SEM in   Graph Pad Prism 7 software. Statistical analysis was performed using one-way ANOVA with Tukey’s 
multiple comparisons and statistical significance denoted as *, ** or *** to indicate p<0.05, p<0.01 and p<0.005, 
respectively for comparisons between vehicle only and other treatments or between pair of treatments.  In some 
cases, the unpaired Student’s t-test was used for comparisons between vehicle only and other treatments, and 
statistical significance is denoted as # and #### to indicate p<0.05 and p<0.0001, respectively. 
 
In addition, the validation showed that MPA did not regulate TNF-induced SLPI, TNF and SERPINAI 
expression (Figure 3.2.3.3 B, C, H). However, the validation established that MPA potentiates TNF-
induced expression of TNFRSF1B and maybe NFKBIA (Figure 3.2.3.3 D, G). STAT3 could not be 
validated due to inability of primers to detect the gene.  Because the samples used in this analysis 
were not the same as those used in the array, a CCL20 confirmatory run was performed. This showed 
that MPA and TNF upregulated CCL20 expression (Figure 3.2.3.3 I). Despite the discrepancies 
between the array and qPCR validation, this analysis could identify another gene co-regulated by 
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MPA and TNF in End1/E6E7 cells. Moreover, of all the genes tested, MPA only potentiates TNF-
induced expression of TNFRSF1B and CCL20. 
 
3.2.4: MPA like DEX, but unlike NET, selectively enhances basal TLR2, GILZ and LPS-induced 
CCL20, suppress LPS-induced IL6, IL8 and IL1β, but does not alter basal TLR4 mRNA 
expression in End1/E6E7 cells. 
In Section 3.2.3, it was established that GCs and MPA, unlike NET, can positively cooperated with 
TNF to enhance CCL20 mRNA expression while retaining their ability to repress TNF-induced IL6, 
IL8 and IL1β mRNA expression in End1/E6E7 cells. Because TNF signals via NFκB activation, it was 
therefore investigated whether GC and MPA can also positively cooperate with other NFκB-activating 
ligands such as LPS to upregulate CCL20 and not IL6, IL8 and IL1β gene expression in End1/E6E7 
cells. To this end, End1/E6E7 cells were treated with 100 nM DEX, MPA or NET alone or in 
combination with 5 µg/mL LPS for 24 hours. 
 
As shown in Figure 3.2.4.1 A - D, LPS treatment significantly increased CCL20, IL6, IL1β and 
potentially IL8 mRNA levels. Concurrent treatment with DEX enhanced CCL20; suppressed IL6 and 
IL1β; and, appeared to inhibit IL8 expression in response to LPS (Figure 3.2.4.1 A – D). Although not 
statistically significant, MPA appeared to enhance CCL20 expression in response to LPS. In addition, 
MPA significantly suppressed LPS-induced IL6 and IL1β expression. Furthermore, MPA seemed to 
inhibit LPS-induced expression of IL8, but this effect was not statistically significant (Figure 3.2.4.1 A 
– D). Unlike DEX and MPA, NET did not affect LPS-induced induction of CCL20, IL6, IL8 or IL1β 
mRNA expression in End1/E6E7 cells. DEX and MPA, but not NET increased GILZ mRNA levels. 
While LPS inhibited the DEX-mediated increase in GILZ mRNA levels, it however did not alter MPA-
induced GILZ mRNA expression (Figure 3.2.4.1 E). 
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Figure 3.2.4.1: MPA like DEX, but not NET, regulates LPS-induced mRNA expression of select 
inflammatory genes in a ligand- and gene-specific manner in End1/E6E7 cells. End1/E6E7 cells 
were treated with 100 nM DEX, MPA, NET or 0.1% (v/v) EtOH (vehicle) in the presence or absence of 5 µg/mL 
LPS for 24 hours.  Thereafter, cells were harvested in Tri-Reagent®, total RNA isolated and converted to cDNA. 
The relative mRNA levels of CCL20 (A), IL6 (B), IL1β (C), IL8 (D) and GILZ (E) was determined by qRT-PCR 
using gene specific primers and normalised to GAPDH mRNA levels. The relative effects of steroid hormones 
and LPS on mRNA levels of the selected genes were determined by normalising to LPS, which has been set to 
100%. The data represent at least three independent biological repeats plotted as mean ± SEM in Graph Pad 
Prism 7 software. For data that was parametric (A, C, E), statistical analysis was performed using one-way 
ANOVA with Tukey’s multiple comparisons. Statistical significance denoted as *, **, *** and **** to indicate 
p<0.05, p<0.01, p<0.005 and p<0.0001, respectively for comparisons between vehicle only and other treatments 
or between other pair of treatments. In some cases, the unpaired Student’s t-test was used for comparison 
between vehicle only and other treatments with statistical significance is denoted as # and ### to indicate p<0.05 
A 
C D 
E 
B 
 
61 
 
and p<0.005, respectively. When the comparison was between other pair of treatments statistical significance 
is denoted as &&& to indicate p<0.005. Non-parametric data (B, D) were analysed using the Mann-Whitney U-
test for comparisons between vehicle only and other treatments with statistical significance denoted as # to 
indicate p<0.05, or the Kolmogorov-Smirnov test for comparison between LPS and LPS + steroids with statistical 
significance denoted as $ to indicate p<0.05.   
 
Previous studies have shown that GCs can co-operate with immune activators to upregulate TLR2 
and TLR4 mRNA levels (Shibata et al., 2009; Zhang et al., 2017; Su et al., 2017), receptors via which 
LPS mediates it biological effects (Yang et al., 1998). LPS has been shown to induce the expression 
of these receptors in human monocytes (Ma & Yang, 2010), but it is currently unknown whether these 
receptors can coregulated by GCs and LPS. However, it is currently controversial whether 
endocervical epithelial cells express TRL4 and thus respond to LPS (Fichorova et al., 2002; Herbst-
Kralovetz et al., 2008; Nold et al., 2012). Therefore, it was next investigated whether DEX, MPA or 
NET regulate TLR2 and TRL4 mRNA expression in the presence or absence of LPS in End1/E6E7 
cells. 
 
              
Figure 3.2.4.2: MPA and DEX unlike NET increases TRL2 but does not alter TRL4 mRNA levels 
in the absence or presence of LPS in End1/E6E7 cells. End1/E6E7 cells were treated with 100 nM 
DEX, MPA, NET or 0.1% (v/v) EtOH (vehicle) in the absence or presence of 5 µg/mL LPS for 24 hours. The 
cells were then harvested in Tri-Reagent®, total RNA isolated and converted to cDNA. The relative mRNA levels 
of TRL2 (A) and TRL4 (B) were determined by qRT-PCR using gene specific primers and normalised to GAPDH 
mRNA levels. The relative effects of steroid hormones and LPS on the mRNA levels of TLR2 and TLR4 were 
determined by normalising to LPS only, which was set to 100%. The data include three independent biological 
repeats plotted as mean ± SEM in Graph Pad Prism 7 software. Statistical analysis was performed using the 
unpaired Student’s t-test with significance denoted as ## or ### to indicate p<0.01 and p<0.0001, respectively. 
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In the absence of LPS, MPA like DEX, but not NET, significantly increased TRL2 mRNA levels in 
End1/E6E7 cells after 24 hours (Figure 3.2.4.2.A). In contrast, neither DEX, MPA nor NET regulated 
TRL4 mRNA levels (Figure 3.2.4.2 B). This result suggests that the MPA- or DEX-induced increase 
in TRL2 levels might be involved in the upregulation of CCL20 mRNA expression in End1/E6E7 cells 
in the presence of LPS. Unlike MPA and DEX, LPS did not regulate TRL2 and TLR4 mRNA levels in 
End1/E6E7 cells. The results suggest that LPS does not need to upregulate the expression of TLR2, 
TLR4 or both receptors in order to enhance its biological effects in End1/E8E7 cells. They also 
suggest that End1/E6E7 cells express TLR4 and respond to treatment with LPS. Differences in 
primers, concentration of LPS, and laboratory-specific changes in the properties of End1/E6E7 cells 
could explain the inconsistency between this study and Fichorova et al (2002).   
 
Taken together, these results suggest that MPA like DEX, but not NET, can modulate LPS-mediated 
transcription of immune mediators in End1/E6E7 cells; positively cooperating with LPS to upregulate 
CCL20 mRNA expression, but antagonising LPS-induced IL6, IL1β and potentially IL8 mRNA 
expression. These results also suggest that LPS inhibits GILZ expression in response to DEX and 
MPA.  
 
3.2.5: MPA increases TNF- and LPS-induced CCL20 protein secretion by End1/E6E7 cells. 
Considering that DEX and MPA, unlike NET, enhanced TNF- and LPS-induced CCL20 mRNA 
expression, it was next determined whether similar changes could be observed in CCL20 protein 
levels. CCL20 ELISA assays were performed using supernatants collected from experiments 
described in Figures 3.2.3.1 and 3.2.4.1.  
 
                                                                                                              
Figure 3.2.5: MPA potentiates both TNF- and LPS-mediated secretion of CCL20 protein by 
End1/E6E7 cells. End1/E6E7 cells were treated with 100 nM DEX, MPA, NET or 0.1% (v/v) EtOH (vehicle) 
in the presence or absence of 1.15 nM TNF (A) or 5 µg/mL LPS (B) for 24 hrs. Thereafter, supernatants were 
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collected and CCL20 ELISA assay was performed to quantify the concentration of secreted CCL20. The data 
include at least three independent biological repeats pooled and plotted as mean ± SEM in Graph Pad Prism 7 
software. For comparisons, the data has been plotted relative to TNF (A) or LPS (B), which are both set to 
100%. Statistical analysis was performed using either one-way ANOVA with Tukey’s multiple comparisons. 
Statistical significance is denoted as *** to indicate p<0.005 for comparisons between vehicle only and other 
treatments or between pair of treatments. In some cases, the unpaired Student’s t-test for comparison between 
TNF and TNF + steroids with statistical significance denoted as $ or $$ to indicate p<0.05 and p<0.01, 
respectively. 
 
As shown in Figure 3.2.5 A, treatment with TNF resulted in a significant increase in CCL20 secreted 
protein. In contrast, neither DEX, MPA nor NET altered basal CCL20 protein secretion. This was a 
surprising observation as DEX and MPA caused an increase in CCL20 mRNA expression. 
Interestingly, co-treatment of cells with DEX or MPA and TNF induced a stronger secretion of CCL20 
protein than TNF alone. Although not statistically significant, treating End1/E6E7 cells with LPS 
resulted in an increase in CCL20 protein secretion (Figure 3.2.5 B). MPA again significantly enhanced 
LPS-induced CCL20 protein secretion (Figure 3.2.5 B). 
 
Taken together, these results suggest DEX and MPA can potentiate TNF or LPS-mediated secretion 
of CCL20 protein in End1/E6E7 cells as found for mRNA. However, the protein expression data 
contrasted with the mRNA data in that neither DEX nor MPA induced basal CCL20 protein secretion.  
 
3.2.7: Summary of Findings 
In this chapter, incubations with 100 nM steroids were performed, and steroid dose-dependency was 
not investigated. The results show that MPA like DEX, but unlike NET, LNG or P4, downregulates 
claudin-4 mRNA levels, but not occludin and ZO-1 mRNA levels in End1/E6E7 cells. However, only 
DEX significantly downregulated occludin protein levels. TNF was found to induce claudin-4, ZO-1 
and potentially occludin mRNA expression and DEX more so than MPA inhibited the TNF-induced 
response. Despite increasing their mRNA levels, TNF was found to reduce occludin and potentially 
claudin-4 protein levels. DEX did not regulate TNF-induced reduction of occludin and claudin-4 protein 
levels.  
 
Results in this chapter also established that MPA like GCs, but unlike NET, differentially regulates 
basal and TNF- or LPS-stimulated expression of CCL20, IL6, IL1β, lL8 and CCL5 mRNA in 
End1/E6E7 cells. More specifically, it was established that in the absence of immune activators MPA 
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like GCs, but not NET, enhanced CCL20 mRNA expression, but suppressed basal IL6 and IL1β 
mRNA expression, and did not alter basal IL8 and CCL5 mRNA expression. In addition, it was shown 
that MPA like GCs, but unlike NET, selectively enhanced CCL20 mRNA expression, but suppressed 
IL6, IL1β and IL8 expression in the presence of TNF or LPS. The results further show that MPA like 
DEX can enhance TNF- or LPS-induced secretion of CCL20 protein secretion by End1/E6E7 cells. In 
addition, it was observed that MPA like DEX, but unlike NET, induced TLR2 mRNA expression in 
End1/E6E7 cells. While TLR2 was not co-regulated by MPA and LPS, it was found that MPA can 
enhance TNF-induced expression of TNF receptor type 2 (TNFRSF1B).  
 
Taken together, MPA like GCs regulates the basal expression of specific tight junction and immune 
function genes in End1/E6E7 cells, but only cooperate with immune activators to upregulate the 
expression of select immune function but not tight junction genes. 
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Chapter Four 
 
The glucocorticoid receptor mediates the potent partial agonistic MPA-induced 
downregulation of claudin-4 gene expression as well as the gene-specific and synergistic 
interactions between MPA and immune activators that upregulate CCL20 gene expression in 
the endocervical epithelial cell line  
 
4.1: Aims 
In the previous chapter, it was established that MPA, unlike other progestins, downregulates select 
TJ genes, and positively cooperates with immune activators to upregulate CCL20, but not IL6 
expression in the endocervical epithelial End1/E6E7 cell line. An intriguing question is whether this 
can occur at physiologically relevant concentrations and what steroid receptor is involved.  Therefore, 
the objectives of this chapter were to investigate aims C and D (section 1.5) with the following specific 
questions: 
• What are the efficacies, potencies and biocharacters of GCs and progestogens for 
regulation of gene expression? 
• Do GCs and progestogens act synergistically with immune activators to regulate gene 
expression? 
• Is the observed regulation dependent on the GR? 
 
These questions were investigated in End1/E6E7 cells because they have been shown to express 
the GR but not the PR (Govender et al., 2014). The role of the GR in the regulation of gene expression 
by GCs and progestogens was investigated using 1 µM RU486. Because the test steroids were used 
at a concentration of 100 nM, it was predicted that about a ten-fold higher concentration of RU486 to 
out-compete the test steroids for receptor binding, given that the affinity is similar or greater than DEX 
for the GR. GR knockdown by siRNA was used in some specific experiments to obtain further proof. 
Dose response analysis was performed to determine the efficacies, potencies and biocharacter of 
progestogens relative to DEX, a synthetic GR ligand on the expression of claudin-4, occludin and 
GILZ. This was done in the absence of TNF as neither DEX nor progestogens coregulated TJ gene 
expression in End1/E6E7 cells. Additional dose-response assessment was performed to determine 
the efficacies, potencies and biocharacter of MPA relative to CORT in the absence or presence of 
TNF on the expression of CCL20, IL6 and GILZ. To determine whether MPA like CORT synergised 
with TNF to upregulate CCL20, End1/E6E7 cells were treated as described in section 4.2.3. The 
biocharacters of MPA were initially compared to DEX, but subsequent comparisons were done 
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relative to CORT as the latter is more physiologically relevant and women using DMPA have been 
shown to have high serum CORT levels (Virutamasen et al., 1986).      
 
4.2: Results 
4.2.1: MPA is a partial agonist in repressing claudin-4 and occludin and upregulating GILZ 
mRNA levels in End1/E6E7 cells 
Dose-response analyses were performed to determine the potency (EC50), efficacy (maximal 
response) and biocharacter of DEX and MPA in regulating claudin-4, occludin and GILZ mRNA levels 
in End1/E6E7 cells. These analyses revealed that the potencies of DEX and MPA in repressing 
claudin-4 mRNA levels were 4.35 nM and 14.27 nM, respectively (Figure 4.2.1 A, B). It was also 
observed that MPA like DEX inhibited occludin mRNA expression in a dose-dependent manner with 
potencies of 131.2 nM and 8.56 nM, respectively (Figure 4.2.1 C, D). Furthermore, MPA like DEX 
increased GILZ mRNA levels in a dose-dependent manner with potencies of 36.07 nM and 12.16 nM, 
respectively. Compared to DEX, the efficacies of MPA for repressing claudin-4 and occludin mRNA 
expression were 53.83% and 29.01%, respectively; while its efficacy for inducing GILZ mRNA 
expression was 33.12%. This suggest that MPA is partial agonist for transrepression and 
transactivation in End1/E6E7 cells (Ronacher et al., 2009). Neither NET nor P4 regulated claudin-4 
and occludin mRNA levels even at higher doses (Appendix B, Figure 1). Taken together, these 
results demonstrate that DEX is more potent and efficacious than MPA in suppressing claudin-4 and 
occludin mRNA expression, and in inducing GILZ expression in End1/E6E7 cells. They also show 
that claudin-4 is much more sensitive than occludin to repression by DEX or MPA.  
 
         
Figure 4.2.1: The regulation of claudin-4 and occludin mRNA levels by DEX and MPA in 
End1/E6E7 cells occurs in a dose-dependent manner. (continued on the next page) 
A B 
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Figure 4.2.1: The regulation of claudin-4 and occludin mRNA levels by DEX and MPA in 
End1/E6E7 cells occurs in a dose-dependent manner. Confluent End1/E6E7 cells were stimulated with 
increasing concentrations of DEX or MPA for 24 hours. Thereafter, the cells were harvested in Tri-Reagent®, 
total RNA isolated and converted to cDNA and relative mRNA levels of claudin-4 (A), occludin (C), GILZ (E) 
were determined by qRT-PCR using gene specific primers and normalised to GAPDH mRNA levels. The relative 
effects of steroid hormones on mRNA levels of the selected genes were determined by normalising to own 
vehicle, which is set to 1. For dose-response curve generation, data shown in (A), (C) and (E) was re-normalised 
by setting maximal response generated by DEX to 100%. Curves for claudin-4 (B), occludin (D) and GILZ (F) 
were plotted using a non-linear regression model, plotting log agonist vs response, with the Hill slope set to 1. The 
data include at least three independent biological repeats plotted as mean ± SEM in GraphPad Prism 7 software. 
Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparisons and statistical 
significance denoted as **, ***, or **** to indicate p<0.01, p<0.005 and p<0.0001, respectively. In some cases, 
the unpaired Student’s t-test was used for comparisons and statistical significance was denoted as #, ## and #### 
to indicate p<0.05, p<0.01 and p<0.0001, respectively.  
 
4.2.2: The repression of claudin-4 mRNA expression by DEX and MPA occurs via the GR 
The steroid receptor antagonist RU486 was used to verify the involvement of the GR in the repression 
of claudin-4 mRNA levels by DEX and MPA in End1/E6E7 cells. Previous studies have shown that 
C 
E F 
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RU486 is not a GR-specific antagonist as it can also antagonise the PR (Beck et al., 1993). In this 
regard, Western blot analysis was performed to check for the expression of the GR and PR in 
End1/E6E7 cells. As shown in Appendix B Figure 2, End1/E6E7 cells expressed detectable levels 
of the GR, but not the PR. This result confirmed previous findings by Govender et al that End1/E6E7 
cells do not express the PR (Govender et al., 2014). Govender and colleagues further showed that 
End1/E6E7 cells also do not express detectable levels of the MR, AR and ER protein (Govender et 
al., 2014). Taken together, this result implied treating End1/E6E7 cells with RU486 would result in the 
inhibition of only GR-regulated pathways.  
 
Next, the involvement of the GR in the DEX- and MPA-induced reduction of claudin-4 mRNA levels 
in End1/E6E7 cells was investigated. Confluent End1/E6E7 cells were pre-treated for 2 hours with 1 
µM RU486 and then exposed to 100 nM DEX or MPA for a further 24 hours. As shown in Figure 
4.2.2, DEX- and MPA-induced reduction in claudin-4 mRNA levels were significantly inhibited in the 
presence of RU486. This result shows that the GR is involved in the reduction of claudin-4 mRNA 
levels in End1/E6E7 cells by DEX and MPA.  
 
       
Figure 4.2.2: The glucocorticoid receptor is required for DEX- and MPA-induced reduction in 
claudin-4 mRNA levels in End1/E6E7 cells. Confluent End1/E6E7 cells were pre-treated with 1 µM 
RU486 or 0.1% (v/v) EtOH (vehicle) for 2 hours and thereafter stimulated with 100 nM DEX, MPA or 0.1% (v/v) 
EtOH (vehicle) for another 24 hours. Cells were then harvested in TriReagent®, total RNA isolated and converted 
to cDNA. The relative mRNA levels of claudin-4 (A), GILZ (B) were determined by qPCR using gene specific 
primers and normalised to GAPDH mRNA levels. The relative effects of steroid hormones in the presence or 
absence of RU486 were determined by normalising to the vehicle only control, which has been set to 1. The 
data includes at least three independent biological repeats plotted as mean ± SEM in GraphPad Prism 7 
software. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparisons and 
statistical significance denoted as *, *** or **** to indicate p<0.05, p<0.005 and p<0.0001, respectively. In some 
cases, the unpaired Student’s t-test was used to compare vehicle only with other ligand conditions and statistical 
significance is denoted as # to indicate p<0.05. 
A B 
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Further experiments to verify the requirement of the GR for DEX- and MPA-induced repression of 
claudin-4 mRNA production were performed. In these experiments, End1/E6E7 cells were transiently 
transfected with 20 nM scramble or GR5 siRNA for 48 hours and then treated with 100 nM DEX or 
MPA for another 24 hours. As shown in Appendix B Figure 3, GR knockdown only slightly lifted the 
DEX- and not the MPA-induced repression of claudin-4 mRNA production. The overall percentage of 
knockdown achieved was approximately about 50%. Under this condition, it is possible that there was 
still enough GR in the cells to mediate the repressive effects of DEX and MPA on claudin-4 mRNA 
expression. However, it remains unclear why DEX-induced repression of claudin-4 and not MPA is 
sensitive to reduced GR levels, given that both DEX- and MPA-induced expression of GILZ was 
partially inhibited. Taken together, these results suggest that GR is required for the DEX- and MPA-
induced repression of claudin-4 mRNA levels in End1/E6E7 cells. In addition, the GR also mediates 
DEX- and MPA-induced expression of GILZ in End1/E6E7 cells.  
 
4.2.3: MPA like CORT dose-dependently regulates CCL20, IL6 and GILZ mRNA levels in 
End1/E6E7 cells  
In Chapter 3, it was established that GCs and MPA enhanced CCL20, but repressed IL6 mRNA 
expression in the absence or presence of TNF in End1/E6E7 cells. It was also observed that TNF 
antagonised GC- and MPA-induced expression of GILZ. Because these effects were observed at 100 
nM GC or MPA and 1.15 nM TNF, it was investigated whether lower doses of the ligands could 
differentially regulate CCL20, IL6 and GILZ. To this end, End1/E6E7 cells were treated for 24 hours 
with; 
1. Increasing concentrations of TNF in the absence or presence of 100 nM MPA or CORT 
2. Increasing concentrations of MPA or CORT in the absence or presence of 1.15 nM TNF 
 
The panel of genes were reduced to GILZ, IL6 and CCL20 to represent transactivation, 
transrepression and transactivation with positive cooperativity models, respectively. Furthermore, the 
steroid hormones were also reduced to MPA and CORT in order to compare MPA with a natural GC. 
NET was excluded because if failed to induce any noticeable responses at 100 nM, a concentration 
that is higher than serum concentrations in women using NET as hormonal contraceptive. 
 
4.2.3.1: Increasing TNF and constant MPA or CORT  
Compared with vehicle control, TNF appeared to increase CCL20 mRNA levels in a dose-dependent 
manner (Figure 4.2.3.1 A). Doses as low as 0.057 nM appeared to induce CCL20 mRNA expression. 
The addition of MPA appeared to enhance TNF-induced increase in CCL20 mRNA levels. For 
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instance, CCL20 mRNA levels induced by 0.057 nM TNF rose from 18.81 in the absence of MPA to 
59.56-fold in the presence of MPA (Figure 4.2.3.1 A). In addition, TNF significantly induced IL6 mRNA 
expression in a dose-dependent manner – an effect blocked by MPA (Figure 4.2.3.1 B). Although not 
statistically significant, it was observed that TNF suppressed basal and MPA-induced increase in GILZ 
mRNA expression (Figure 4.2.3.1 C). Concentrations of TNF as low as 0.057 nM might reduce basal 
GILZ and MPA-induced mRNA expression.  
 
             
               
Figure 4.2.3.1: The regulation of CCL20, IL6 and GILZ mRNA levels by TNF in the absence or 
presence of MPA or CORT in End1/E6E7 cells is dose-dependent. (continued on the next page) 
A       D 
B E 
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Figure 4.2.3.1: The regulation of CCL20, IL6 and GILZ mRNA levels by TNF in the absence or 
presence of MPA or CORT in End1/E6E7 cells is dose-dependent. End1/E6E7 cells were stimulated 
with increasing concentrations of human TNF in the presence or absence of 100 nM MPA for 24 hours. In 
another non-parallel experiment, the cells were stimulated with increasing concentrations of human TNF in the 
presence or absence of 100 nM CORT for 24 hours the Thereafter, cells were harvested in Tri-Reagent®, total 
RNA was isolated and converted to cDNA. The relative mRNA levels of CCL20 (A, D), IL6 (B, E), GILZ (C, F) 
were determined by qPCR using gene specific primers and normalised to GAPDH mRNA levels. The relative 
effects of each ligand and ligand combinations on mRNA levels of the selected genes were determined relative 
to TNF 5.76 nM, which was set to 100%. The data include at least three independent biological repeats pooled 
and plotted as mean ± SEM in GraphPad Prism 7 software. (B, D) was analysed using one-way ANOVA with 
Tukey’s multiple comparison. Statistical significance is denoted as *, ** or *** to indicate p<0.05, p<0.01 and 
p<0.005, respectively for comparison between vehicle only and other treatments. In some cases, the unpaired 
Student’s t-test was used for comparisons between vehicle only and other treatments and statistical significance 
denoted as #, ## or #### to indicate p<0.05, p<0.01 and p<0.0001, respectively. When the comparison is between 
corresponding TNF doses in the presence or absence of MPA statistical significance is denoted as $, $$ or $$$ to 
indicate p<0.05, p<0.01 and p<0.005, respectively. (A, C, E, F) was analysed using Kruskal-Wallis with Dunn’s 
multiple comparison and in some cases, the Mann-Whitney U-test for pairwise comparisons. 
 
It was also observed that the effects of MPA on TNF-induced gene expression were like those of 
CORT. As shown in Figure 4.2.3.1 D, CORT at 100 nM significantly enhanced TNF-induced CCL20 
mRNA expression even at TNF doses as low as 0.057 nM. In contrast to CCL20, CORT suppressed 
TNF-induced IL6 mRNA expression and retained this ability even at higher doses of TNF (Figure 
4.2.3.1 E). On the other hand, TNF at doses as low as 0.057 nM appeared to suppress CORT-induced 
GILZ mRNA expression (Figure 4.2.3.1 F).  
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4.2.3.2: Increasing MPA or CORT and constant TNF 
Compared to vehicle control, MPA increased CCL20 in a dose-dependent manner, with significant 
expression occurring at 100 nM (Figure 4.2.3.2 A). The addition of TNF at 1.15 nM enhanced MPA-
mediated increase in CCL20 mRNA expression. It was observed that TNF was able to enhance MPA-
induced response at concentrations as low as 1 nM. In contrast, MPA inhibited basal as well as TNF-
induced expression of IL6 in a dose-dependent manner, with significant inhibition occurring at 100 nM 
and 1 nM, respectively. It was also observed that MPA induced GILZ transcription in a dose-
dependent manner. MPA-induced increase of GILZ mRNA levels was inhibited by TNF (Figure 
4.2.3.2 A, B). 
 
                     
             
Figure 4.2.3.2: The regulation of CCL20, IL6 and GILZ mRNA levels by MPA or CORT in the 
absence or presence of TNF in End1/E6E7 cells is dose-dependent. (continued on the next 
page) 
A  
B 
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Figure 4.2.3.2: The regulation of CCL20, IL6 and GILZ mRNA levels by MPA or CORT in the 
absence or presence of TNF in End1/E6E7 cells is dose-dependent. End1/E6E7 cells were treated 
with increasing concentrations of MPA in the presence or absence of 1.15 nM human TNF for 24 hours. In 
another non-parallel experiment, cells were treated with increasing concentrations of CORT in the presence or 
absence of 1.15 nM human TNF for 24 hours. Thereafter, the cells were harvested in Tri-Reagent®, total RNA 
isolated and converted to cDNA. The relative mRNA levels of CCL20 (A, D), IL6 (B, E), GILZ (C, F) were 
determined by qPCR using gene specific primers and normalised to GAPDH mRNA levels. The relative effects 
of various MPA and TNF combinations on mRNA levels of the selected genes were determined by normalising 
the date to TNF 1.15 nM (A, B, C), which is set to 100%. The data include at least three independent biological 
repeats pooled and plotted as mean ± SEM in GraphPad Prism 7 software. (A) was analysed using one-way 
ANOVA with Tukey’s multiple comparisons and statistical significance denoted as * or **** to indicate p<0.05 
and p<0.0001, respectively for comparison between vehicle only and other treatments. In some cases, the 
unpaired Student’s t-test was used for comparisons between TNF only and other treatments with statistical 
significance denoted as $ or $$ to indicate p<0.05 and p<0.01, respectively. (B, C) was analysed using the Mann-
Whitney U-test (or Kolmogorov-Smirnov test when TNF is set to 100%). Statistical significance is denoted as # 
to indicate p<0.05 for pairwise comparison between vehicle only and other treatments. For pairwise 
comparisons between TNF only and other treatments, significance is denoted as $ to indicate p<0.05. When the 
comparison was between corresponding MPA doses ±TNF, significance is denoted as & to indicate p<0.05.   
 
The effects of MPA on basal and TNF-induced gene expression mirrored those of CORT (Figure 
4.2.3.2 D – F). CORT appeared to increase basal and TNF-induced CCL20 mRNA expression in a 
dose-dependent manner. CORT doses as low as 1 nM might enhanced TNF-induced but not basal 
CCL20 mRNA expression; CORT appeared to increase basal expression of CCL20 mRNA at 10nM 
and not 1nM (4.2.3.2 D). It was also observed that only higher doses of CORT (>100 nM) may block 
basal and TNF-induced IL6 mRNA expression (Figure 4.2.3.2 E). Lastly, CORT appeared to induce 
GILZ mRNA expression in a dose-dependent manner and TNF at 1.15 nM might inhibit the CORT-
mediated effect (Figure 4.2.3.2 F). 
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In summary, these results demonstrate a reciprocal regulation of gene expression by MPA (as well 
as CORT) and TNF. They also demonstrate that TNF may increase or decrease the sensitivity of a 
gene to MPA or CORT.  
 
4.2.3.3: MPA/CORT and TNF mutually alter each other’s efficacies and potencies as they 
coregulate CCL20, IL6 and GILZ mRNA levels in End1/E6E7 cells. 
In Figure 4.2.3.1 and Figure 4.2.3.2, it is seen that the transactivation of CCL20 and GILZ by MPA 
and CORT can either be increased (CCL20) or antagonised (GILZ) by TNF. Likewise, MPA and CORT 
increased TNF-induced CCL20 mRNA expression, but inhibited TNF-induced IL6 mRNA expression. 
These observations suggest that in some cases MPA or CORT and TNF positively cooperate to 
enhance gene expression (CCL20) and in others they antagonise each other (GILZ and IL6). It was 
next investigated whether this reciprocal regulation is achieved by altering each other’s potencies for 
activating or inhibiting gene expression. 
 
        
       
Figure 4.2.3.3.1: The co-regulation of CCL20, IL6 and GILZ mRNA levels by MPA and TNF in 
End1/E6E7 cells involves the ligands affecting each other’s efficacies and maybe potencies. 
(continued on the next page) 
A D 
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Figure 4.2.3.3.1: The co-regulation of CCL20, IL6 and GILZ mRNA levels by MPA and TNF in 
End1/E6E7 cells involves the ligands affecting each other’s efficacies and maybe potencies. 
In (A, B and C), End1/E6E7 cells were stimulated with increasing concentrations of human TNF in the presence 
or absence of 100 nM MPA for 24 hours. In (D, E and F), End1/E6E7 cells were treated with increasing 
concentrations of MPA in the presence or absence of 1.15 nM human TNF for 24 hours. Cells were then 
harvested in Tri-Reagent®, total RNA isolated and converted to cDNA. The relative mRNA levels of CCL20 (A, 
D), IL6 (B, E), GILZ (C, F), were determined by qPCR using gene specific primers and normalised to GAPDH 
mRNA levels. The relative effects of steroid hormones and TNF on mRNA levels of the selected genes were 
determined by either normalising to TNF5.76 nM or TNF1.15 nM, with both TNFs set to 100%. The data include 
at least three independent biological repeats pooled and plotted as mean ± SEM in GraphPad Prism 7 software.        
 
      
      
Figure 4.2.3.3.2: The co-regulation of CCL20, IL6 and GILZ mRNA levels by CORT and TNF in 
End1/E6E7 cells involves the ligands affecting each other’s efficacies and maybe potencies. 
(continued on the next page) 
C F 
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Figure 4.2.3.3.2: The co-regulation of CCL20, IL6 and GILZ mRNA levels by CORT and TNF in 
End1/E6E7 cells involves the ligands affecting each other’s efficacies and maybe potencies. 
In (A, B and C), End1/E6E7 cells were stimulated with increasing concentrations of human TNF in the presence 
or absence of 100 nM CORT for 24 hours. In (D, E and F), End1/E6E7 cells were treated with increasing 
concentrations of CORT in the presence or absence of 1.15 nM human TNF for 24 hours. Cells were then 
harvested in TriReagent®, total RNA isolated and converted to cDNA. The relative mRNA levels of CCL20 (A, 
D), IL6 (B, E), GILZ (C, F), were determined by qPCR using gene specific primers and normalised to GAPDH 
mRNA levels. The relative effects of steroid hormones and TNF on mRNA levels of the selected genes were 
determined by either normalising to TNF5.76 nM or TNF1.15 nM, with both TNFs set to 100%. The data include 
at least three independent biological repeats pooled and plotted as mean ± SEM in GraphPad Prism 7 software.      
 
Data presented in Figures 4.2.3.1 and Figure 4.2.3.2 were used to generate dose-response curves, 
which are now shown in Figure 4.2.3.3.1 and Figure 4.2.3.3.2. The maximum responses (efficacies) 
and potencies (EC50) were deduced from these curves for each gene and have been summarised in 
Tables 4.2.1.1. As shown in Table 4.2.1.1, GILZ was induced by MPA, while co-treatment with TNF 
significantly reduced GILZ maximum mRNA expression from 459.2 ± 33.30 to 231.1 ± 53.59. IL6 was 
induced by TNF and the presence of MPA significantly reduced the efficacy of TNF from 113.6 ± 
8.839 to 42.16 ± 19.32. When CCL20 was induced by MPA, co-treatment with constant TNF increased 
the maximum response from 40.92 ± 23.12 to 481.2 ± 148.  When CCL20 was induced by TNF, co-
treatment with 100 nM MPA enhanced the maximum response from 127.0 ± 40.76 to 260.0 ± 50.56. 
Given the error in the EC50 value, and few points on the slope, it could not be determined whether the 
potencies of each ligand for transactivation and transrepression were affected in the presence of the 
other. Further experiments to include more doses are needed to provide clarity on the matter.  
 
CORT also increased the maximum response of TNF for transactivating CCL20 from 97.18 ± 10.77 
to 361.4 ± 43.15. CORT also reduced TNF’s efficacy for inducing IL6 from 104.9 ± 16.56 to 46.15 ± 
21.16. On the other hand, TNF increased the efficacy of CORT for CCL20 gene expression from 
35.79 ± 9.368 to 803.0 ± 332.8. No major differences in potencies were recorded for similar reasons 
mentioned above. 
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Table 4.2.1.1: The changes in efficacies (maximum responses) and potencies (EC50) of selected inflammatory genes coregulated by 
MPA/CORT and TNF in End1/E6E7 cells 
 
 CCL20 IL6 GILZ 
Efficacy (%TNFab) EC50 (nM) Efficacy (%TNFab) EC50 (nM) Efficacy (%TNFab) EC50 (nM) 
MPA ↑ 40.92 ± 23.12 65.92 ± 111.7 1.988 ± 0.866 26.12 ± 31.65 459.2 ± 175.5 25.54 ± 33.30 
MPA ↑ + constant TNFa 481.2 ± 148.8# 14.87 ± 14.00 36.48 ± 12.86# 45.82 ± 80.87 231.1 ± 53.59# 4.891 ± 4.007 
TNF ↑ 127.0 ± 40.79 0.545 ± 0.150 113.6 ± 8.839 0.901 ± 0.935 ~ 89543 ± 154789 ~0.023 ± 0.017 
TNF ↑ + constant MPAb 260.0 ± 50.56*** 0.199 ± 0.094 42.16 ± 19.32*** 1.208 ± 1.559 ~ 194.5 ± 146.8 ~0.0194 ± 0.314 
CORT ↑ 35.79 ± 9.368 31.92 ± 12.76 5.217 ± 5.823 68.90 ± 115.1 901.0 ± 416.1 82.33 ± 73.53 
CORT ↑ + constant TNFa 803.0 ± 332.8 59.97 ± 68.88 32.87 ± 11.84 75.08 ± 103.5 557.3 ± 71.92 801.9 ± 1209 
TNF ↑ 97.18 ± 10.77 0.087 ± 0.047 104.9 ± 16.56 0.171 ± 0.129 ~ 105.8 ± 9.967 ~0.035 ± 0.035 
TNF ↑ + constant CORTb 361.4 ± 43.15*** 0.266 ± 0.286 46.15 ± 21.16# 0.308 ± 0.200 ~ 247.4 ± 24.40 ~0.008 ± 0.014 
  a For MPA dose, constant 1.15 nM human TNF was used, and this was set to 100% 
 b For TNF dose the highest concentration i.e. 5.76 nM was set to 100% 
Statistics: One-way ANOVA with Tukey’s multiple correction and statistical significance is denoted as *** to indicate p<0.005.  
Mann-Whitney U-test and statistical significance denoted as # to indicate p<0.05 
NB: Data indicates mean ± SD 
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4.2.3.4: The cooperative upregulation of CCL20 mRNA levels in End1/E6E7 cells by MPA or CORT 
and TNF is synergistic 
To determine whether the coregulation of CCL20 mRNA production by TNF and MPA or CORT in 
End1/E6E7 cells is synergistic, the data presented in Figures 4.2.3.1,2 was subjected to Chou Analysis. 
This method was introduced by Chou and Talalay (Chou, 2010) and was designed to determine whether 
a combination of drugs can elicit a response that is synergistic. This is achieved by computing a 
combination index (CI) for each drug combination using the Compusyn software. An CI less than 1 is 
defined as synergism. Using this method, CI values for each MPA or CORT: TNF combination were 
determined and are shown in Figure 4.2.3.4. It was observed that MPA or CORT doses ranging from 
10 nM to 1000 nM strongly synergised with 1.15 nM TNF to upregulate CCL20 transcription in 
End1/E6E7 cells. Similarly, TNF doses ranging from 0.057 nM to 5.76 nM strongly synergised with 100 
nM MPA or CORT to upregulate CCL20 mRNA levels in this cell line.  
 
      
Figure 4.2.3.4: MPA like CORT synergises with TNF to upregulate CCL20 mRNA levels in 
End1/E6E7 cells. In one experiment, End1/E6E7 cells were treated with varying concentrations of MPA in the 
absence or presence of constants 1.15 nM TNF. In another, the cells were treated with increasing concentration 
of TNF in the absence or presence of 100 nM MPA or CORT for 24 hours. Thereafter, the cells were harvested in 
Tri-Reagent®, total RNA isolated and converted to cDNA. The relative mRNA levels of CCL20 and GAPDH were 
determined by qPCR using gene specific primers. The average GAPDH Ct values for one experiment was used 
to normalised GAPDH Ct values in the other and fold changes in CCL20 expression in were determined by 
normalising to adjusted GAPDH levels.  The relative effects of various MPA (A) or CORT (B) and TNF 
combinations on CCL20 mRNA expression was determined by normalising vehicle only control. Thereafter, 
highest fold change for each biological repeat was set to 0.99 and others calculated relative to this value. Each 
single or ligand combination dose and their respective response were keyed into the Compusyn software to 
determine the Combination indices (CI). The CI were then plotted in GraphPad Prism 7 software as mean ± SEM. 
CI values below the red dotted line indicate synergism (CV < 1).  CI below the black dotted line indicates very 
strong synergism. 
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4.2.4: MPA like GCs acts via the GR to synergise with immune activators to upregulate CCL20 
mRNA levels, repress IL6 mRNA levels and increase GILZ mRNA levels in End1/E6E7 cells. 
To examine the role of the GR in the differential regulation of CCL20, IL6 and GILZ, End1/E6E7 cells 
were pre-treated with 1 µM RU486 for 2 hours before concurrent stimulation with hormones and TNF. 
As shown in Figure 4.2.4.1 A, DEX, CORT and MPA, but not NET appeared to increase basal and TNF-
induced production of CCL20 mRNA. These effects were completely prevented in the presence of 
RU486, showing that the GR is involved in the enhancement of basal and TNF-induction of CCL20 by 
DEX, CORT and MPA.  In addition, both basal and TNF-induced IL6 expression was significantly 
suppressed by DEX, CORT and MPA, but not NET. This suppression was, however, lifted in the 
presence of RU486, again showing that the GR was required for the DEX-, CORT- and MPA-induced 
repression of IL6 expression (Figure 4.2.4.1 B). Furthermore, RU486 prevented the induction of GILZ 
by DEX, CORT and MPA in the absence or presence of TNF (Figure 4.2.4.1 C).  
 
 
Figure 4.2.4.1: The GR is required for DEX, CORT and MPA upregulation of TNF-induced CCL20 
mRNA levels, suppression of TNF-induced IL6 mRNA levels, and upregulation of GILZ mRNA 
levels in End1/E6E7 cells.  (continued on the next page) 
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Figure 4.2.4.1: The GR is required for DEX, CORT and MPA upregulation of TNF-induced CCL20 
mRNA levels, suppression of TNF-induced IL6 mRNA levels, and upregulation of GILZ mRNA 
levels in End1/E6E7 cells. End1/E6E7 cells were pre-treated for 2 hours with 1 µM RU486 or 0.1% (v/v) EtOH 
(vehicle) and thereafter treated with 100 nM DEX, CORT, MPA, NET or 0.1% (v/v) EtOH in the absence or 
presence of 1.15 nM TNF for another 24 hours.  The cells were the harvested in Tri-Reagent®, total RNA isolated 
and cDNA made. The relative mRNA levels of CCL20 (A), IL6 (B) and GILZ (C) were determined by qPCR using 
gene specific primers and normalised to GAPDH mRNA levels. The relative effects of steroid hormones and TNF 
on mRNA levels of the selected genes were determined by normalising the data to TNF only, which is set to 100%. 
The data include at least three independent biological repeats was plotted as mean ± SEM in GraphPad Prism 7 
software. (B) was analysed using one-way ANOVA with Tukey’s multiple comparisons and statistical significance 
denoted as *, ** or **** to indicate p<0.05, p<0.01 and p<0.0001, respectively for comparisons between vehicle 
only and other treatments or between other pair of treatments. In some cases, the unpaired Student’s t-test was 
used for comparisons between vehicle and other treatments and statistical significance denoted as # to indicate 
p<0.05. When the comparison was between TNF and other treatments, statistical significance is denoted as $$$ to 
indicate p<0.005. When the comparison was between treatments in control and their corresponding treatments in 
B 
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the presence of RU486, significance is denoted as &, &&, &&& or &&&& to indicate p<0.05, p<0.01, p<0.005 and 
p<0.0001, respectively. (A, C) were analysed using Kruskal-Wallis with Dunn’s multiple comparison and in some 
cases, the Mann-Whitney U-test for pairwise comparisons.  
 
Next, it was investigated whether the GR mediates the upregulation of LPS-induced CCL20 expression 
by DEX or MPA in End1/E6E7 cells. As shown in Figure 4.2.4.2 A, RU486 strongly inhibited 
upregulation of LPS-induced CCL20 mRNA expression that occurs in the presence of DEX or MPA. In 
addition, RU486 significantly inhibited the suppression of LPS-induced IL6 mRNA expression by DEX 
and MPA (Figure 4.2.4.2 B). Furthermore, RU486 inhibited the DEX and MPA-induction of GILZ mRNA 
expression in the absence or presence of LPS (Figure 4.2.4.2 C). 
 
 
Figure 4.2.4.2: The GR is required for DEX and MPA enhancement of LPS-induced CCL20 mRNA 
levels, suppression of LPS-induced IL6 mRNA levels, and upregulation of GILZ mRNA levels in 
End1/E6E7 cells. (continued on the next page) 
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Figure 4.2.4.2: The GR is required for DEX and MPA enhancement of LPS-induced CCL20 mRNA 
levels, suppression of LPS-induced IL6 mRNA levels, and upregulation of GILZ mRNA levels in 
End1/E6E7 cells. End1/E6E7 cells were pre-treated for 2 hours with 1 µM RU486 or 0.1% (v/v) EtOH (vehicle) 
and thereafter treated with100 nM DEX, MPA, NET or 0.1% (v/v) EtOH (vehicle) in the presence or absence of 5 
µg/mL LPS for another 24 hours. The cells were then harvested in Tri-Reagent®, total RNA isolated and converted 
to cDNA. The relative mRNA levels of CCL20 (A), IL6 (B) and GILZ (C) were determined by qRT-PCR performed 
using gene specific primers and normalised to GAPDH mRNA levels. The relative effects of steroid hormones and 
LPS on mRNA levels of the selected genes were determined by normalising to LPS only, which has been set to 
100%. The data include at least three independent biological repeats plotted as mean ± SEM in GraphPad Prism 
7 software. The data was then tested for normality using the Shapiro-Wilk test and found to be non-parametric. 
Statistical analysis was performed using the Mann-Whitney U-test (or Kolmogorov-Smirnov test when the control 
was set to 100%). Statistical significance is denoted as # to indicate p<0.05 for pairwise comparison between 
vehicle only and other treatments. For pairwise comparisons between TNF and other treatments, significance is 
denoted as $ to indicate p<0.05. When the comparison was between conditions in control and their corresponding 
treatments in the presence of LPS or RU486, significance is denoted as & to indicate p<0.05. 
B 
C 
 
83 
 
Taken together, these results show that MPA like GCs, but unlike NET, acts via the GR to upregulate 
basal GILZ and CCL20 mRNA levels, while repressing IL6 mRNA levels in End1/E6E7 cells. In addition, 
these results show that the GR is involved in the expression of GILZ by MPA in the presence of immune 
activators.  Because immune activators only partially repressed GILZ expression, these results suggest 
some components of GC- and MPA-induced pathways are insensitive to inhibition by LPS and TNF. 
 
4.2.5: The potentiation of TNF-induced CCL20 mRNA production by DEX and MPA in End1/E6E7 
cells does not require changes in GR protein levels 
In the previous section, it was shown that the GR was required for the regulation of basal and TNF-
induced CCL20 by DEX and MPA (Figure 4.2.4.1). However, it does not indicate the features of the GR 
that are involved in the DEX or MPA enhancement of TNF-induced expression of CCL20. GCs are 
known to induce rapid turnover of GR protein levels. In contrast, previous studies have shown that TNF 
can induce nascent and/or stabilise pre-existing GR cellular levels. It was next investigated whether the 
synergistic upregulation of CCL20 mRNA levels by DEX or MPA and TNF occurs because TNF prevents 
DEX or MPA-induced GR turnover.  
 
To verify these hypotheses, two parallel experiments were setup in which End1/E6E7 cells were treated 
with either 100 nM DEX or MPA in the absence or presence of 1.15 nM TNF for 24 hours. One 
experiment was harvested for RNA preparation to verify CCL20 mRNA levels and the other for protein 
to asses GR protein levels.  
 
                             
Figure 4.2.5: The synergistic regulation of CCL20 mRNA levels by DEX or MPA and TNF in 
End1/E6E7 cells does not involve changes in GR protein levels. (Continued on the next page) 
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Figure 4.2.5: The synergistic regulation of CCL20 mRNA levels by DEX or MPA and TNF in 
End1/E6E7 cells does not involve changes in GR protein levels. Parallel experiments were set up in 
which End1/E6E7 cells were treated with 100 nM DEX, MPA or 0.1% (v/v) EtOH (Vehicle) in the presence or 
absence of 1.15 nM TNF for 24 hours. In (A), cells were then harvested in Tri-Reagent®, total RNA isolated and 
converted to cDNA and relative mRNA levels of CCL20 (A), were determined by qRT-PCR performed using gene 
specific primers and normalised to GAPDH mRNA levels. The relative effects of steroid hormones only or in 
combination with TNF on mRNA levels of the selected genes were determined by normalising to TNF, which has 
been set to 100%. The data include at least three independent biological repeats plotted as mean ± SEM in Graph 
Pad Prism 7 software. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple 
comparisons and statistical significance denoted as *, or ** to indicate p<0.05 and p<0.01, respectively. In (B), 
cells were harvested in 2X SDS Loading Buffer and equal amounts were resolved on an 8% SDS-PAGE. 
Thereafter, western blot analysis was performed with antibodies specific for GR and GAPDH. B is a representative 
blot and C is the densitometric analysis of blots from four independent biological repeats. The data is plotted 
relative to vehicle control, which has been set to 1.  
 
As shown in Figure 4.2.5 A, both DEX and MPA significantly enhanced the TNF-induced increase in 
CCL20 mRNA levels. However, neither DEX nor MPA altered steady state GR protein levels after 24 
hours (Figures 4.2.5 B, C). In addition, TNF did not alter GR protein levels both in the absence or 
presence of DEX/MPA (Figures 4.2.5 B, C). This result suggests that DEX, MPA or TNF alone or in 
combination does not induce changes in the synthesis or degradation of GR protein in End1/E6E7 cells. 
This implies that changes in GR protein levels might not be required for the upregulation of TNF-induced 
CCL20 mRNA expression by DEX and MPA. 
 
4.2.6: Summary of Findings 
The results demonstrated that MPA like DEX, but unlike NET or P4, represses claudin-4 and occludin 
mRNA levels in End1/E6E7 cells in a dose-dependent manner. When compared to DEX, MPA was 
found to act as a partial GR agonist in repressing claudin-4 and occludin mRNA expression and inducing 
GILZ mRNA expression. Like CORT, MPA may act like a full GR agonist in inducing CCL20 and 
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repressing IL6 mRNA expression, but unlike CORT acts like a partial GR agonist in inducing GILZ mRNA 
expression. It was also established that MPA like CORT exhibited true synergism with TNF to increase 
CCL20 mRNA expression in a gene-specific manner. Interestingly, TNF was found to enhance the 
efficacy of MPA from 40.92% to 481.2 % or that of CORT from 35.79% to 803.0% for upregulating 
CCL20 mRNA expression in End1/E6E7 cells. MPA like CORT was found to enhance the efficacy of 
TNF for upregulating CCL20 mRNA expression but reduces its efficacy for upregulating IL6 mRNA 
expression in End1/E6E7 cells.  These processes were found to be mutual. Finally, it was established 
that all these observed effects of MPA occurred via the GR. 
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Chapter Five 
 
MPA unlike NET downregulates desmoglein-1 mRNA levels in ectocervical tissue explants, 
positively cooperate with immune activators to increase HIV-1 infection in TZM-bl cells and 
augments CCL20 expression in PBMCs 
 
5.1: Aims 
The previous chapters established that MPA unlke NET downregulates TJ genes in an endocervical 
epithelial cell line. In addition, it was established that MPA unlike NET cooperatess with immune 
activators to upregulate the expression of select pro-inflammatory genes (CCL20 and TNFRSF1B) in 
End1/E6E7 cells. Therefore, the objectives of this chapter were to investigate aims E and F (section 
1.5) with the following specific questions: 
• Does regulation of TJ and immune function genes by MPA and NET occur in physiologically relevant 
primary human tissue and cell models from the FGT and blood?  
 More specifically, under this aim, it will be determined for MPA and NET whether: 
a. they cooperate with immune activators to regulate the expression of select immune 
function genes in ectocervical tissue explants. 
b. they regulate mucosal barrier function and the expression of select TJ genes in 
primary epithelial cells or tissue explants from the FGT. 
c. they coregulate with immune activators the expression of select immune function 
genes in PBMCs 
• What are the effects of progestins alone or in combination with immune activators on mucosal barrier 
function and HIV-1 infection? 
More specifically, under this aim, it will be determined for select progestins whether:  
a. the progestins alone or in combination with immune activators increase HIV-1 
infection and replication in TZM-bl indicator cells. 
b. the changes in gene expression in PBMCs affects HIV-1 infection and replication in 
TZM-bl indicator cells. 
 
This section of the thesis intends to answer the question whether the results reported in the previous 
chapters can occur in a physiologically relevant model. Because of constraints on obtaining endocervical 
tissue explants, ectocervical tissue explants were used instead. The tissue explants were treated with 
100 nM DEX, MPA, NET and P4, alone or in combination with TNF. The levels of soluble immune 
 
87 
 
mediators secreted in respond to MPA alone or in combination with TNF were assessed using a 
customised 22-plex Luminex assay. The following 22 proteins were selected to include the following: i) 
cytokines (TNF, IL6, IL1β, IL7, IL15, IL2, IL16, IL1α, G-CSF, GM-CSF), ii) chemokines (CCL2, IL8, 
CCL5, CCL4, CXCL10, CCL8, CCL20), iii) antimicrobial and antiviral factors (secretory leukocyte 
protease inhibitor [SLPI], CXCL12) and iv) growth factor (TGFβ). Gene expression analysis for all 
sample sets was also investigated by real-time PCR. This sections also intends to provide answers to 
the question whether MPA and DEX can coregulate mucosal permeability with HIV-1 IMCs. In this 
regard, PGECs were exposed to HIV-1 IIIB IMCs to assess whether DEX and MPA enhance HIV-1-
mediated disruption of genital epithelial mucosal barrier. HIV-1 IIIB like other HIV-1 IMCs have been 
shown to disrupt mucosal barriers formed by PGECs in vitro (Nazli et al., 2010). HIV-1 infection assays 
were performed in TZM-bl cells, using HIV-1BaL-Renilla IMCs. LPS was used to stimulate a pro-
inflammatory response in PBMCs as TNF based on the protocol used in this study could induce such a 
response. It was also investigated whether secretions from PBMCs treated with GCs and progestogens 
alone or in combination with LPS affect HIV-1 replication in TZM-bl cells.       
 
5.2: Results 
5.2.1: MPA like DEX suppresses basal secretion of select soluble immune mediators, appears to 
increase CCL20 expression in a gene-specific manner, while TNF does not appear to modulate 
these responses in ectocervical tissue explants 
In the previous sections, treating End1/E6E7 cells with DEX or MPA resulted in the differential regulation 
of basal and TNF-induced expression of immune mediators. Of interest was the observation that DEX 
or MPA synergised with TNF to upregulate CCL20 mRNA expression and protein secretion.  It was next 
investigated whether similar regulation could be seen in a more physiologically relevant model such as 
ectocervical tissue explants.  Ectocervical tissue explants from pre-menopausal women were treated 
with 100 nM DEX or MPA in the presence or absence of 1.15 nM TNF for 24 hours. Thereafter 
supernatants were collected and subsequently analysed by Luminex assay for secreted immune 
mediators. A 22-plex panel was selected comprising TNF, IL8, CCL2, IFNβ, IFNγ, TGFβ, G-CSF, IL1β, 
CCL5, CXCL12, CCL4, CXCL10, IL6, GM-CSF, IL12, CCL8, IL7, IL15, IL1α, IL2, CCL20 and IL16. Of 
these, 11 cytokines fell below the limit of detection and thus could not be quantified: TNF, IFNβ, IFNy, 
CXCL10, GM-CSF, IL12, CCL8, IL7, IL15, IL1α and IL2. 
 
In the absence of TNF, MPA like DEX significantly reduced GCSF and IL8 protein levels when compared 
with vehicle only control (Figure 5.2.1.1 A, B). Although not statistically significant, DEX and MPA also 
appeared to decrease IL6, IL16 and CXCL9 protein levels (Figure 5.2.1.1 C – E). In contrast, MPA 
appeared to increase CCL5 and CCL20 protein secretion by ectocervical tissue explants (Figure 5.2.1.1 
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H, I). In the presence of TNF, GCSF protein level was significantly increased when compared with 
vehicle only control (Figure 5.2.1.1 A). TNF also appeared to increase IL6, CXCL9 and TGFβ protein 
secretion by ectocervical tissue explants, but these increases were not statistically significant (Figure 
5.2.1.1 C, E, J). MPA like DEX appeared to inhibit IL6 secretion in the presence of TNF (Figure 5.2.1.1 
C). MPA also appeared to block CCL2 secretion, but it may increase IL1β and CCL20 secretion in the 
presence of TNF (Figure 5.2.1.1 F, G, I). 
 
                
                                                                     
               
Figure 5.2.1.1: The MPA like DEX inhibits basal secretion of select soluble immune mediators 
but does not appear to regulate their secretion in the presence of TNF in ectocervical tissue 
explants. (continued on the next page) 
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Figure 5.2.1.1: The MPA like DEX inhibits basal secretion of select soluble immune mediators 
but does not appear to regulate their secretion in the presence of TNF in ectocervical tissue 
explants. Ectocervical tissue explant samples from pre-menopausal women were co-treated with 100 nM DEX, 
MPA or 0.1% (v/v) EtOH (vehicle) in the presence or absence of 1.15 nM TNF for 24 hours. Thereafter, 
supernatants were collected and stored at -80°C until used. Aliquots of these were sent to Professor R. Shattock’s 
lab at Imperial College London (UK) where cytokine levels were analysed by Luminex assay. The graphs are 
plotted in Graph Pad Prism 7 software as mean ± SEM and include data from three donors. (A - K) are plotted 
relative to TNF (which has been set to 1), whereas in (L) only absolute values have been plotted because of 
missing values in the TNF control. Statistical analysis was performed using the unpaired Student’s t-test for 
comparison between vehicle only and other treatments and statistical significance is denoted as # to indicate 
p<0.05. This test was used only when the data was parametric; for data that was non-parametric the Kruskal-
Wallis with Dunn’s multiple comparisons test was used. 
 
As indicated in the legend of Figure 5.2.1.1, the Luminex analysis was performed in Professor Robin 
Shattock’s lab at Imperial College (London, UK). Because samples had to be shipped overseas for 
analysis, it is possible that some analytes degraded during the process. To make sure this was not the 
case, aliquots of these samples and those collected from fresh experiments were (re-)analysed by 
ELISA for IL6, CCL5 and CCL20 protein levels. In parallel, total RNA was isolated from cultured tissue 
explant pieces and used to quantify IL6, CCL20 and GILZ (positive control) expression by qRT-PCR. 
Prominent biomarkers for FGT inflammation include IL1β, IL6, IL8, CCL5 and CCL20 (Morrison et al., 
2014; Fichorova et al., 2015; Mauck et al., 2016). From this group, IL6, CCL5 and CCL20 were selected 
and their expression was quantified using ELISA and/or qRT-PCR.  
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Figure 5.2.1.2: The effects of DEX and MPA on CL20, IL6 and GILZ mRNA levels in human 
ectocervical tissue explants in the absence and presence of TNF. Ectocervical tissue explants from 
pre-menopausal women were treated with 100 nM DEX, MPA or 0.1% (v/v) EtOH (vehicle) in the presence or 
absence of 1.15 nM TNF for 24 hours. Thereafter, supernatants were collected and stored at -80°C until used and 
the rest of the tissue pieces were homogenised in Tri-Reagent®, total RNA isolated and converted to cDNA. In (A 
– C), CCL20 (A), IL6 (B) and GILZ (C) mRNA levels were quantified by qRT-PCR and normalised to GAPDH 
mRNA levels. The relative effects of the ligands on mRNA levels of the selected genes were determined by 
normalising to TNF only, which is set to 100%. The data was plotted in Graph Pad Prism 7 software as mean ± 
SEM. Sample size: [CCL20; Vehicle (n = 10), DEX (n = 9), MPA (n = 6)], [IL6: Vehicle (n = 8), DEX (n = 7), MPA 
(n = 5)], [GILZ; Vehicle (n = 6), DEX (n = 5), MPA (n = 6)]. Statistical analysis was performed using the Kolmogorov-
Smirnov test and statistical significance is denoted as # or #### to indicate p<0.05 and p<0.0001, respectively for 
comparisons between vehicle only and TNF only; or as $$ to indicate p<0.05 for comparison between TNF and 
other treatments.  
 
As shown in Figure 5.2.1.2 A, MPA but not DEX appeared to enhance TNF-induced CCL20 mRNA 
expression in ectocervical tissue explants. Although the effect of MPA on CCL20 mRNA levels in the 
presence of TNF was not statistically significant, it appeared to be ligand specific as neither P4 nor NET 
could generate a similar effect (Appendix C, Figure 1A). In addition, it was observed that this occurs 
in some but all not donor samples, suggesting Interdonor variation in the response (Appendix C, Figure 
2).  Basal IL6 mRNA levels appeared to be downregulated by DEX but not MPA (Figure 5.2.1.2 B). In 
addition, DEX unlike MPA significantly inhibited TNF-induced increase in IL6 mRNA levels. In contrast, 
P4 was found to suppress IL6 mRNA levels both in the absence and presence of TNF. NET did not 
regulate basal CCL20 and IL6 mRNA levels but was found to suppress IL6 and not CCL20 mRNA levels 
in the presence of TNF (Appendix C, Figure 1 B).  Neither DEX, MPA nor NET significantly regulated 
GILZ mRNA levels (Figure 5.2.1.2 C and Appendix C Figure 1 C) 
 
At the protein level, it was observed that MPA appeared to induce CCL20 secretion in the absence TNF 
in some (2 out of 5), but not all donor samples, suggesting inter-donor variations in the response. It was 
B C A 
 
 
91 
 
also observed that TNF failed to induce CCL20 secretion, which could explain the apparent lack of 
cooperativity between the ligands to upregulate CCL20 secretion (Figure 5.2.1.3 A). TNF appeared to 
induce IL6 and CCL5 protein secretion in ectocervical tissue explants. In contrast, MPA seemed to 
suppress basal IL6 and not CCL5 secretion. Additionally, MPA appeared to block TNF-induced secretion 
of IL6 and CCL5. Due to the small sample size, statistical analysis could not be performed to determine 
whether the putative effects of TNF and MPA on IL6 and CCL5 secretion were significantly different 
compared with vehicle control (Figure 5.2.1.3 B, C). More experiments are needed to build on the 
sample size and hence improve the power of the statistical analysis. 
 
             
Figure 5.2.1.3: The effects of MPA on CCL20, IL6 and CCL5 protein secretion in ectocervical 
tissue explants in the absence and presence of TNF. Ectocervical tissue explants from pre-menopausal 
women were treated with 100 nM DEX, MPA or 0.1% (v/v) EtOH (vehicle) in the presence or absence of 1.15 nM 
TNF for 24 hours. Thereafter, supernatants were collected and stored at -80°C until used. ELISA assays were 
then performed to determine the levels of CCL20 (A), IL6 (B) and CCL5 (C) secreted in supernatants. The relative 
effects of the ligands on the levels of the selected cytokines were determined by normalising to TNF, which is set 
to 100%. The data was plotted in Graph Pad Prism 7 software as mean ± SEM. (A) was analysed using one-way 
Kruskal-Wallis test with Dunn’s multiple comparisons. 
 
Taken together, these results suggest that MPA can suppress GSCF, IL8 and potentially IL6 protein 
secretion by ectocervical tissues. However, MPA might enhance CCL20 mRNA expression and CCL20 
protein secretion in ectocervical tissue explant in the presence of TNF. This might occur against the 
backdrop of MPA suppressing TNF-induced secretion of IL6. The results further suggest that the 
potential enhancement of CCL20 expression in ectocervical tissues by MPA is ligand-specific as neither 
DEX, P4 nor NET could induce a similar effect. 
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5.2.2: MPA supresses desmoglein-1 mRNA in ectocervical tissue explants, but fails to disrupt 
tight junction formation in endometrial and endocervical primary epithelial cell cultures even in 
the presence of HIV-1 
Next, it was investigated whether DEX, MPA and NET regulate tight junction gene expression in 
ectocervical tissue explants. For these assessments, cDNA generated from experiments described in 
Figure 5.2.2.1 and Appendix C (Figure 1) were used to quantify by qPCR mRNA levels of claudin-4, 
occludin and the adherens junction gene desmoglein-1. Desmoglein-1 was included in this analysis to 
verify a report by Quispe-Calla et al (2016) that suggested a decrease in its expression in ectocervical 
biopsy tissues from women on MPA. As shown in Figure 5.2.2.1 A, B, treatment of ectocervical tissue 
explants with DEX, but not MPA or NET resulted in a significant reduction in claudin-4 mRNA levels. 
Neither DEX, MPA nor NET reduced occludin mRNA expression. It was also observed that MPA, unlike 
DEX and NET, significantly suppressed desmoglein-1 mRNA production (Figure 5.2.2.1 C).  
 
                
Figure 5.2.2.1: The effects of DEX, MPA and NET on claudin-4, occludin and desmoglein-1 mRNA 
expression in ectocervical tissue explants. Ectocervical tissue explant samples from pre-menopausal 
women were treated with 100 nM DEX, MPA, NET or 0.1% (v/v) EtOH (vehicle) for 24 hours. Thereafter, tissue 
pieces were homogenised, total RNA isolated and converted to cDNA. The relative mRNA levels of claudin-4 (A), 
occludin (B) and desmoglein-1 (C) were determined by qRT-PCR performed using gene specific primers and 
normalised to GAPDH mRNA levels. The relative effects of steroid hormones were determined by further 
normalising by setting vehicle to 1. The data includes at least three independent biological repeats (DEX, n = 5; 
MPA, n = 3; NET, n = 4) plotted as mean ± SEM. Statistical analysis was performed using the Kolmogorov-Smirnov 
test and statistical significance denoted as # to indicate p<0.05.  
 
The inability of MPA to suppress claudin-4 and occludin mRNA expression contrasted with previous 
findings in End1/E6E7 cells. However, by suppressing desmoglein-1 mRNA production, MPA might 
disrupt the mucosal surface of the ectocervix. It should be recalled that TJs are needed to maintain the 
integrity of mucosal surfaces. It is currently not known whether DEX or MPA can disrupt mucosal barrier 
functions in the upper FGT by altering TJ gene expression. One way to determine this is by growing 
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epithelial cells from the FGT on permeable Transwell filters and using transepithelial electrical resistance 
(TER) measurements to evaluate barrier function after exposing the monolayers to MPA or DEX in the 
presence or absence of HIV-1. 
 
These experiments were conducted in the laboratory of Prof. Charu Kaushic at McMaster University, 
Hamilton (Ontario, Canada) and had as aim to verify whether MPA like DEX cooperates with HIV-1 to 
disrupt the mucosal integrity of confluent PGECs. PGECS were isolated from the endometrium and 
endocervix using the protocol established by Kaushic et al (2011). Confluent epithelial monolayers were 
pre-treated for 24 hours with 100 nM DEX, MPA or 0.1% vehicle in serum-free media. Thereafter, the 
monolayers were exposure to 105 IU/mL HIV-1 IIIB (X4 tropic) for 24 hours. Pre- and post-exposure 
TER measurements were recorded. Supernatants from the apical chamber were collected for TNF-
alpha ELISA. 
 
           
             
Figure 5.2.2.2: DEX, MPA or HIV-1 IMCs did not alter barrier function of primary genital epithelial 
monolayers. In (A, C), confluent primary epithelial cells from the FGT where pre-treated with 100 nM DEX, MPA 
or 0.1% (v/v) EtOH (vehicle) for 24 hours, and thereafter exposed to 105 IU/mL HIV-1 IIIB (X4-Tropic,) or virus 
control made up in fresh serum-free media containing 100 nM DEX, MPA or 0.1% (v/v) EtOH (vehicle) for another 
24 hours. NB: pre-virus supernatants were not washed away. TER measurements were taken before and after 
exposure to hormones and HIV-1 and expressed as percentage pre-exposure [i.e. (TER after HIV-1 exposure/TER 
A B 
D C 
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before hormonal pre-treatment) X 100]. In (B, D), Supernatants collected after HIV-1 exposure were used to 
determine by ELISA the level of secreted TNF. The data includes at least two independent biological repeats 
(endocervical, n = 2; and endometrial, n = 3) was plotted as median with 95% confidence interval in GraphPad 
Prism 7 software. 
 
As shown in Figure 5.2.2.2 A and C, neither DEX nor MPA reduced the TER of confluent primary 
endometrial and endocervical epithelial cells. Similarly (and contrary to expectations), HIV-1 exposure 
failed to decrease the TER of confluent cultures both in the absence and presence of DEX or MPA. HIV-
1 exposure also failed to induce TNF production in all but in one endocervical sample (Figure 5.2.2.2 
B, D). It is not known whether the failure of HIV-1 to induce a pro-inflammatory response resulted in its 
inability to disrupt the mucosal barriers evaluated herein. It should be noted that no significant reduction 
in TER was recorded for the endocervical experiment that saw TNF induced by HIV-1 exposure.  
 
Taken together, these results show that MPA like NET does not regulate the expression of TJ genes in 
the ectocervix in vitro, but unlike NET downregulates the expression of desmoglein-1. Considering that 
MPA downregulated select TJ genes in End1/E6E7, it might be that MPA targets these genes to disrupt 
mucosal barrier function in the endocervix, but not ectocervix. However, MPA did not alter mucosal 
barrier function of primary endometrial and endocervical epithelial cells. Thus, it remains to be 
established whether MPA can increase the permeability of upper FGT mucosal tissues.  
 
Attempts were made to investigate this question using End1/E6E7 cells. It was investigated whether this 
endocervical epithelial cell line form confluent monolayers and thus be used as an in vitro model to study 
mucosal barrier functions of the endocervix. Using confocal microscopy, it was observed that 
End1/E6E7 cells (grown on cover-slips) form discontinuous claudin-4 TJs (Appendix C, Figure 3 A). 
Continuous TJs are formed when the TJ proteins are expressed around the apical perimeter of 
neighbouring epithelial cells creating a structure that resembles honey-comb lattices in the field of view.   
The formation of discontinuous TJs are a result of the cells growing on top of each other forming a multi- 
rather than a monolayer (Appendix C, Figure 3 B). This suggests that End1/E6E7 cells are not a 
suitable in vitro model to study the mucosal barrier properties of the endocervical epithelial cells   
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5.2.3: MPA like DEX, but not NET, upregulates TNF- or LPS-induced increase in HIV-1 replication 
in TZM-bl Cells. 
Next, it was investigated whether DEX, MPA and NET regulate HIV-1 replication in TZM-bl indicator 
cells in the presence of immune activators. In this regard, TZM-bl cells were exposed to 10 IU/mL HIVBaL-
Renilla for 24 hours and subsequently treated with 100 nM DEX, MPA or NET in the presence or absence 
of 1.15 nM TNF for another 48 hours before measuring replication. At the end of this incubation period, 
cells were harvested in the Bright-Glo™ Luciferase Assay System reagent and luminescence quantified 
using the luminometer. As shown in Figure 5.2.3.1 A, DEX and maybe MPA increased HIV-I replication 
in TZM-bl cells when compared with virus only control. TNF also significantly increased HIV-1 
replication, and together with DEX or MPA induced an even bigger increase in replication. In contrast, 
NET did not alter basal nor TNF-induced increase in HIV-1 infection and replication. This result suggests 
that DEX and MPA positively cooperative with TNF to enhance HIV-1 infection of TZM-bl cells. 
 
                 
Figure 5.2.3.1: DEX and MPA, unlike NET, enhance HIV-1 replication in TZM-bl cells in the 
absence and presence of TNF or LPS. TZM-bl cells were treated with 10 IU/mL of HIV-1BaL_Renilla IMCs or 
Mock control for 24 hours. Thereafter, the cells were co-stimulated with 100 nM DEX, MPA or 0.1% (v/v) EtOH 
(vehicle) and 1.15 nM TNF (A) or 5 µg/mL LPS (B) for another 48 hours. At the end of the 72 hours incubation 
period with HIV, luciferase activity was quantified using the Bright-Glo™ Luciferase Assay System reagent 
(Promega, USA) on the Turner Biosystems Modulus Microplate reader (Promega, USA). Relative light units (RLU) 
were normalised relative to MTT optical density (OD) scores from a parallel experiment. The data represent at 
least three independent biological repeats plotted as mean ± SEM in GraphPad Prism 7 software. Statistical 
analysis was performed using one-way ANOVA with Tukey’s multiple comparisons. Statistical significance is 
denoted as **** to indicate p<0.0001 for comparisons between vehicle only and other treatments or between pair 
of treatments. In some cases, the unpaired Student’s t-test was used to compare pair of treatments; when 
comparison was between vehicle and other treatments, statistical significance is denoted as # to indicate p<0.05; 
when comparison was between TNF or LPS and other treatments significance is denoted as $, $$$ or $$$$ to indicate 
A B 
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p<0.05, p<0.005 and p<0.0001, respectively; when comparison was between other pair of treatments significance 
is denoted as &, && or &&& to indicate p<0.05, p<0.01 and p<0.005, respectively. 
 
Next, it was investigated whether DEX and MPA can cooperate with LPS to enhance HIV-1 infection 
and replication. In this regard, TZM-bl cells were exposed to 10 IU/mL HIVBaL-Renilla IMCs or no virus 
control for 24 hours and then treated with 100 nM DEX, MPA or NET in the presence or absence of 5 
µg/mL LPS for another 48 hours before measuring replication. As shown in Figure 5.2.3.1 B, DEX, MPA 
and NET significantly increased HIV infection when compared to vehicle control. The ability of NET to 
slightly enhance infection and replication in this experiment was unexpected as it did not induce a similar 
effect in Figure 5.2.3.1 A. Treating TZM-bl cells exposed to HIV-1 with LPS resulted in an increase in 
infection and replication. DEX and MPA enhanced HIV replication in the presence of LPS when 
compared with LPS only or hormones only. Although NET increased infection and replication in the 
absence of LPS in this experiment, it did not enhance LPS-induced increase in infection and replication. 
Moreover, when data from experiments in Figure 5.2.3.1 were pooled (experiments done in parallel), 
MPA but not NET enhanced HIV-1 infection and replication (Appendix C, Figure 4).   
 
5.2.4: MPA and NET differentially and selectively regulate pro-inflammatory gene expression in 
PBMCs. 
In the previous chapters, it was shown that MPA like DEX, but unlike NET, differentially regulate the 
expression of select immune mediators in the presence of immune activators in End1/E6E7 cells. It was 
next investigated whether and how DEX, MPA and NET regulate the expression of pro-inflammatory 
immune mediators in the presence of immune activators in PBMCs. PBMCs isolated from healthy female 
donors were treated with either 100 nM DEX, MPA or NET in the absence or presence of immune 
activators (LPS or TNF) for 24 hours. Only results from experiments involving LPS have been reported 
herein as TNF failed to induce the expression of immune mediators investigated (data not shown).   
 
As shown in Figure 5.2.4.1 A - D, treatment with DEX significantly reduced IL1β, but did not alter CCL20, 
IL6 and IL8 mRNA levels. The presence of MPA did not change basal CCL20, IL6, IL1β, IL8 and CCL5 
mRNA expression (Figure 5.2.4.1 A – D and Figure 5.2.4.1 A - D). NET did not significantly alter basal 
CCL20, IL6, IL1β and IL8 and CCL5 mRNA levels (Figure 5.2.4.1 A – D and Figure 5.2.4.1 A – D). It 
was also observed that MPA like DEX, but unlike NET, significantly induced GILZ mRNA expression 
(Figure 5.2.4.1 F).  
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Treating PBMCs with LPS resulted in an increase in CCL20, IL6, IL8 and IL1β mRNA levels (Figure 
5.2.4.1 A - D). On the contrary, LPS significantly reduced basal CCL5 and GILZ mRNA levels (Figure 
5.2.4.1 E, F).  As was the case with End1/E6E7 cells, MPA like DEX significantly enhanced LPS-induced 
CCL20 mRNA expression; in contrast, they suppressed LPS-induced IL6 and IL8 mRNA expression 
(Figure 5.2.4.1 A – D). MPA like DEX significantly induced a reduction in CCL5 mRNA levels in the 
presence of LPS in the same degree as they would in the absence of LPS (Figure 5.2.4.1 E).  Although 
not statistically significant, LPS appeared to inhibit DEX- and MPA-induced increase in GILZ mRNA 
levels (Figure 5.2.4.1 F). On the other hand, NET in the presence of LPS slightly reduced CCL20 and 
IL8 mRNA levels, slightly increased IL1β mRNA levels, but did not alter IL6 and CCL5 mRNA levels 
(Figure 5.2.4.1 A – E). 
 
          
                  
5.2.4.1: DEX, MPA and NET selectively regulate CCL20, IL6, IL1β, IL8, CCL5 and GILZ mRNA 
levels in a gene-specific manner in the presence of LPS in PBMCs. (continued on the next page)  
A B 
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5.2.4.1: DEX, MPA and NET selectively regulate CCL20, IL6, IL1β, IL8, CCL5 and GILZ mRNA 
levels in a gene-specific manner in the presence of LPS in PBMCs. PBMCs were treated with 100 nM 
DEX, MPA, NET or 0.1% (v/v) EtOH (vehicle) in the presence or absence of 5 µg/mL LPS for 24 hrs.  Thereafter, 
the cells were harvested in Tri-Reagent®, total RNA isolated and converted to cDNA. The relative mRNA levels of 
CCL20 (A), IL6 (B), IL1β (C), IL8 (D), CCL5 (E), GILZ (F) were determined by qPCR using gene specific primers 
and normalised to GAPDH mRNA levels. Relative fold changes were calculated with reference to LPS only, which 
has been set to 100%. The data from at least 5 subjects was plotted in Graph Pad Prism 7 software as mean ± 
SEM. Statistical analysis was performed using the non-parametric Kolmogorov-Smirnov test. For comparisons 
between vehicle only and other treatments, statistical significance is denoted as #, ##, ### or #### to indicate p<0.05, 
p<0.01, p<0.005 and p<0.0001, respectively. When the comparison was between LPS and other treatments, 
statistical significance is denoted as $, $$, $$$ or $$$$ to indicate P<0.05, p<0.01, p<0.005 and p<0.0001, respectively.  
 
It has previously been established that PBMCs express the GR and not the PR (Tomasicchio et al., 
2013). Therefore, to verify whether the GR was involved in the MPA-induced enhancement of LPS-
induced CCL20 mRNA expression, PBMCs were pre-treated with 1 µM RU486 for 2 hours before co-
treatment with 100 nM MPA and 5 µg/mL LPS for 24hrs. As shown in Figure 5.2.4.2, LPS and MPA 
cotreatment appeared to increase (although not statistically significant) CCL20 mRNA expression and 
this was prevented in the presence of RU486. This result suggests that the GR might be involved in the 
MPA enhancement of CCL20 transcriptional regulation by LPS in PBMCs. However, due to Inter-donor 
variations in response to MPA, more biological repeats would be required to improve the power of the 
statistical analysis.  
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Figure 5.2.4.2: The GR appears to be required for the MPA enhancement of LPS-induced CCL20 
mRNA expression in PBMCs. PBMCs isolated from 6 healthy female donors were pre-treated for 2 hours with 
1 µM RU486 or 0.1% (v/v) EtOH (vehicle) and thereafter treated with 100 nM MPA or 0.1% (v/v) EtOH (vehicle) in 
the presence or absence of 5 µg/mL LPS for another 24 hours. The cells were then harvested in Tri-Reagent®, 
total RNA isolated and converted to cDNA and relative CCL20 mRNA level was determined by qRT-PCR 
performed using gene specific primers and normalised to GAPDH mRNA level. The relative effects of steroid 
hormones and LPS on mRNA levels of the CCL20 were determined by normalising data to LPS, which has been 
set to 100%. The data from 6 donors was plotted in Graph Pad Prism 7 software as mean ± SEM. Statistical 
analysis was performed using the Kruskal-Wallis test with Dunn’s multiple comparisons test.  
 
Next, it was determined whether DEX, MPA and NET can regulate LPS-induced secretion of CCL20 by 
PBMCs. Supernatants collected from the experiment described in Figure 5.2.4.2 were used to perform 
a CCL20 ELISA. As shown in Figure 5.2.4.3, LPS induced CCL20 protein secretion by PBMCs and this 
was strongly enhanced by DEX and MPA but not NET. Additional ELISAs also found that MPA unlike 
NET suppresses LPS-induced secretion of IL6, CCL5 and possibly IL1β by PBMCs. 
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Figure 5.2.4.3: MPA, unlike NET, enhances CCL20, but suppressed IL6, CCL5 and maybe IL1β 
LPS-induced protein secretion by PBMCs. PBMCs isolated from 12 healthy female donors were treated 
with 100 nM DEX, MPA, NET or 0.1% (v/v) EtOH (vehicle) in the presence or absence of 5 µg/mL of LPS for 24 
hrs. Thereafter, supernatants were collected, and ELISA assays performed to measure the levels of CCL20 (A), 
IL6 (B), IL1β (C) and CCL5 (D). To determine fold changes, the data was normalised relative to LPS, which is set 
to 100% and plotted in Graph Pad Prism 7 software as mean ± SEM. Statistical analysis was performed using the 
Kolmogorov-Smirnov test. For comparison between vehicle only and other treatments, statistical significance 
denoted as #, ##, or #### to indicate p<0.05, p<0.01 and p<0.0001, respectively. For comparisons between LPS and 
other treatments, statistical significance denoted as $, $$ or $$$ to indicate p<0.05, p<0.01 and p<0.005, respectively. 
 
Taken together, these results suggest DEX, MPA and NET differentially regulated LPS-induced CCL20, 
IL6, IL1β, IL8 and CCL5 mRNA expression in PBMCs. Like with End1/E6E7 cells, MPA like DEX 
enhanced LPS-induced CCL20, but inhibited LPS-induced IL6, IL1β and IL8 mRNA expression. 
Additionally, MPA like DEX suppressed CCL5 mRNA expression in the presence of LPS in PBMCs. 
This finding corresponded with the inhibition of TNF-induced CCL5 mRNA expression in End1/E6E7 
cells by DEX and MPA: the effect of LPS on CCL5 mRNA expression was not investigated in End1/E6E7 
cells. Whereas NET did not affect LPS-induced mRNA expression in End1/E6E7 cells, it however slightly 
inhibited CCL20 and IL8, but enhanced IL1β mRNA expression in response to LPS in PBMCs. Unlike 
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in End1/E6E7 cells, basal mRNA levels of CCL20, IL6, IL8 and CCL5 was not altered by DEX and MPA 
in PMBCs. Only DEX significantly inhibited IL1β mRNA expression in PBMCs.  
 
Besides regulating mRNA expression, DEX and MPA, unlike NET, also modulated LPS-induced protein 
secretion. Results from this study suggest MPA like DEX enhanced LPS-induced CCL20 secretion by 
PBMCs, confirming previous observations in End1/E6E7 cells.  In addition, the results also suggest 
MPA, but not NET inhibit LPS-induced IL6, CCL6 and IL1β secretion by PBMCs. By selectively 
enhancing CCL20, while suppressing Il6, IL8, IL1β and CCL5 expression MPA might be controlling a 
pathway that could enhance HIV-1 infection.  
 
5.2.5: Supernatants from PBMCs co-treated with MPA and LPS, but not NET and LPS, enhance 
HIV-1 replication in TZM-bl cells 
Cytokines and chemokines play an important role in HIV-1 infection particularly in reactivating HIV-1 
replication in latently infected target cells (Chun et al., 1998; Cameroon et al., 2010). Changes in their 
secretion profile and concentrations might affect the ability of HIV-1 to infect and replicate in target cells. 
Considering that MPA and NET differentially regulate LPS-mediated expression of pro-inflammatory 
cytokines in PBMCs, it was next investigated whether supernatants from PBMCs treated with MPA or 
NET in combination with LPS would differentially modulate HIV-1 replication. To this end, supernatants 
collected from experiments described in Figure 5.2.5 and control ligand-conditioned media were diluted 
4-fold and the diluted solutions used in add-back TZM-bl HIV-1 infection assays. In brief, pre-seeded 
TZM-bl cells or HIV-1BaL-Renilla IMCs at 10 IU/mL were incubated separately in the diluted supernatants 
or ligand-conditioned control media for 1 hour. Thereafter, the virus was added to the cells and incubated 
for another 72 hours, at the end of which the cells were harvested and assayed for infection and 
replication. As shown in Figure 5.2.5 A., when compared with supernatant from cells treated with 
vehicle-only, supernatants from PBMCs treated with LPS, MPA or NET had no effect on HIV-1 infection 
and replication. However, supernatants from PBMCs co-treated with MPA and LPS, but not NET and 
LPS significantly increased HIV-1 replication in TZM-bl cells when compared with LPS-only 
supernatants. No change in replication was observed in TZM-bl cells exposed to ligand-conditioned 
control media (Figure 5.2.5 B).  
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Figure 5.2.5: Conditioned media from PBMCs co-treated with MPA and LPS, but not NET and LPS 
increase HIV-1 infection and replication in TZM-bl cells. (A) TZM-bl cells were pre-exposed for 1 hour to 
supernatants from PBMCs incubated with 100 nM MPA, NET or 0.1% (v/v) EtOH alone or in combination LPS. 
The cells were subsequently treated for 72 hours with 20 IU HIV-1BaL that was made up and equilibrated in PBMC 
supernatants. (B) TZM-bl cells were treated similarly as in (A) except that PBMC supernatants was replaced with 
culture media containing ligands only, which was set up in parallel with the PBMC experiment described in (A). At 
the end of the 72 hours incubation period with HIV-1, luciferase activity was quantified using the Bright-Glo™ 
Luciferase Assay System reagent (Promega, USA) on the Turner Biosystems Modulus Microplate reader 
(Promega, USA). Relative light units (RLU) were normalised relative to MTT optical density (OD) scores from a 
parallel experiment. The data is normalised relative to LPS, which is set to 100% and plotted in Graph Pad Prism 
7 software as mean ± SEM. Statistical analysis was performed using Kolmogorov-Smirnov test to compare 
treatment pairs and statistical significance denoted as $ to indicate p<0.05.   
 
Taken together, these results suggest that secreted soluble mediators from PBMCs treated with LPS 
do not affect HIV-1 infection and replication. However, the presence of MPA, but not NET modifies the 
secretome of LPS-treated PBMCs in a manner that favours HIV-1 infection and replication.  
 
 5.7: Summary of Findings 
This chapter showed that MPA selectively supressed basal GCSF, IL8 and possibly IL6 protein secretion 
in ectocervical tissue explants, in a gene-specific manner. It was also found that MPA might increase 
TNF-induced CCL20 mRNA expression in some but not all samples due to larger sample variance. This 
observation, although not statistically significant, was unique to MPA as neither P4 nor NET enhanced 
CCL20 mRNA expression. It was also observed that MPA in the absence of TNF might enhance CCL20 
protein secretion in some but not all tissue samples. 
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It was established that MPA like NET does not significantly regulate TJ mRNA levels; but unlike NET 
MPA was found to reduce desmoglein-1 mRNA expression in ectocervical tissue explants. This 
suggests that MPA might regulate desmosomal but not TJ gene expression in ectocervical mucosal 
tissues. MPA alone or in the presence of HIV-1 IMCs did not alter mucosal barrier integrity of primary 
genital epithelial cells. Thus, it could not be established whether synergistic interactions between MPA 
and HIV-1 were involved in the regulation of mucosal barrier function. 
 
It was observed that MPA unlike NET acted singly or additively with immune activators to enhance HIV-
1 infection and replication in the presence in TZM-bl cells. This suggest that MPA but not NET might 
cooperate with immune activators in the FGT or blood to increase HIV-I infection and replication.  
 
This chapter also established that MPA unlike NET enhanced CCL20 mRNA levels, but inhibited IL6, 
IL1β, IL8 and CCL5 mRNA levels in the presence but not absence of LPS in PBMCs. In addition, MPA 
enhanced CCL20, but inhibited IL6, CCL5 and potentially IL1β protein secretion by PBMCs in the 
presence of LPS. Finally, conditioned media from PBMCs exposed to MPA and LPS enhanced HIV-1 
infection and replication in TZM-bl cells when compared with supernatants from PBMCs treated with 
LPS or possibly MPA alone. Finally, it was observed that NET enhanced IL1β, but inhibited CCL20 and 
IL8 mRNA expression in the presence of LPS in PBMCs. However, these changes in mRNA expression 
induced by NET were not reflected in protein levels. In addition, supernatants from PBMCs co-treated 
with NET and LPS did not affect HIV-1 infection and replication. This suggest that NET-induced changes 
in protein secretion, unlike those induced by MPA, do not affect HIV-1 replication. 
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Chapter Six 
 
Discussion, Conclusions and Future Perspective 
 
6.1: Discussion 
 
6.1.1: Limitations of the current study 
One of the limitations of the current study is that all of the experiments were performed in vitro, raising 
the question of whether these effects occur in vivo in women.  One of the initial objectives was to 
investigate hypotheses and establish mechanisms in End1/E6E7 cells and then investigate whether 
these occurred in primary endocervical epithelial cells isolated from endocervical tissues obtained from 
pre-menopausal women. Due to constraints in obtaining endocervical tissues, only a few experiments 
could be done using primary endocervical epithelial cells. Hence experiments were performed using 
other model systems such as primary endometrial epithelial cells and ectocervical tissue explants.  
Previous studies showed that End1/E6E7 cells, PBMCs and TZM-bl cells express mRNA and protein 
for the GR, but not the PR (Govender et al., 2014; Tomasicchio et al., 2013; Maritz et al., 2018). 
Ectocervical tissues have been reported to express both receptors (Ray et al., manuscript under review). 
Therefore, the effects elicited by MPA like those elicited by GCs in End1/E6E7 cells, TZM-bl cells and 
PBMCs are more likely to be mediated by the GR but not the PR. On the other hand, the GR as well as 
PR may mediate these effects in ectocervical tissues. Thus, the results obtained in End1/E6E7 cells 
may be different to those in primary endocervical cells. While in vitro studies can investigate direct effects 
of ligands on target cells or tissue and control for the experimental environment, whether such effects 
occur in women is difficult to investigate due to complex interconnected endocrine and other organismal 
indirect effects, as well as confounding intrinsic factors of the study population.  Nevertheless, several 
of the findings from this study are consistent with published clinical data, as discussed in detail in this 
chapter. Furthermore, the in vitro findings provide novel proof of concept and mechanistic insights into 
possible side effects, choice of progestins and mechanisms for further investigation in primary cell and 
tissue models and in vivo.  
 
6.1.2: MPA but not NET downregulates genes associated with maintaining endocervical mucosal 
barrier integrity and selectively upregulates expression of CCL20 and TLR2 in the endocervical 
epithelial cell line in the absence of immune activators  
The current study has shown for the first time that MPA unlike NET downregulates the expression of 
select TJ genes in the End1/E6E7 endocervical epithelial cell line. While it is difficult to translate in vitro 
results to in vivo effects, this indicates that DMPA might increase the permeability of the endocervix via 
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this mechanism in women. This is consistent with findings from a clinical study showing that DMPA use 
disrupts the mucosal barrier of the ectocervix in women (Quispe-Calla et al., 2016). However, others 
have shown that DMPA-IM increases claudin-8 expression in the cervical transition zone in vivo 
(Goldfien et al., 2015). This suggests that MPA may enhance the integrity of the mucosal barrier of the 
transition zone of the cervix in women (Goldfien et al., 2015). Thus, it is possible that effects of DMPA 
on the mucosal barrier in women are tissue-specific and differ between the endocervix and other 
compartments of the FGT.   
 
The results also show that MPA like GCs, but unlike NET, increases CCL20 mRNA levels against the 
backdrop of reducing IL6 and IL1β mRNA levels in End1/E6E7 endocervical epithelial cell lines. This is 
consistent with findings from a recent in vitro study showing that MPA increases CCL20 mRNA levels 
in primary endometrial epithelial cells (Woods et al., 2018).  However, the increase in CCL20 mRNA 
levels observed in End1/E6E7 cells in the presence of MPA may not result in a corresponding increase 
in the levels of secreted CCL20 protein.  However, it is possible that a change in protein levels occurs 
at a different time to that measured or under different experimental conditions. Evidence from previous 
clinical studies showed that DMPA-IM use did not alter the levels of CCL20 protein secreted in the FGT 
in heathy women in vivo (Morrison et al., 2014; Fichorova et al., 2015). Thus, it is possible that MPA, in 
the absence of immune activators, regulates CCL20 mRNA levels, but not CCL20 protein levels 
secreted by genital epithelial cells. Whether this happens in women is unclear since none of the 
published clinical or in vitro studies (Woods et al., 2018; Morrison et al., 2014; Fichorova et al., 2015) 
simultaneously assessed mRNA and protein expression. This study is the first to do so. However, there 
is evidence from an in vitro study showing that GCs, in the absence of immune stimulation, regulate 
both CCL20 mRNA and protein expression by bronchial epithelial cells (Zijlstra et al., 2014). The lack of 
correlation between mRNA and protein expression in End1/E6E7 endocervical epithelial cells suggests 
that MPA might increase the stability of CCL20 mRNA transcripts in the cytoplasm but decrease the rate 
at which they are translated into protein and secreted (Greenbaum et al., 2003). This could increase the 
half-life and therefore the relative abundance of CCL20 mRNA transcripts. This is consistent with 
findings from an in vitro study showing that DEX increased calgranulin A mRNA levels but not protein 
levels in thioglycolate-elicited murine macrophages; however, stimulation with LPS increased protein 
expression in DEX-treated compared to controls (Hsu et al., 2005). Others have also described a 
mechanism whereby superantigens induced the formation of cytoplasmic TNF, IL8, CCL3 and CCL4 
mRNA “reserves” in HA1.7 CD4+ T cell clones and how these reserves are rapidly translated into protein 
and secreted after anti-CD3 and IL2 activation (Schall et al., 1992). It is possible that MPA induces the 
formation of CCL20 mRNA reserves in End1/E6E7 endocervical epithelial cell lines, which sensitives 
them towards a rapid CCL20-specific response in the presence of immune activators. Alternatively, MPA 
might increase CCL20 mRNA levels, but might not affect its translation to protein or the post-translational 
modifications that are required in order for the newly synthesised protein to be secreted.   
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The thesis results also suggest that by upregulating TLR2 expression in End1/E6E7 endocervical 
epithelial cells in vitro, MPA like DEX might enhance the sensitivity of these cells for TLR2 agonists. 
This agrees with results from previous studies showing that HeLa and airways epithelial cells primed 
with DEX responded vigorously to stimulation to TLR2 agonists. (Imasato et al., 2002; Shuto et al., 2002; 
Hermoso et al., 2004; Sakai et al., 2004; Homma et al., 2004; Busillo et al., 2011; Frank et al., 2014). 
The present study did not investigate whether MPA upregulates TLR2 protein levels in End1/E6E7 cells. 
However, Findings from a previous study showed that DEX increased TLR2 protein levels in HeLa cells 
(Sakai et al., 2004). Because MPA and DEX elicited similar effects on gene expression in End1/E6E7 
and HeLa cells (Govender et al., 2014), it is very likely that MPA upregulates TLR2 protein levels in 
End1/E6E7 cells as well. Nevertheless, future experiments will investigate whether MPA indeed 
upregulates TLR2 protein levels in End1/E6E7 cells. It remains unknown whether DMPA upregulates 
TLR2 expression in vivo.  
 
It has been reported that CD4+ T cells treated in vitro with TLR2 agonists are more permissive to HIV-1 
infection than control cells (Thibault et al., 2007; Ding et al., 2010). In addition, it has been demonstrated 
that CD4+ T subsets with high levels of expression of TLR2 such as Th17 cell are more susceptible to 
HIV-1 infection in vitro than cells with low expression of the receptor (Bolduc et al., 2017). Therefore, 
the result that MPA induces TLR2 expression in End1/E6E7 cells suggests that MPA might enhance 
HIV-1 uptake by endocervical cervical epithelial cells via TLR2.  Although they are not HIV-1 target cells, 
endocervical epithelial cells have been shown to take up HIV-1 viral particles via clathrin-dependent 
endocytosis – a process enhanced in the presence of MPA (Ferreira et al., 2015a). Interestingly, TLR2 
ligation in some cell types have been shown to enhance clathrin-dependent endocytosis in vitro (Shen 
et al., 2014). Thus, it possible that the MPA-induced increase of TLR2 expression might enhance 
clathrin-dependent TLR2-mediated endocytosis of HIV-1 viral particles into endocervical epithelial cells, 
and in doing so, prime the cells for increased HIV-1 entry.    
 
The current study did not find evidence suggesting that MPA alters the sensitivity of the End1/E6E7 cells 
to TRL4 ligands. However, endometrial biopsies from women using DMPA-IM have been reported to 
express lower levels of TLR3 and TLR4 in vivo compared to controls. This suggests the MPA might 
reduce the ability of the endometrium to respond to TLR3 and TLR4 ligands (Goldfien et al., 2015). It 
has been reported by a recent in vitro study that MPA upregulates TNF receptor 2 (TNFRSF1B) mRNA 
expression in primary endometrial cells (Woods et al., 2018). The current study found that MPA does 
not regulate basal TNFRSF1B mRNA levels in End1/E6E7 cells.  Collectively these studies suggest that 
MPA alters the expression of specific innate immune receptors in genital epithelial cells in vivo to 
modulate their sensitivity to specific pathogen associated molecular patterns, including HIV-1 viral 
particles. Whether these effects are compartment-specific remains to be investigated.  
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The result that MPA does not alter CCL5 expression levels in End1/E6E7 endocervical epithelial cells 
in the absence of immune activators suggests that this may not be a mechanism whereby MPA might 
induce CCR5+CD4+T cells to infiltrate the endocervix. Current evidence from a clinical study that showed 
that healthy women using DMPA-IM had higher levels of CCL5 in cervical secretions compared to 
controls (Fichorova et al., 2015). Furthermore, others have shown that the proportion of CCR5+CD4+ T 
cells in the endocervix is higher in healthy women using DMPA-IM compared in controls (Smith-McCune 
et al., 2017; Byrne et al., 2016). However, the study by Smith-McCune and colleagues did not find 
elevated levels of CCL5 in CVL from women using DMPA-IM (Smith-McCune et al., 2017), suggesting 
that mechanisms other than CCL5 expression by endocervical epithelial cells are responsible for the 
increase in CCR5+CD4+ T cells in the endocervix. It is possible that DMPA-IM induces the expression 
of CCR5 on resident CD4+ T cells in the endocervix. This is very likely as recent findings from two in 
vitro studies showed that MPA increased CCR5 expression on CD4+T cells and in ectocervical tissues 
(Maritz et al., 2018; Ray et al., manuscript under review).  
 
Collectively, the thesis results suggest that in the absence of genital tract infection or inflammation, MPA 
might enhance susceptibility of the FGT in vivo to HIV-1 infection by (i) enhancing endocervical mucosal 
permeability by downregulating claudin-4, (ii) enhancing the sensitivity of genital mucosal surfaces by 
upregulating TLR2 and (iii) increasing CCL20 mRNA reserves that may be rapidly converted into protein 
upon immune challenge with microbial or viral antigens.   
 
6.1.3: MPA, unlike NET, acts synergistically with immune activators to upregulate select immune 
function, but not TJ genes in End1/E6E7 endocervical epithelial cells 
This is the first study to report that TNF increases claudin-4, ZO-1 and potentially occludin mRNA levels 
in End1/E6E7 cells. However, this increase in TJ mRNA levels may not with associated with increases 
in protein levels and is consistent with observations made by others (Amasheh et al., 2010; Amoozadeh 
et al., 2017). As discussed in section 6.1.2 for MPA, this suggests that TNF might have differential 
effects on mRNA and protein synthesis and stability.   
 
TJ disruption is one of the potential mechanisms by which GTIs enhance the risk of HIV-1 acquisition in 
women (Burgener et al., 2015; Vitali et al., 2017). The present study found that MPA like DEX does not 
cooperate with immune activators to downregulate TJ gene expression in End1/E6E7 endocervical 
epithelial cells. Moreover, this study found that MPA in the presence of immune activators inhibits the 
expression of IL1β, which is known to disrupt TJs (Al-Sadi et al., 2007). This suggests that enhanced 
mucosal barrier impairment via TJ disruption might not be a mechanism by which DMPA further 
increases HIV-1 susceptibility in women with GTIs.   
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Unlike TJ genes, the current study is the first to show that MPA like GCs, but unlike NET, acts 
synergistically with immune activators to upregulate CCL20 expression in End1/E6E7 endocervical 
epithelial cells. This is consistent with findings from previous in vitro studies that GCs and immune 
activators synergised to upregulate CCL20 expression in bronchial epithelial cells and monocyte-derived 
macrophages (Zijlstra et al., 2014; van de Garde et al., 2014), although these studies did not investigate 
whether true synergism occurred. The current study also shows that MPA enhances TNFRSF1B 
expression by MPA in the presence of TNF in End1/E6E7 cells. Moreover, it was observed that the 
presence of LPS did not alter MPA-induced expression of TLR2 expression in End1/E6E7 cells. It is not 
clear why MPA and immune activators synergize to selectively upregulate CCL20 expression. The 
upregulation of innate immune receptors by MPA suggests that a feedforward regulatory loop might be 
involved. This is consistent with findings that GCs enhance pro-inflammatory responses by upregulating 
the expression of innate immune receptors specific for some immune regulators (Homma et al., 2004; 
Busillo et al., 2011). However, the current study did not investigate the involvement of TLR2 and 
TNFRSF1B in the upregulation of CCL20 expression by LPS or TNF in the presence of MPA.   
 
The underlying molecular mechanisms for synergistic upregulation of CCL20 by MPA and TNF in 
End1/E6E7 cells were not investigated in the current study and so remain unclear. In addition, it is 
unclear why MPA, like GCs, selectively upregulates the expression of some pro-inflammatory genes but 
inhibits the expression of others in the same cell, although it was established that GR is involved in 
these responses. Basal and induced expression of pro-inflammatory genes in End1/E6E7 cells is very 
likely to occur via the MAPK and NFκB signalling pathways (Yang et al., 2015; Ayyar & Reddy, 2018). 
The MAPK signalling pathways is subject to feedback inhibition by MKP-1 (Shah et al., 2016; Newton 
et al., 2017).  Interestingly, MPA like DEX has been shown to induce MKP-1 expression in End1/E6E7 
cells (Grantham, 2012). It is therefore possible that in the presence of MPA, MKP-1 mediates the 
deactivation of the MAPK pathway which results in the inhibition of basal IL6 and IL1β expression. This 
proposed mechanism is also likely involved in the repression of claudin-4 mRNA levels by MPA.  
However, this scheme does not explain why the opposite effect is observed with CCL20. Gene-specific 
responses are likely due to differences in intracellular signalling pathways, promoter architecture and 
chromatin structure.  
 
It has recently been demonstrated that the phosphatidylinositol 3-kinases/protein kinase B (PI3K/AKT) 
pathway is an alternative mechanism by which CCL20 and TNF expression are upregulated in A549 
cells (Wang et al., 2016) and SiHa cervical epithelial cells, respectively (Yang et al., 2015). PI3K/AKT is 
deactivated by GCs in some cell types via a mechanism involving MKP-1-mediated deactivation of p38 
MAPK (Lawan et al., 2018; Perdiguero et al., 2011; Zhao et al., 2009). This suggests that GCs should 
 
109 
 
also repress CCL20. However, in some cell types it has been demonstrated that GC-induced inhibition 
of PI3K/AKT prevents deactivation of forkhead box protein O1 (FOXO1) by phosphorylation. The active 
FOXO1 is unphosphorylated and resides in the nucleus where it has been shown to interact with the 
C/EBPβ binding site in the promoter of genes such as CCL20 and muscle ring finger-1 (Miao et al., 
2012; Zhao et al., 2009). Therefore, it is possible that in End1E6E6 cells CCL20 is regulated by the 
PI3K/AKT pathway, whereas IL1β, IL6, IL8 and CCL5 are regulated by MAPK pathway. In this way, 
MPA like GCs can enhance CCL20 via MKP-1/p38 MAPK/PI3k/AKT-mediated activation of FOXO-1. 
Taken together, basal expression of proinflammation genes in End1/E6E7 cells is possibility mediated 
via MAPK pathway. In the presence of MPA, MKP-1 deactivates the MAPK pathway resulting in the 
repression of most pro-inflammatory genes. However, some genes depending on their promoters are 
selectively upregulated via a mechanism involving MKP-1-mediated deactivation of p38 
MAKP/PI3K/AKT signalling loop.  
  
The signalling loops described above may also explain why MPA like GCs selectively upregulate some 
genes, while repressing others in the presence of immune activators. However, the MKP-1/p38 
MAPK/PI3K/AKT loop that activates FOXO-1 might be amplified in the presence of immune activators 
in order to synergistically upregulation CCL20 expression. This is possible as some immune activators 
induce MKP-1 activity and moreover deactivate PI3K/AKT (Shah et al., 2016; Newton et al., 2017). In 
addition, previous studies found that MPK-1-mediated deactivation of p38 and JNK MAPKs was required 
in the synergistic upregulation of TLR2 by GCs and immune activators in HeLa cells (Shuto et al., 2002; 
Imasato et al., 2002; Sakai et al., 2004; Hermosa et al., 2004). Interestingly, it has previously been 
reported that inhibiting JNK and ERK1/2, but not p38 activity enhanced TNF-induced expression of IL6 
in End1/E6E7 cells in the presence of MPA (Verhoog, 2010). This suggests that MKP-1 might be an 
essential component in regulating the expression of pro-inflammatory genes including TNFRSF1B. How 
MKP-1 interacts with other signalling pathways may determine whether it’s effects are pro- or anti-
inflammatory.   
 
Synergism between GCs and immune activators may amplify immune responses that impact on HIV-1 
infection. For example, GCs have been shown to synergise with immune activators to upregulate HIV-
1 replication in chronically infected cells in vitro (Bressler et al., 1993; Kinter et al., 2001) or to prolong 
the survival of activated CD4+ T cells in vitro (Cima et al., 2006). The results shown in the current study 
suggest that synergism between MPA and immune activators may increase the density of CCR6+CD4+ 
T cells in the endocervix, rendering it more vulnerable to infection 
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The selective synergistic upregulation of CCL20 expression by MPA in the presence of immune 
activators suggests that MPA might induce CCR6+CD4+ T cells, macrophages and Langerhans cells to 
infiltrate the endocervix in vivo. Evidence from clinical and animal studies suggests that DMPA induces 
CD4+ T cells and macrophages to home to mucosal tissues in the FGT (Quispe-Calla et al., 2018; Goode 
et al., 2014; Smith-McCune et al., 2017). However, it is currently unknown whether the migrating CD4+ 
T cells express CCR6, which would suggest that CCL20 is involved in their immigration. Should they 
express CCR6, this would suggest that DMPA in the presence of immune activators enriches the 
endocervix with a CD4+ T subtype that is very permissive to HIV-1 infection (Gosselin et al., 2010; 
Gosselin et al., 2017; Bolduc et al., 2017; Rodriguez-Garcia et al., 2014; Stieh et al., 2016). Other 
chemokines besides CCL20 could be responsible for recruiting HIV-1 target cells into the FGT. However, 
CCL20, more so than CCL2, CCL3, CCL4, CCL5, CCL7 and CCL8, induces the migration of Langerhans 
precursor cells in vitro (Dieu-Nosjean et al., 2000). This suggests that CCL20 might play an important 
role in HIV-1 target cell migration. Thus, the selective synergistic upregulation of CCL20 by MPA in the 
presence of immune activators, such as during a genital tract infection, might create an immune 
microenvironment that is favourable for HIV-1 infection.  
 
An MPA-induced CCL20-rich microenvironment in the endocervix is very likely to promote latent HIV-1 
infection in resting CCR6+CD4+ T cells (Cameron et al., 2010; Gosselin et al., 2010; Gosselin et al., 
2017). Furthermore, the predominantly anti-inflammatory immune milieu created by MPA in vitro might 
restrict the ability of the virus to replicate (Guha & Ayyavoo, 2013). This might enable infected 
CCR6+CD4+ T cells to escape early immune detection by cytolytic CD8+ T cells, which have been shown 
to accumulate in the endocervix of women using DMPA (Smith-McCune et al., 2017). However, this 
hypothesis is inconsistent with evidence in the literature suggesting that HIV-1 replication in enhanced 
in the presence of MPA (Huijbregts et al., 2013; Sampah et al., 2015; Irvin & Herold, 2015; Tasker et 
al., 2017; Maritz et al., 2018; Ray et al., manuscript under review). Latent HIV-1 infection is established 
when cells take up and integrate viral DNA, but do not make new RNA. Because the above studies only 
assessed viral replication as determined by p24 levels, it remains unclear whether MPA enhances viral 
DNA integration especially at time points whereby replication is not yet apparent. Findings from a recent 
in vitro study suggest that this may correspond to periods whereby treatment with MPA initially inhibits 
the expression of pro-inflammatory cytokines such as IL6 in ectocervical tissue explants (Ray et al., 
manuscript under review). Interestingly, this study also showed that at later time points MPA induces 
rather than inhibits IL6 expression and further showed that this correlated with HIV-1 replication in tissue 
samples infected in vitro with HIV-1 IMCs (Ray et al., manuscript under review). This suggests that there 
is correlation between time-dependent expression of immune mediators and HIV-1 replication in 
ectocervical tissues.  
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The thesis results showed that MPA inhibits CCL5 expression in End1/E6E7 cells in the presence of 
immune activators. This is inconsistent with findings from previous clinical studies that DMPA-IM 
increases CCL5 protein levels in cervical secretions from women with specific GTIs using DMPA-IM 
compared to their counterparts not using DMPA-IM or healthy controls on DMPA-IM (Morrison et al., 
2014; Fichorova et al., 2015a). In addition, findings from in vitro studies showed that MPA enhanced 
CCL5 expression by primary endometrial epithelial cells in the presence of HIV-1 IMCs (Ferreira et al., 
2015a). Similarly, CCL5 has been reported to be upregulated in the vagina of DMPA-treated mice 
challenged with HSV-2. These results suggest that DMPA use might enhance the infiltration of 
CCR5+CD4+ T cells into endocervix of women with GTIs. However, the results presented herein suggest 
that MPA might prevent the recruitment of CCR5+ cells in the FGT in the presence of immune activators. 
In addition, by inhibiting CCL5 expression, the results also suggest that MPA in presence of bacterial 
infection might reduce the ability of HIV-1 target cells to self-protect themselves or neighbouring cells 
against HIV-1 infection (Alvarez et al., 2011).  
 
Collectively, the results presented herein suggest that MPA but not NET cooperates with immune 
activators to create an immune microenvironment that renders the endocervix vulnerable to HIV-1 
infection.   
 
6.1.4: MPA like GCs, but unlike NET, acts like a potent GR agonist in terms of regulating TJ and 
inflammatory genes at physiologically relevant concentrations in endocervical epithelial cells 
The current study investigated whether the effects of MPA and NET on gene expression occurs at 
physiologically relevant concentrations. Dose response analyses were performed to determine the 
potencies (EC50) and efficacies (maximal responses). Serum concentrations of MPA after a 150 mg 
DMPA-IM injection have been reported to range between 3 nM and 100 nM with peak concentrations 
averaging 21 nM before plateauing at 2.6 nM (Hapgood et al., 2018). However, lower peak serum 
concentrations of 2.3 (1.6 – 4.4) nM are reported with the low dose DMPA-SC, although comparisons 
were not performed in parallel (Hapgood et al., 2018). The current study shows that MPA significantly 
increases CCL20 expression in the absence of immune activators, with an EC50 of about 66 nM. CORT 
appears to be slightly more potent in activating CCL20 expression in the absence of immune activators 
with an EC50 of 31 nM. In the presence of immune activators, however, MPA at concentrations as low 
as 1 nM upregulates CCL20 expression with an EC50 of about 15 nM. Similarly, CORT at 1 nM appears 
to upregulate CCL20 expression in the presence of an immune activator, with an EC50 of 60 nM. This 
suggests that MPA like CORT at physiological concentrations may upregulate basal CCL20 expression 
in the endocervix in vivo. This may occur in DMPA-IM, but not DMPA-SC users shortly after injection. 
However, the presence of GTIs or inflammation may enhance the sensitivity of endocervical epithelial 
cells to MPA. Therefore, MPA concentrations higher than or equal to 1 nM will cooperate with immune 
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activators in the FGT to upregulate CCL20 expression in the endocervix. This could happen in women 
using DMPA-IM as well as those using DMPA-SC.  
This study shows that MPA at 100 nM significantly reduces claudin-4 expression by 53.93% at 24 hours, 
with an EC50 of 14.27 nM. Furthermore, MPA at 1 µM represses occludin expression by 29.01% at 24 
hours, with an EC50 of 131.2 nM. This suggests that DMPA-IM might regulate claudin-4, but not occludin 
at physiological concentrations Moreover, the effects of MPA on claudin-4 and occludin expression 
might be time-specific. Therefore, longer exposure to lower concentrates of MPA might downregulate 
claudin-4 and occludin expression in endocervical epithelial cells. Unlike CCL20, cotreating End1/E6E7 
cells with 100 nM MPA and 1.15 nM TNF did not coregulate TJ gene expression in End1/E6E7 cells. 
Thus, MPA dose response curves in the presence of immune activators could not be performed in the 
current study.  
 
It is very unlikely that NET-EN regulates CCL20 or TJ gene expression in vivo. This is because NET at 
100 nM regulates neither CCL20 nor TJ genes in End1/E6E7 cells. Collectively, this study has revealed 
via dose response analyses that the downregulation of claudin-4 expression and upregulation of CCL20 
expression by MPA occurs at physiological concentrations and thus may occur in vivo. However, 
whether tissue concentrations of MPA in DMPA users are greater or less than serum concentrations 
remain to be determined.   
 
6.1.5: The GR mediates the downregulation of select TJ genes by MPA as well as the synergistic 
upregulation of select pro-inflammatory immune mediators by MPA and immune activators 
The current study shows for the first time that the GR mediates the downregulation of claudin-4 
expression by MPA and DEX in End1/E6E7 cells. However, further details of the molecular mechanisms 
are unknown. The GR downregulates gene expression by tethering to transcription factors such as NFκB 
and AP-1 or binding compositely to STATs (De Bosscher & Haegeman, 2009; Langlais et al., 2012; 
Ratman et al., 2013; De Bosscher et al., 2014). It is unclear whether there are functional NFκB sites in 
the promoter region of claudin-4, but it has been reported to have functional SP-1 and AP-1 sites (Honda 
et al., 2006; Ikari et al., 2013; Noda et al., 2014). It is therefore possible that the GR interacts with the 
AP-1 binding sites to repress basal claudin-4 expression in endocervical epithelial cells.  
 
Previous in vitro studies have shown that the GR transactivates the occludin promoter in murine brain 
endothelial cEND cells and in human retinal epithelial cells in vitro via a distal imperfect GRE (Harke et 
al., 2008; Felinski et al., 2008). Because the GR does not transrepress via GREs, it is very unlikely that 
the GR mediates the repression of occludin expression by MPA in End1/E6E7 cells via this site. It is 
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also very unlikely the GR mediates the downregulation of occludin expression by MPA in End1/E6E7 
cells. This study found that MPA represses occludin mRNA expression at doses higher than 100 nM, 
which is more than the Kd of MPA for the GR [between 4nM to 11 nM] (Hapgood, 2013) in the promoter 
region of occludin gene.  
 
The results presented herein show that the GR mediates the downregulation of claudin-4 mRNA levels 
by MPA and DEX in End1/E6E7 cells, suggesting that MPA like DEX might act via the GR to disrupt the 
integrity of endocervical mucosal tissues in vivo. However, findings from a single animal study showing 
that MPA might act via the PR to increase the permeability of ectocervical and vaginal mucosal tissues 
in DMPA-treated mice via the downregulation of desmosomal and not TJ gene expression (Quispe-
Calla et al., 2016). Morphological differences between the human endocervical End1/E6E7 cell line [that 
has been shown to express the GR and not the PR (Govender et al., 2014)] and the mucosal tissues of 
the murine lower FGT. In addition, it is possible that MPA regulates TJ and desmosomal gene 
expression in the different compartment of the FGT via different steroid receptors. That is MPA acts via 
the PR mediates the downregulation of desmosomes in ectocervical and vaginal mucosal tissues but 
acts via the GR mediates the downregulation of TJ genes in the endocervix. Because it was not 
investigated in the current study, it is currently unknown whether MPA can act via the GR to regulate 
the expression of desmosomes in the End1/E6E7 cell line, which do not express the PR. Future 
experiments are needed to provide clarity on this question. In addition, there is a need to investigate 
CORT can regulate TJ gene expression in the FGT. Results from a previous study show that peak serum 
CORT levels in healthy females is about 444.18 nM (Cho et al., 2017), which is higher than the 
concentration of GCs used in this study. This suggests that CORT like DEX might downregulate TJ gene 
expression.  
 
The results from the present study show that the predominantly anti-inflammatory effects of MPA in the 
End1/E6E7 cell line in vitro are mediated by the GR. This is consistent with findings from a previous in 
vitro study that showed the GR mediates the MPA-induced suppression of pro-inflammatory gene 
expression in End1/E6E7 cells (Govender et al., 2014). Against this backdrop, however, the GR 
mediates the selective upregulation of CCL20 by either MPA alone or synergistically in combination with 
immune activators. Additional underlying molecular mechanisms involved were not investigated but 
could include several possibilities. Immune activators such as TNF have been shown to enhance the 
transcriptional activity of the GR by stabilising intracellular GR protein level (Bergann et al., 2009). The 
current study investigated and found that TNF does not stabilise GR protein levels in End1/E6E7 cells. 
Alternatively, some immune activators may enhance the site-specific phosphorylation of the GR at Ser-
211 and Ser-226 and/or induce nuclear translocation and binding of the receptor to the promoters of 
target genes, in this case CCL20 (Hapgood et al., 2016). The CCL20 proximal promoter region has no 
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identifiable GRE but contains binding sites for C/EBPβ and NFκB transcription factors. It is thus possible 
that in the presence of MPA the GR interacts with these transcription factors to induce CCL20 mRNA 
expression in the presence or absence of immune activators. This is consistent with evidence that the 
GR interacts with C/EBPβ and NFκB to enhance IL12p40 mRNA expression in Ect1/E6E7 cells co-
treated with MPA and TNF (Louw-du Toit et al., 2014). Therefore, the synergistic upregulation of CCL20 
by MPA and immune activators in End1/E6E7 cells may result from the enhanced recruitment of GR to 
the promoter. 
 
Previous research has shown that the GR mediates the upregulation of genes relevant for HIV-1 
infection in the presence of MPA or GCs. These include CCR5 and CD4 in TZM-bl cells and PBMCs 
(Maritz et al., 2018) and TLR2 in HeLa cells (Shuto et al., 2002; Imasato et al., 2002; Sakai et al., 2004). 
The current study shows that the GR mediates the downregulation of claudin-4 and the upregulation of 
CCL20 in End1/E6E7 cells. Collectively, this suggests that GR is pivotal in modulating biological 
processes that are essential to HIV-1 infection in the FGT. These processes include epithelial mucosal 
permeability (claudin-4), migration of target cells (CCL20) and HIV-1 entry into target cell (CCR5, CD4 
and TLR2).  
 
6.1.6: MPA might cooperate with immune activators to selectively upregulate CCL20 mRNA 
expression in ectocervical tissues from some, but not all donors   
Due to constraints in obtaining endocervical tissue, the current study could only investigate the effects 
of MPA on the expression of pro-inflammatory genes in ectocervical tissue explants. From results 
obtained it appears MPA might cooperate with immune activators to upregulate CCL20 mRNA levels in 
ectocervical tissues in vitro, although the effects were not statistically significant. It was observed that 
MPA and TNF appear to enhance CCL20 mRNA expression in some (3 out of 6), but not all samples 
from donors in vitro. This shows that there are high inter-donor variability samples used in the current 
study and suggests that about 50% of donors do respond to MPA. The different responses may be due 
to underlying intrinsic donor factors such as immune status, hormonal therapy, phase of menstrual cycle 
and age. Increasing the sample size might reduce the sample variance. Other factors such as time could 
have also influenced the outcome of the responses observed in ectocervical tissues in vitro. Evidence 
from previous studies suggest that primary genital epithelial cells or tissue explants are more responsive 
to MPA after 48 hours of treatment (Arici et al., 1995; Ray, 2015; Cordeaux et al., 2010). In the current 
study, however, ectocervical tissue explants were only exposed to MPA for 24 hours. Therefore, longer 
exposure to the ligands could change the outcome of the results reported in the current study.  Further 
experiments are required to determine whether MPA acts additively or synergistically with immune 
activators to enhance HIV-1 infection and the expression of genes relevant to infection in FGT tissue 
from women using DMPA-IM ex vivo.    
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6.1.7: The downregulation of desmoglein-1 but not occludin and claudin-4 by MPA in ectocervical 
tissue explant might enhance mucosal permeability and HIV-1 infection. 
The results presented herein show that in the absence of inflammation MPA represses desmoglein-1, 
but not occludin and claudin-4 expression in ectocervical tissue explants. This agrees with previous 
studies showing that MPA selectively downregulates desmosomal but not TJ genes in ectocervical 
mucosal tissues in women on DMPA (Quispe-Calla et al., 2016; Chandra et al., 2013). This suggests 
that MPA targets desmosomes but not TJs to disrupt the ectocervical mucosal barrier and hence 
increase the susceptibility of the ectocervix to HIV-1 infection.  
 
It has been observed that MPA increases HIV-1 infection in ectocervical tissue explants from 
premenopausal women, via a mechanism involving CCR5 (Ray et al., manuscript in preparation). The 
current finding implies that the downregulation of desmoglein-1 is another mechanism by which MPA 
renders the ectocervix vulnerable to HIV-1 infection. Due to constraints on tissue availability, the current 
study was unable to investigate whether MPA regulates desmosomes and TJ gene expression and the 
molecular mechanisms thereof in primary endocervical tissue. Nonetheless, considering results from 
End1/E6E7 cells, it is possible that MPA selectively downregulates TJs in the endocervix, but not in the 
ectocervix to enhance mucosal permeability. Therefore, TJs may be relevant in maintaining the integrity 
of mucosal surfaces of the upper but not the lower FGT.  
 
The current study investigated whether MPA enhances mucosal permeability of endocervical and 
endometrial epithelial monolayers in the absence or presence of HIV-1. The results show that MPA does 
not affect endocervical and endometrial mucosal permeability in vitro. However, they should be 
interpreted with caution. It was observed that exposure to HIV-1 IMCs failed to disrupt the integrity of 
PGEC monolayers, which is inconsistent with findings from previous studies (Nazli et al., 2010; Ferreira 
et al., 2015b; Nazli et al., 2013). The primary genital epithelial cells used in the current study took 
between two to three weeks to establish confluent monolayers. This is in contrast with what has been 
reported previously that PGECs establish confluent monolayers within five to seven days after seeding 
(Nazli et al., 2010; Kaushic et al., 2011; Nazli et al., 2013; Ferreira et al., 2015b). The disruptive effects 
of HIV-1 on mucosal barrier integrity have been shown to be mediated via TLR2 and TRL4 in vitro (Nazli 
et al., 2013). Because the expression of TLR4 in primary endocervical epithelial cells has been shown 
to be time dependent (Ma & Yang, 2010), it is possible that these receptors are lost when primary genital 
epithelial cells are cultured for a very long time. This could restrict their ability to respond to HIV-1.   
 
This study was also unable to verify whether MPA regulates mucosal permeability in End1/E6E7 cells. 
This cell line was generated by immortalising primary endocervical epithelial cells isolated from a pre-
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menopausal woman with the HPV E6E7 oncogene (Fichorova et al., 1997). Compared to other 
endocervical epithelial cell lines, End1/E6E7 cells are non-cancerous in origin and closely resemble 
primary endocervical epithelial cells (Fichorova et al., 1997; Fichorova et al., 1999). One of the initial 
goals of the current study was to verify whether End1/E6E7 cells can be used as an in vitro model to 
study the barrier functions of endocervical mucosal epithelial tissue. The results shown in this study 
suggest that End1/E6E7 cells do not form confluent monolayers but grow into multilayers. This is 
consistent with findings from some previous studies (Gali et al., 2010; Nold et al., 2012; Nold et al., 
personal communication), but in contrast to other findings (Sathe & Reddy, 2014; Das et al., 2014). The 
reason for this discrepancy remains unclear, but variations in growth condition may account for these 
differences. However, it could be that End1/E6E7 cells do no longer form polarised cultures after several 
passages. This growth tendency is typical of squamous and not columnar epithelial cells. The cells used 
in this study were between passage 9 and 40. It was beyond the scope of this study to investigate the 
effect of passage number on the ability of End1/E6E7 cells to form confluent monolayers.  
 
6.1.8: MPA  acts additively with select immune acivators to increase HIV-1 replication in TZM-bl 
cells 
The current study shows that MPA like DEX, but unlike NET, acts alone or additively with immune 
activators to increase HIV-1 replication in TZM-bl cells. This is consistent with fndings from previous 
studies that showed GCs cooperate in a synergistic manner with immune activators to upregulate HIV-
1 replication in chronically infected U1 cells in vitro (Bressler et al., 1993; Kinter et al., 2001). This 
suggests that target cells from women with GTIs using DMPA-IM are more likely to be infected with HIV-
1 compared to those of their healthy counterparts. This study used TNF and LPS to induce inflammatory 
responses in TZM-bl cells and found that they both cooperated with MPA but not NET to increase HIV-
1 replication in HIV-1 exposed cells. Some meta-analyses of observational studies have reported that 
DMPA-IM use enhanced the risk of HIV-1 acquisition associated with BV, but not HSV-2 (Ralph et al., 
2015; Morrison et al., 2015; Haddad et al., 2018). This suggests that not all GTIs are likely to cooperate 
with DMPA to further enhance the risk of HIV-1 infection in women. TNF and LPS elicit similar responses 
on HIV-1 replication in the presence of MPA because they target the same signalling pathways although 
via different receptors. However, during an infection the signalling pathways activated are more complex 
and may result in different inflammatory responses. Therefore, DMPA use may modify the risk of HIV-1 
acquisition associated with some GTIs but not others due to differences in soluble immune mediator 
expression profiles.  
 
The mechanism(s) involved in the additive upregulation of HIV-1 replication by MPA and immune 
activators in TZM-bl cells exposed to HIV-1 IMCS were not investigated in this study. Because TZM-bl 
cells are endocervical in origin, it is possible that MPA increases TLR2 expression in this indicator cell 
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line and makes them more permissive to HIV-1 infection and replication, as shown in CD4+ T cells (Ding 
et al., 2012; Bolduc et al., 2017; Thibault et al., 2007). Furthermore, since MPA has been found to 
increase CCR5 and CD4 expression in TZM-bl cells (Maritz et al., 2018), this may explain why MPA 
increases TNF- and LPS-induced HIV-1 replication in TZM-bl cells. Future studies could investigate 
whether these receptors play a role in the additive upregulation of HIV-1 replication by MPA and select 
immune activators. 
 
Collectively, the result suggests that MPA alone enhances the risk of HIV-1 acquisition. This is 
consistent with findings from previous laboratory and clinical studies that suggest MPA increases the 
risk of HIV-1 acquisition (Hijbregst et al., 2013; Sampah et al., 2015; Irvin & Herold, 2015; Tasker et al., 
2017; Maritz et al., 2018; Quispe-Calla et al., 2018; Martin et al., 1998; Baeten et al., 2007; Leclerc et 
al., 2008; Wand & Ramjee, 2012; Heffron et al., 2012; Crook et al., 2014; Noguchi et al., 2015; Ralph et 
al., 2015; Morrison et al., 2015; Brind et al., 2015; Polis et al., 2016; Hapgood et al., 2018; Hickey et al., 
2016). In addition, they also suggest that DMPA-IM may cooperate with GTIs to further enhance the risk 
of HIV-1 acquisition in women. This is consistent with findings from observational studies suggesting 
DMPA-IM enhances the risk of HIV-1 acquisition associated with bacterial vaginosis (Haddad et al., 
2018; Morrison et al., 2015). Therefore, DMPA-IM use may not be a better choice of hormonal 
contraception in women living in regions with or without a high prevalence of GTIs. However, NET alone 
or in the presence of immune activators did not increase HIV-1 infection in TZM-bl cells. This suggests 
that NET-EN might not cooperate with GTIs to enhance the risk of HIV-1 acquisition in women and could 
serve as a safer alternative to DMPA-IM.   
 
6.1.9: Soluble factors secreted by PBMCs in the presence of MPA and immune activators 
increase HIV-1 replication in TZM-bl cells.  
In the absence of immune activation, this study shows that MPA does not regulate the expression of 
pro-inflammatory immune mediators investigated herein in PBMCs after 24 hours of treatment. This 
could be time dependent as some studies have shown that MPA unlike NET regulates the expression 
of select pro-inflammatory immune mediators in PBMCs after 48 hours of treatment (Maritz et al., 2018; 
Hapgood et al., 2014; Ray, 2015). The current studies collectively showed that MPA selectively 
enhances the expression of innate immune receptors and markers of cellular activation but inhibits or 
does not alter the expression of soluble immune factors by PBMCs. Evidence from clinical and animal 
studies also suggest that DMPA-IM reduces serum levels of some select pro-inflammatory soluble 
factors, but mostly does not the alter serum levels of others (Michel et al., 2016; Batista et al., 2017; 
Goode et al., 2014). There is no consensus on which pro-inflammatory immune mediators are regulated 
by DMPA-IM in women. This may be attributed to interindividual variability of the samples and 
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differences in study design including the fact that different studies investigate the different immune 
mediators.     
 
This study investigated the effects of MPA on LPS-induced gene expression in PBMCs in vitro and found 
that MPA is anti-inflammatory for several modulators investigated. This is consistent with findings from 
other in vitro studies that showed that MPA mostly suppressed the expression of pro-inflammatory 
immune mediators in the presence of immune activation (Kleynhans et al., 2011; Huijbregts et al., 2013; 
Huijbregts et al., 2014; Michel et al., 2016). While it may be predominantly anti-inflammatory in vitro, 
MPA nonetheless upregulates the expression of select pro-inflammatory immune mediators in the 
presence of immune activators, as shown in this study for CCL20. However, others have shown that 
CXCL10 and G-CSF are co-regulated in vitro by MPA and immune activators (Kleynhans et al., 2011). 
This suggests that MPA modifies the cytokine and chemokine secretion profiles of PBMCs in the 
absence or presence of LPS. How this affects HIV-I infection remains unknown.                                                                                                                                                                                 
 
This study thus investigated the effects of soluble immune mediators secreted by PBMCs treated with 
MPA alone or in combination with immune activators on HIV-1 infection in TZM-bl cells. The results 
show that secretions from PBMCs treated with MPA do not affect HIV-1 replication in TZM-bl cells. This 
can be explained by the fact that MPA at 100 nM does not alter the levels of soluble immune mediators 
secreted by PBMCs after 24 hours of treatment in the absence of LPS. Others have some that secretions 
from vaginal epithelial cells incubated in vitro with 388 µM MPA increased HIV-1 replication in the 
chronically infected Jurkat-Tat-CCR5 (JT-CCR5) cells as did recombinant IL6, TNF and GM-CSF (Irvin 
& Herold, 2015). This suggest that pro-inflammatory soluble factors secreted by vaginal epithelial cells 
in response to MPA mediated the increase in HIV-1 replication.  Contrary to the current study that saw 
no changes in the levels of soluble immune mediators, Irvin and Herold (2015) found that supernatants 
from vaginal epithelial Vk2/E6E7 cells incubated with 388 µM MPA overwhelmingly had high levels of 
IL6, IL8, TNF, CCL3, CCL4, CCL5 and GM-CSF. Variations in cell type and the concentration of MPA 
used may explain these differences. However, in the current study, secretions from PBMCs co-treated 
with 100 nM MPA and LPS did enhance HIV-1 replication in TZM-bl cells. Although secretions from 
PBMCs co-treated with MPA and LPS had low levels of IL6 and CCL5, they also were found to have 
high levels of CCL20 compared to secretions from untreated cells. It remains unknown which soluble 
factors are involved, but they could include CCL20 in conjunction with some unidentified factors not 
investigated herein. Current evidence suggests that CCL20 enhances HIV-1 entry and integration into 
target cells but suppresses viral replication by inducing the expression of APOBEC3G (Lafferty et al., 
2010). This suggests that MPA and LPS also induce a yet to be identified soluble factor that prevent 
APOBEC3G-mediated suppression of viral replication but one that equally activates viral replication. 
 
119 
 
Future experiments could investigate whether involvement of CCL20 secreted by PBMCs co-treated 
with MPA and LPS in enhancing HIV-1 replication.           
 
Previous studies have shown that serum levels of CCL20 are elevated in HIV-1 positive patients 
(Fontaine et al., 2011; Aziz et al., 2016; Valverde-Villegas et al., 2018). The results presented herein 
suggest that DMPA-IM use might further increase CCL20 serum levels in HIV-1 positive patients. High 
CCL20 serum levels in HIV-1 infected patients have been associated with the homing and depletion of 
Th17 cells in mucosal tissues of the gut (Loiseau et al., 2016; Lee & Körner, 2017; Valverde-Villegas et 
al., 2015; Peng et al., 2013; Falivene et al., 2015; Singh et al., 2014). This suggests that MPA-induced 
upregulation of systemic CCL20 protein levels in HIV-1 patients might enhance the homing and 
subsequent depletion of Th17 cells at mucosal surfaces. A drop in Th17 cell numbers in HIV-1 patients 
has been associated with poor disease outcome (Falivene et al., 2015). While no direct association has 
been established between DMPA-IM use and HIV-1 disease progression (Richardson et al., 2007; 
Stringer et al., 2009; Morrison et al., 2011; Heffron et al., 2013; Whiteman et al., 2016), DMPA-IM use 
might indirectly influence an unfavourable disease prognosis via upregulating CCL20 expression in HIV-
1 positive patients, followed by a lowering of Th17 cell numbers. 
 
Plasma LPS levels may be elevated in HIV-1 infected women with concentrations ranging between 87.2 
pg/mL and 170.8 pg/mL (Brenchley et al., 2006; Funderburg et al., 2012; Valiathan et al., 2016). 
However, the current study used LPS at a concentration of 5 µg/mL. This raises the question whether 
lower concentrations of LPS can cooperate with MPA to upregulation CCL20 expression in End1/E6E7 
cells and PBMCs. Moreover, it also questions whether the in vitro effects observed in the current study 
can occur in vivo in HIV-1 negative women. In HIV-1 infected women, the source of plasma LPS is 
predominantly the gut (Vassallo et al., 2012; Zhang et al., 2015). However, the vaginal microbiome may 
also contribute to plasma LPS levels, especially in women with bacterial vaginosis (Si et al., 2017). One 
study reported that women in the Texas, USA with bacterial vaginosis had vaginal LPS levels of 323.5 
ng/mL (Aroutcheva et al., 2008). Given that bacterial vaginosis in prevalent in Sun-Saharan Africa and 
that women of Sub-Saharan African descent have a more diverse vaginal microbiome compared to 
women elsewhere, it is possible that higher serum and vaginal LPS can be detected.     
 
Taken together, although others have shown that in vitro MPA is predominantly anti-inflammatory, this 
study shows that it upregulates the expression of select pro-inflammatory immune mediators in the 
presence of immune activators in vitro. This may create a microenvironment that allows (i) more HIV-1 
target cells to become infected and/or (ii) migrate to mucosal tissues where they are depleted in women. 
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6.1.10: MPA like LNG but unlike NET may not be a better choice of hormonal contraceptive for 
women at risk of HIV-1 infection. 
The results in the this and previous studies show that MPA differs from other progestogens in the manner 
in which it regulates gene expression in vitro (Koubovec et al., 2014; Ronacher et al., 2009; Africander 
et al., 2011; Hapgood et al., 2014; Govender et al., 2014; Maritz et al., 2018; Tomasicchio et al., 2013; 
Huijbregts et al., 2013; Huijbregts et al., 2014; Shen et al., 2017). This study shows that MPA unlike 
NET, LNG and P4 downregulates claudin-4 expression in vitro in endocervical epithelial End1/E6E7 
cells. This suggests that unlike MPA, neither NET, LNG nor P4 might enhance the permeability of the 
endocervix in vivo and thus render it vulnerable to HIV-1 infection. However, evidence from clinical 
studies suggest that DMPA-IM and LNG-IUD use increase the permeability of ectocervix and vagina in 
vivo (Quispe-Calla et al., 2016; Quispe-Calla et al., 2017). Because it has not been investigated, the in 
vivo effects of NET-EN on genital mucosal permeability remains unknown. Nonetheless, based on 
available evidence in the literature and findings from the current study, DMPA-IM might not be safe for 
use by women at high risk of HIV acquisition.  
 
Data from animal studies suggest that female macaques treated with exogenous P4 or in luteal phase 
are more susceptible to SHIV infection (Sodora et al., 1998; Vishwanathan et al., 2011 Kersh et al., 
2014; Marx et al., 1996; Smith et al., 2000). This suggest that a progestogen-dominant state enhances 
the risk of infection. However, not all progestogens used in hormonal contraception increase the 
likelihood for HIV-1 infection in women. Evidence from observational studies suggests that DMPA-IM 
but not NET-EN significantly increases the risk of HIV-1 acquisition in women (Ralph et al., 2015; 
Morrison et al., 2015). While there is paucity in the literature on the effect of LNG-IUD use on the risk of 
HIV-1 acquisition, evidence from the few studies that investigated this question found no association 
between HIV-1 acquisition and LNG-IUD. However, evidence from clinical studies show that LNG-IUD 
use increased the proportion of CCR5+CD4+ T cells in the blood (Sciaranghella et al., 2015) and FGT 
(Shanmugasundaram et al., 2016), besides increasing the permeability of the ectocervix (Quispe-Calla 
et al., 2017). This suggest that LNG-IUD may also enhance the risk of HIV-1 infection  
 
The recent in vitro findings showing that MPA but not NET acts via the GR to increase HIV-1 infection 
of CD4+ T cells and TZM-bl cells (Maritz et al., 2018). The current study extends these findings by 
showing that MPA but not NET acts alone or additively with immune activators to increase the infectibility 
of TZM-bl cells. Taken together with the published literature, the thesis findings suggest that NET-EN 
may be a safer choice of hormonal contraception use by women at risk of HIV-1 infection than DMPA-
IM, while the LNG-IUD may also not be a suitable choice  
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6.2: Conclusions 
The in vitro results presented herein show for the first that physiologically relevant concentrations of 
MPA, unlike NET and LNG, acting as a partial GR agonist relative to DEX, may increase the permeability 
of endocervical epithelial End1/E6E7 cells in the absence of immune activators by downregulating the 
expression of the tight junction gene claudin-4. In contrast, MPA unlike NET may disrupt the ectocervical 
mucosal barrier by downregulating desmoglein-1 but not claudin-4 expression, suggesting that different 
mechanisms may operate in the endocervix and ectocervix. This study also suggests that physiologically 
relevant concentrations of MPA, unlike NET, acts as a full GR agonist like CORT to upregulate CCL20 
and TLR2 expression in End1/E6E7 cells in the absence of immune activators, suggesting that MPA 
might increase the sensitivity of the endocervical epithelial cell line toward CCL20 and TLR2 specific 
inflammatory responses. Taken together, this study provides new insights into plausible mechanisms 
by which MPA but not NET and LNG may increase the susceptibility of the FGT.  
 
In the presence of immune activators, this study showed for the first time that MPA, unlike NET, at 
physiologically relevant concentrations acts via the GR to cooperate, in some instance synergistically, 
with immune activators to upregulate CCL20 and TNF receptor 2, but not tight junction gene expression 
in End1/E6E7 cells. This occurred against the backdrop of MPA suppressing IL1β, IL6, IL8 and CCL5 
expression in the presence of immune activators and suggests that MPA might enhance immunological 
responses mediated via TNF receptor 2 and moreover enhance the recruitment of CCL20-responsive 
HIV-1 target cells in the endocervix in women. The in vitro results show that MPA but not NET might 
cooperate with immune activators to upregulate CCL20 expression in the ectocervical tissues in some, 
but not all women. This indicates interindividual variations in responses induced by MPA. Nonetheless, 
MPA selectively potentiated LPS-induced expression of CCL20, but repressed LPS-induced expression 
of IL1β, IL6 and IL8 in PBMCs in vitro. The study shows that synergistic effects of GR ligands like MPA 
with proinflammatory modulators are highly gene-specific, while the precise intracellular mechanism for 
CCL20 remains to be determined.  
 
This study found that MPA, unlike NET, can act alone or additively with immune activators to enhance 
HIV-1 replication in TZM-bl cells. In addition, this study found that secretions from PBMCs cotreated 
with MPA and LPS, but not MPA alone or NET and LPS, had high CCL20 but low CCL5 and enhanced 
HIV-1 replication in TZM-bl cells. This suggests that women with GTIs using DMPA-IM but not NET-EN 
are more likely to acquire HIV-1.    
 
The current study was unable to establish via statistical analysis whether MPA cooperates with immune 
activators to upregulate CCL20 expression in ectocervical tissue explants, although this was shown in 
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PBMCs. The small sample size coupled with a large degree of inter-donor variability could have 
confounded the results. Increasing the sample size will improve the significance of the data.    
 
The in vitro findings herein show that when responses to MPA are obtained, these are different to those 
of NET, or LNG or P4 where investigated, are GR-mediated and are plausibly likely to increase HIV-1 
acquisition and/or pathogenesis. This adds to the accumulating body of evidence that MPA acts as a 
potent partial to full GR agonist, in multiple cell and tissue models, and is biochemically and functionally 
different to other progestins used in endocrine therapy, as well as luteal phase P4 levels. 
  
6.3: Future perspectives 
This study has raised many intriguing questions and identified several potentially important mechanisms 
whereby MPA, unlike NET, could affect immune function and HIV-1 acquisition or pathogenesis. There 
are many possible avenues to explore in future, and this section will focus on those that appear to be 
the most relevant and interesting. Because all the experiments described herein are in vitro, using cell 
lines, PBMCs and ectocervical tissue explants, there is a need to investigate whether the results shown 
in the current study can occur in vivo in women using injectable hormonal contraception. Thereafter, 
molecular mechanisms will be established in vitro using primary cells. 
 
6.3.1:  Investigate the effects of DMPA-IM and NET-EN on claudin-4, desmoglein-1, TLR2 and 
CCL20 expression where possible in the endocervix, ectocervix and PBMCs  
The results shown in the current study suggest that DMAP-IM use might increase the permeability of 
the endocervix by downregulating claudin-4 expression. Due to paucity of data for NET-EN, it’s effects 
on mucosal permeability in the FGT remain unknown. However, results shown in the current study 
suggest that NET-EN might not disrupt the mucosal barrier of the endocervix. Therefore, future 
experiments could assess and compare the mucosal permeability of endocervical tissue biopsies from 
healthy women using DMPA-IM, NET-EN or no HC, using methods previously described by others 
(Quispe-Calla et al., 2016; Quispe-Calla et al., 2017). 
 
Evidence shown in the current study suggests that MPA downregulates the expression of desmoglein-
1 but not TJ genes in ectocervical tissues in vitro. This is consistent with findings from a previous study 
in mice showing that DMPA increased the permeability of the ectocervix by downregulating 
desmosomes but not TJ genes (Quispe-Calla et al., 2016). However, it remains unclear whether MPA 
differentially regulate desmosomes and TJ genes in the endocervix. Therefore, the expression of 
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desmoglein-1 and claudin-4 mRNA and protein could be investigated in endocervical tissue biopsies 
from healthy women using DMP-IM, NET-EN or no HC. 
  
Another intriguing question to investigate is whether MPA and NET regulate CCL20 and TLR2 
expression in the endocervix, ectocervix and blood in vivo. Tissue biopsies and PBMCs from healthy 
women using DMPA-IM, NET-EN or no HC could be evaluated for CCL20 and TRL2 mRNA and protein 
levels. In addition, cervical tissue biopsies and PBMCs from women using DMPA-IM and NET-EN could 
be treated with TRL2 ligands ex vivo and assessed for the expression of soluble immune mediators 
particularly CCL20. This will confirm whether progestogens can cooperate with immune activators to 
upregulate CCL20 expression. In addition, it could be investigated whether TLR2 ligands enhance HIV-
1 infection in cervical tissue biopsies and PBMCs from women using DMPA-IM and NET-EN ex vivo.    
 
An intriguing question is whether DMPA or NET-EN can alter the proportion of CCR6+CD4+ T cells in 
the FGT in vivo in the absence or presence of immune activation. The results shown in the current study 
suggest that MPA is more likely than NET to cause CCR6+CD4+ T cells to infiltrate the FGT in the 
presence of immune activators via upregulating the expression of CCL20. Therefore, endocervical and 
ectocervical tissue biopsies could be obtained from using women DMPA-IM, NET-EN or no HC with or 
without GTIs. Immunohistochemistry and confocal microscopy will then to use to establish the effects of 
HC use alone or in combination with GTIs on the density of CCR6+CD4+ T cells in the tissue samples. 
Furthermore, in vitro migration assay could be used to investigate whether secretions from tissue 
biopsies from women using DMPA-IM, NET-EN or no HC treated ex vivo with TLR2 ligands can induce 
the migration of CCR6+CD4+ T cells.    
 
 6.3.2: Investigate molecular mechanisms in primary endocervical epithelial cells    
Future experiments could investigate whether the GR is involved in the regulation of claudin-4, 
desmoglein-1, CCL20, TLR2 and TNF receptor 2 expression by MPA in primary genital epithelial cells 
in the absence or presence of immune activators. Preliminary results from studies in the Hapgood 
Laboratory suggest that primary genital epithelial cells express both the GR and the PR (Hapgood et 
al., unpublished). Thus, it remains unclear which steroid receptor would mediate the regulation of the 
target genes by MPA in primary genital epithelial cells. Because is RU486 antagonises both receptors, 
the role of GR could be investigated using GR knockdown with siRNA. 
 
The results shown herein suggest that MPA might enhance CCL20 mRNA levels in the cytoplasm in the 
absence of immune activators. Whether this contributes to the synergistic upregulation of CCL20 mRNA 
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levels in the presence of immune activators remains unclear. Therefore, future experiments using 
actinomycin D (transcription inhibitor) could be performed to establish the effects of MPA on CCL20 
mRNA stability in the absence and presence of immune activators.  
 
This thesis showed that MPA upregulates the expression of TLR2 and TNF receptor 2 but suppresses 
claudin-4 and desmoglein-1. Although a requirement for the GR was established in the current study, 
the molecular mechanisms remains unknown. The GR has been shown to be recruited to a GRE in the 
proximal promoter region of TLR2 in HeLa cells in responses to GCs (Hermoso et al., 2002). It possible 
that in the presence of MPA the GR transactivates TLR2 expression via this site in End1/E6E7 cells. 
However, it is unclear which sites does the GR interacts with to regulate CCL20, claudin-4, desmoglein-
1 and TNF receptor 2 expression in response to MPA. The promoter region of CCL20 has been shown 
to contain a C/EBPβ binding site. It is possible that the GR is recruited to this site to transactivate basal 
expression in response to MPA.  In addition, potential GREs or binding sites of other transcription factors   
could be identified in the proximal promoter regions of using in silico transcription factor binding site 
prediction tools. Thereafter, chromatin immunoprecipitation (CHIP) assays could be used to established 
whether treatment with MPA causes the GR to interact with these sites in the promoter of the target 
genes. 
 
It could also be investigated whether co-treatment with immune activators and MPA results in an 
enhances recruited of the GR to the CCL20 promoter to result to synergistic upregulation of CCL20 
expression. Because the results shown herein suggest that the effects of MPA and immune activators 
on CCL20 expression are mutual, it is possible that co-treatment with MPA and immune activators also 
results to the recruitment of transcription factors such as p65 to the CCL20 promoter. Interestingly, GCs 
have been shown to enhance the recruitment of p65 to the CCL20 promoter. Conversely, immune 
activators may also enhance the interaction of the GR with the CCL20 promoter. Therefore, future 
experiments will use assays investigate whether the GR is recruited to C/EBPβ site. Furthermore, CHIP 
assays will also be used to investigate whether MPA enhances p65 recruitment to the CCL20 promoter 
in the presence of immune activators or whether immune activators enhance GR recruitment to the 
promoter. 
 
Future research will also investigate the role of MKP-1/p38 MAPK and MKP-1/p38 MAPK/PI3K/AKT 
signalling pathways in the selective synergistic upregulation of CCL20 by MPA and TNF in End1/E6E7 
cells. Previous studies have shown that MKP-1/p38 MAPK signalling pathway is involved in the 
synergistic upregulation of TRL2 expression by GCs and immune activators in HeLa cells (Shuto et al., 
2002; Imasato et al., 2004; Sakai et al., 2004; Hermosa et al., 2004). However, this study is proposing 
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that the MKP-1/p38 MAPK pathway mediates MPA-induced inhibition of basal and TNF-induced IL6, 
IL1β and IL8 expression by MPA in End1/E6E7 cells. On the other hand, the MKP-1/p38 
MAPK/PI3K/AKT pathway selectively mediates MPA-induced upregulation of basal and TNF-induced 
expression of CCL20 in End1/E6E7 cells. To verify this hypothesis, initial experiments could be 
performed to investigate the role of MKP-1 in MPA-induced regulation of IL6 and CCL20 in End1/E6E7 
cells using siRNA knockdown technology. In addition, specific pharmacological inhibitors assign roles 
to specific MAPKs and PI3K/AKT.     
 
Besides CCL20, chemokines such as CCL21 and CCL19 have been shown to induce latent HIV-1 
infection in resting CD4+ T cells (Cameroon et al., 2010; Saleh et al., 2007). Unlike CCR6+CD4+ T cells 
that respond uniquely to CCL20, CCR7+CD4+ T cells respond to CCL21 as well as CCL19. However, 
there are populations of CD4+ T cells that express both receptors and so are capable of responding to 
all three chemokines. These are mainly Th17 cells of central memory phenotype. A previous study 
reported that MPA increased basal CCL21 mRNA levels in the endocervix of macaque monkeys (Goode 
et al.., 2014). It remains unknown whether CCL19 is regulated by MPA, but there is evidence that GCs 
upregulate its expression in airways epithelial cells in the presence of TNF (Oakley et al., 2017). The 
intriguing question to pursue is whether MPA can act alone or via these chemokines to induce latent 
infection in HIV-1 target cells. To answer this question, Th17 cells could be differentiated from PBMCs. 
The cells could then be pre-treated with MPA and then stimulated with TNF. The cotreated cells could 
then be exposed to HIV-1 IMCs and cultured at specific time points. At the end of each time point, cells 
could be harvested for DNA and RNA extraction to assess HIV integration and mRNA levels of select 
immune mediators, respectively. In addition, cell culture supernatants could be collected and used to 
quantify by ELISA the levels of HIV-1 reverse transcriptase and select immune mediators This time-
course approach could facilitate the identification of the window in which latent infection is established 
and how changes in immune mediator secretion profiles affect this over time. Specific neutralising 
antibodies could be used to established whether MPA acts via CCL19, CCL20 and CCL21 to induce 
latent HIV-1 infection.    
 
This study also showed that secretions from PBMCs cotreated with MPA and LPS enhanced HIV-1 
replication in TZM-bl cells. These secretions were found to have high levels of CCL20, but low levels of 
CCL5, IL6 and possibly IL1β. Future experiments could investigate the role of CCL20 or other soluble 
immune mediators in the upregulation of HIV-1 replication by secretions from PBMCs cotreated with 
MPA and LPS using neutralising antibodies.    
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Appendix A 
 
Supplementary data for chapter three 
 
 
 
 
Figure 1: The regulation by DEX, MPA and NET of basal and induced CCL20, IL6 and GILZ mRNA 
levels in End1/E6E7 cells is time-dependent. End1/E6E7 cells were stimulated with 100 nM DEX, MPA, 
NET or 0.1% (v/v) EtOH (vehicle) in the presence or absence of 1.15nM human TNF for 4, 24 and 48 hours. At 
A 
B 
C 
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the end of each incubation time, cells were harvested in TriReagent® and Stored at -80˚C until total RNA isolated 
and converted to cDNA. The relative mRNA levels of CCL20 (A), IL6 (B), and GILZ (C) were determined by qRT-
PCR using gene specific primers and normalised to GAPDH mRNA levels. The relative effects of steroid hormones 
and TNF on mRNA levels of the selected genes were determined by normalising to the vehicle control of each 
time point, which have been set to 1. The data include at least 3 independent biological repeats plotted as mean 
± SEM in Graph Pad Prism 7 software. 
 
 
 
Figure 2: MPA and TNF jointly upregulate CCL20 mRNA expression in End1/E6E7 samples used 
in RT2 PCR Array analysis. End1/E6E7 cells were treated with 100 nM MPA or 0.1% (v/v) EtOH (vehicle) in 
the presence or absence of 1.15 nM TNF for 24 hours. Thereafter, total RNA was isolated using RNeasy Mini kit 
(Qiagen, USA), assessed for integrity by Bioanalysis and then converted to cDNA using the RT2 First Strand kit 
(Qiagen). The relative mRNA levels of CCL20 was determined by qRT-PCR using gene specific primers and 
normalised to GAPDH mRNA levels. The relative effects of steroid hormones on mRNA levels were determined 
by normalising to TNF only, which has been set to 100%. Statistically analysis was performed using one-way 
ANOVA with Tukey’s multiple comparison and statistical significance is denoted as * to indicated p<0.05 (TNF vs 
TNF + MPA). In some cases, the unpaired Student’s t-test was used, and statistical significance is denoted as #### 
to indicate p<0.0001 (Vehicle vs TNF). 
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Table 1: The effects of MPA and TNF on mRNA levels of genes relevant to HIV-1 pathogenesis in 
End 1 E6E7 cells 
 
Position 
Gene 
Symbol 
Fold Change (comparing to vehicle control set to 1)  
TNF MPA TNF + MPA 
Fold 
Change 
p-value  Comments  
Fold 
Change 
p-value  Comments  
Fold 
Change 
p-value  Comments  
A01 APEX1  0.69 0.566953 
 
0.78 0.709290 
 
0.57 0.528825 
 
A02 APOBEC3G  0.86 0.773880 C 0.93 0.947102 C 1.07 0.961797 C 
A03 BAD  0.91 0.804554 
 
0.76 0.630536 
 
0.97 0.776030 
 
A04 BANF1  0.90 0.694157 
 
0.98 0.819093 
 
0.93 0.688958 
 
A05 BAX  0.91 0.692354 
 
0.88 0.855164 
 
1.02 0.838513 
 
A06 BCL11B  0.57 0.462289 
 
0.84 0.923458 
 
0.53 0.369369 
 
A07 BCL2  0.90 0.681536 
 
0.99 0.882180 
 
0.69 0.590751 
 
A08 BTRC  0.73 0.547760 
 
0.77 0.653562 
 
0.85 0.609549 
 
A09 CASP3  0.78 0.688821 
 
0.94 0.767208 
 
0.97 0.800565 
 
A10 CASP8  0.79 0.637932 
 
0.96 0.907481 
 
0.79 0.642802 
 
A11 CBX5  0.80 0.704360 
 
0.77 0.708837 
 
0.97 0.795792 
 
A12 CCL2  1.29 0.642777 B 0.89 0.865563 B 1.24 0.707658 B 
B01 CCL3  0.93 0.842015 B 0.93 0.947102 C 1.07 0.961797 C 
B02 CCL4  0.86 0.773880 C 0.93 0.947102 C 1.12 0.926316 B 
B03 CCL5  3.69 0.229996 A 0.41 0.468883 B 2.60 0.293128 B 
B04 CCL8  0.86 0.773880 C 0.93 0.947102 C 1.07 0.961797 C 
B05 CCNT1  0.75 0.607005 
 
0.82 0.742427 
 
0.85 0.646911 
 
B06 CCR2  0.86 0.773880 C 0.93 0.947102 C 1.07 0.961797 C 
B07 CCR3  0.64 0.481925 B 0.69 0.543583 B 0.80 0.578428 B 
B08 CCR4  0.75 0.561261 B 1.05 0.818144 B 2.10 0.609705 B 
B09 CCR5  0.86 0.773880 C 0.93 0.947102 C 1.07 0.961797 C 
B10 CD209  0.86 0.773880 C 0.99 0.925627 B 1.07 0.961797 C 
B11 CD247  0.60 0.465384 B 0.89 0.903950 B 0.53 0.338800 B 
B12 CD4  0.72 0.781230 B 0.58 0.647430 B 0.97 0.755550 B 
C01 CD44  1.03 0.881389 
 
0.98 0.823304 
 
1.19 0.996040 
 
C02 CD69  2.39 0.301556 B 0.93 0.948652 B 3.38 0.174812 B 
C03 CD74  3.41 0.352820 
 
1.03 0.898560 
 
3.58 0.387811 
 
C04 CDK7  1.07 0.741983 
 
1.30 0.955650 
 
1.22 0.870574 
 
C05 CDK9  0.85 0.744979 
 
0.90 0.758517 
 
0.89 0.676216 
 
C06 CDKN1A  1.07 0.955046 
 
0.85 0.731819 
 
1.26 0.974219 
 
C07 CEBPB  1.32 0.956748 
 
0.84 0.703234 
 
1.32 0.874793 
 
C08 COPS6  0.76 0.607523 
 
0.85 0.785303 
 
0.89 0.724971 
 
C09 CR2  1.06 0.740023 B 2.38 0.559231 B 1.18 0.665613 B 
C10 CREBBP  0.74 0.379961 
 
0.94 0.568696 
 
0.90 0.565962 
 
C11 CX3CL1  1.42 0.605603 B 0.93 0.947102 C 1.79 0.397519 B 
C12 CXCL12  0.86 0.773880 C 0.93 0.947102 C 1.07 0.961797 C 
D01 CXCR4  0.56 0.692755 B 0.40 0.433418 B 0.83 0.994917 B 
D02 ELANE  0.82 0.701371 B 0.89 0.858970 B 1.56 0.573067 B 
D03 EP300  1.08 0.941727 
 
1.12 0.943733 
 
1.28 0.954505 
 
D04 FCAR  0.86 0.773880 C 0.93 0.947102 C 1.07 0.961797 C 
D05 FOS  0.68 0.570625 
 
1.29 0.825717 
 
0.89 0.933635 
 
D06 GADD45A  0.92 0.871267 
 
0.76 0.600842 
 
0.97 0.847735 
 
D07 HCK  0.99 0.923509 B 0.93 0.947102 C 1.07 0.961797 C 
D08 HTATSF1  0.69 0.635756 
 
0.57 0.806585 
 
1.22 0.800354 
 
D09 IFNA1  0.79 0.582851 
 
0.68 0.859505 
 
0.95 0.776255 
 
D10 IFNB1  1.24 0.925179 B 0.80 0.907435 B 0.89 0.969059 B 
D11 IFNG 0.77 0.540798 B 0.51 0.507023 B 1.59 0.432693 B 
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D12 IL10  0.86 0.773880 C 0.93 0.947102 C 1.07 0.961797 C 
E01 IL12B  0.75 0.540638 B 0.71 0.610448 B 1.13 0.830816 B 
E02 IL16  0.86 0.766090 B 0.93 0.938008 B 1.87 0.383458 B 
E03 IL1B  0.89 0.752639 B 0.45 0.339375 B 1.22 0.988359 B 
E04 IL2 3.47 0.246307 
 
1.23 0.991180 
 
3.29 0.290000 
 
E05 CXCL8  0.86 0.773880 C 0.93 0.947102 C 1.07 0.961797 C 
E06 IRF1  5.98 0.229158 
 
0.93 0.828674 
 
7.22 0.226727 
 
E07 IRF2  1.77 0.645576 
 
0.94 0.811082 
 
1.99 0.571660 
 
E08 KLRD1  1.39 0.722563 
 
1.02 0.932455 
 
1.59 0.640749 
 
E09 LTBR  0.86 0.739689 B 0.89 0.884121 B 0.95 0.906611 B 
E10 MAP3K5  0.84 0.662812 
 
0.99 0.931167 
 
1.00 0.820074 
 
E11 MBL2  0.75 0.498105 
 
1.12 0.915475 
 
0.93 0.818110 
 
E12 NFATC1  1.00 0.922962 B 0.93 0.947102 C 1.07 0.961797 C 
F01 NFKB1  1.08 0.886728 
 
1.08 0.920545 
 
1.13 0.965401 
 
F02 NFKBIA  2.55 0.285442 
 
1.05 0.961026 
 
3.41 0.185347 
 
F03 PPIA 0.88 0.751514 
 
0.87 0.902017 
 
1.16 0.857912 
 
F04 PRDX1  1.02 0.895047 
 
0.38 0.924716 
 
1.15 0.911979 
 
F05 PTK2B  0.93 0.769421 
 
0.28 0.908156 
 
1.15 0.795774 
 
F06 RBL2  0.94 0.676546 
 
1.13 0.869129 
 
1.18 0.968140 
 
F07 SELL  2.42 0.373382 B 0.93 0.947102 C 3.44 0.348633 B 
F08 SERPINA1  5.66 0.231363 A 0.79 0.582216 B 6.83 0.285199 A 
F09 SERPINC1  0.73 0.525841 B 1.04 0.825516 B 0.71 0.477332 B 
F10 SLPI  1.20 0.936995 
 
0.99 0.918523 
 
1.62 0.631448 
 
F11 SMARCB1  0.83 0.657977 
 
1.01 0.911114 
 
0.97 0.783471 
 
F12 STAT1  1.09 0.987071 
 
1.16 0.942652 
 
1.27 0.776042 
 
G01 STAT3  1.22 0.926631 
 
1.07 0.981203 
 
1.67 0.582451 
 
G02 TFCP2  1.62 0.600129 
 
1.94 0.342448 
 
1.94 0.316682 
 
G03 TGFB1  1.16 0.929176 
 
1.04 0.976662 
 
1.46 0.743320 
 
G04 TNF  10.66 0.187637 B 1.09 0.718594 B 16.40 0.120217 B 
G05 TNFRSF1B  2.19 0.380946 B 0.96 0.669255 B 3.66 0.237804 A 
G06 TNFSF10  0.98 0.924582 
 
1.13 0.890301 
 
1.31 0.780171 
 
G07 TRIM5  0.81 0.637268 
 
0.95 0.765587 
 
0.95 0.716534 
 
G08 TSG101  0.95 0.717690 
 
1.07 0.931220 
 
1.20 0.837136 
 
G09 VPS4A  0.85 0.592572 
 
0.97 0.879363 
 
0.89 0.693001 
 
G10 XCL1  0.86 0.773880 C 0.93 0.947102 C 1.07 0.961797 C 
G11 XPO1  0.77 0.559885 
 
1.03 0.861393 
 
0.91 0.748066 
 
G12 YY1  0.97 0.828124 
 
1.23 0.899896 
 
1.09 0.998045 
 
H01 ACTB  1.02 0.816577 
 
0.97 0.909324 
 
1.19 0.192713 
 
H02 B2M  2.60 0.591403 
 
2.31 0.738273 
 
3.36 0.361168 
 
H03 GAPDH  1.00 0.000000 
 
1.00 0.000000 
 
1.00 0.000000 
 
H04 HPRT1  0.85 0.589640 
 
1.02 0.904048 
 
1.10 0.809794 
 
H05 RPLP0  0.86 0.579716 
 
0.98 0.924038 
 
1.05 0.962510 
 
 
A: This gene’s average threshold cycle is relatively high (> 30) in either the control or the test sample and is 
reasonably low in the other sample (< 30). 
These data mean that the gene’s expression is relatively low in one sample and reasonably detected in the other 
sample suggesting that the actual fold-change value is at least as large as the calculated and reported fold-change 
result. 
This fold-change result may also have greater variations if p value > 0.05; therefore, it is important to have a 
sufficient number of biological replicates to validate the result for this gene. 
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B: This gene’s average threshold cycle is relatively high (> 30), meaning that its relative expression level is low, 
in both control and test samples, and the p-value for the fold-change is either unavailable or relatively high (p > 
0.05). 
This fold-change result may also have greater variations; therefore, it is important to have a sufficient number of 
biological replicates to validate the result for this gene. 
C: This gene’s average threshold cycle is either not determined or greater than the defined cut-off (default 35), in 
both samples meaning that its expression was undetected, making this fold-change result erroneous and un-
interpretable. (Explanatory notes from Qiagen Data Analysis Centre website) 
 
 
 
    
  
   
Figure 3: MPA differentially regulates TNF-induced transcription of genes relevant to HIV-1 
pathogenesis in End1/E6E7 cells. The Human Host HIV-1 Response RT2 Profiler PCR array was used to 
study the effect of MPA on TNF transcriptional regulation of genes relevant to HIV-1 pathogenesis. End1/E6E7 
cells were treated with 100 nM MPA or 0.1% (v/v) EtOH (vehicle) in the presence or absence of 1.15 nM TNF for 
24 hours. Thereafter, total RNA was isolated using RNeasy Mini kit (Qiagen, USA), assessed for integrity by 
Bioanalysis and then converted to cDNA using the RT2 First Strand kit (Qiagen). Samples were loaded onto the 
plates and sent to a commercial facility for analysis. (A - C) show the Fold changes of genes plotted relative to 
TNF, which was set to 100%. The data include three independent biological repeats plotted as mean ± SEM in 
Graph Pad Prism 7 software. Statistical analysis was performed using the unpaired Student’s t-test for 
comparisons between vehicle only and other ligands with statistical significance denoted by #, ##, ###, or #### to 
indicate p<0.05, p<0.01, p<0.005 and p<0.0001, respectively. When the comparison was between TNF and other 
A B 
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ligands statistical significance is denoted by $ to indicate p<0.05. (B) is the hierarchical clustering heatmap with 
genes (rows) and ligands (columns) showing similar effects clustered together. 
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Appendix B 
 
Supplementary data for chapter four 
 
 
     
Figure 1: Neither P4 nor NET regulates claudin-4 nor occludin mRNA levels in End1/E6E7 cells. 
Confluent End1/E6E7 cells were stimulated with increasing concentrations of P4, NET or 01% (v/v) EtOH (vehicle) 
for 24 hours. Cells were then harvested in TriReagent®, total RNA isolated and converted to cDNA. The relative 
mRNA levels of claudin-4 (A) and occludin (B) were determined by qRT-PCR using gene specific primers and 
normalised to GAPDH mRNA levels. The relative effects of steroids on mRNA levels were determined by 
normalising to vehicle control, which has been set to 1. The data include at least two independent biological repeats 
plotted as mean ± SEM in GraphPad Prism 7 software. Statistical analysis was performed using one-way ANOVA 
with Tukey’s multiple comparison. 
 
 
Figure 2: End1/E6E7 express detectable levels of GR protein, but not PR-A or PR-B. End1/E6E7 
cells were harvested in 2X SDS Loading Buffer, boiled for 10mins and resolved on an 10% SDS-PAGE. Resolved 
B A 
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proteins were then transferred onto nitrocellulose membrane, blocked and probed using antibodies specific for the 
GR, PR-A, PR-B and GAPDH. Control samples were generated by transiently transfecting COS-1 cells with 
plasmids expressing the GR, PR-A, PR-B or empty vectors. The blot above is representative of 3 independent 
experiments.  
 
 
          
 
                           
Figure 3: GR knockdown partially lifts the DEX- but not MPA-induced repression of claudin-4 
mRNA levels End1/E6E7 cells.  Confluent End1/E6E7 cells were transiently transfected with 10 nM of GR 
HS_NR3C1_5 (GR5) siRNA or non-silencing scrambled sequence control (NSC) siRNA for 48 hrs. Thereafter, 
cells were treated with 100 nM DEX, MPA or 0.1% (v/v) EtOH (Vehicle) for another 24 hrs. Cells were then 
harvested in TriReagent®, total RNA isolated and converted to cDNA. The relative mRNA levels of claudin-4 (B) 
and GILZ (D) were determined by qRT-PCR using gene specific primers and normalised to GAPDH mRNA levels. 
The relative effects of steroid hormones on mRNA levels were determined by normalising to vehicle NSC control, 
which has been set to 1. In (A), extra wells of cells transiently transfected with10 nM of GR HS_NR3C1_5 (GR5) 
siRNA or non-silencing scrambled sequence control (NSC) siRNA for 72 hrs were harvested in 2X SDS Loading 
Buffer, resolved on an 10% SDS-PAGE and western blot analysis was done using antibodies specific for the GR 
and GAPDH. The blots from four biological repeats were scanned, quantified and for comparisons expressed 
relative to the untransfected (UT) cells (C). The data was plotted as mean ± SEM in Graph Pad Prism 7 software. 
Statistical analysis was performed using one-way ANOVA with Turkey’s multiple comparisons and statistical 
significance denoted as *, ** and **** to indicate p<0.05, p,0.01 and p<0.0001, respectively. In some cases, the 
unpaired Student’s t-test was used to compare corresponding treatments in the NSC and GR5 siRNA groups with 
statistical significance denoted as $ or $$ to indicate p<0.05 and p<0.01, respectively.
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Appendix C 
 
Supplementary data for chapter five 
 
 
   
Figure 1: DEX, NET and P4 differentially regulate CCL20, IL6 and GILZ mRNA expression in 
the presence of TNF in human ectocervical tissue explants. Ectocervical tissue explants from pre-
menopausal women were treated with 100 nM DEX, NET, P4 or 0.1% (v/v) EtOH (vehicle) in the presence or 
absence of 1.15 nM TNF for 24 hours. Thereafter, supernatants were collected and stored at -80°C until used 
and the rest of the tissue pieces were homogenised in TriReagent®, total RNA isolated and converted to cDNA. 
In (A – C), CCL20 (A), IL6 (B) and GILZ (C) mRNA levels were quantified by qPCR and normalised to GAPDH 
mRNA levels. The relative effects of the ligands on mRNA levels of the selected genes were determined by 
normalising to TNF, which has been set to 100%. The data was plotted in Graph Pad Prism 7 software as mean 
± SEM. Statistical analysis was performed using the Kolmogorov-Smirnov test and statistical significance is 
denoted as # to indicate p<0.05 for comparisons between vehicle only and TNF; or as $ or $$ to indicate p<0.05 
and p<0.01 for comparison between TNF and other treatments. 
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Figure 2: Inter-individual variations of human ectocervical tissue explant responses to DEX 
and MPA in the absence and presence of TNF. Ectocervical tissue explants from pre-menopausal 
women were treated with 100 nM DEX, MPA or 0.1% (v/v) EtOH (vehicle) in the presence or absence of 1.15 
nM TNF for 24 hours. Thereafter, supernatants were collected and stored at -80°C until used and the rest of the 
tissue pieces were homogenised in TriReagent®, total RNA isolated and converted to cDNA. CCL20 mRNA 
levels were quantified by qPCR and normalised to GAPDH mRNA levels. The relative effects of the ligands on 
mRNA levels of the selected genes were determined by normalising to TNF, which has been set to 100%. (A) 
shows results obtained from tissue samples in which MPA and TNF appear to coregulate CCL20 mRNA 
expression, while (B) shows results from tissue samples in which MPA and TNF appears not to coregulate 
CCL20 mRNA levels. The data was plotted in Graph Pad Prism 7 software as mean ± SEM.  
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Figure 3: Subcellular localization of claudin-4 between cell-cell junctions of confluent 
End1/E6E7 cells.  End1/E6E7 cells were seeded at 100,000 cells/mL onto glass cover slips and grown from 
5 to 18 days. Thereafter, cells were harvested by washing 1X with cold PBS, fixed with cold methanol and 
stained with anti-claudin4 (red) and DAPI (blue). Scale bars: 20 µM. (A) Z stack images were acquired for each 
day and en face 2D images (representing the middle slice) were generated using the Carl Zeiss Zen 2.3 
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software. (B) XZ projections of Z stacks were obtained using the Image J software. The figure above is 
representative of two independent experiments (n = 2). Differential Interference Contrast (DIC) is used to 
enhance he contrast in unstained, transparent samples. 
 
 
                                                          
Figure 4: MPA but not NET enhances HIV-1 infection and replication in TZM-bl cells. TZM-bl cells 
were treated with 10 IVU of HIV-1BaL_Renilla IMCs or Mock control for 24 hours. Thereafter, the cells were co-
stimulated with 100 nM of DEX, 100 nM MPA or 0.1% v/v EtOH (vehicle) for another 48 hours. At the end of the 
72 hours incubation period with HIV, luciferase activity was quantified using the Bright-Glo™ Luciferase Assay 
System reagent (Promega, USA)) on the Turner Biosystems Modulus Microplate reader (Promega, USA). The 
data represent at least three independent biological repeats plotted as mean ± SEM in GraphPad Prism 7 
software. Statistical analysis was performed using the unpaired Student’s t-test was used to compare pair of 
treatments; when comparison was between vehicle and other treatments, statistical significance is denoted as 
### to indicate p<0.005. This figure includes pooled data from the minus LPS or TNF groups from experiments 
described in Figure 4.3.8 (Chapter 4).  
 
 
 
 
 
 
 
 
 
 
 
